Subtype specific metabolic vulnerabilities in pancreatic cancer by Cunningham, Richard
 
 
 
 
 
 
 
 
Cunningham, Richard (2020) Subtype specific metabolic vulnerabilities in 
pancreatic cancer. PhD thesis. 
 
 
 
https://theses.gla.ac.uk/80267/ 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Subtype Specific Metabolic 
Vulnerabilities in Pancreatic 
Cancer 
 
 
 
 
 
Richard Cunningham 
BA (Mod), MSc 
 
Submitted to the University of Glasgow in fulfilment of the 
requirements for the Degree of the Doctor of Philosophy 
 
 
Institute of Cancer Sciences 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
October 2019 
  
  
 
2 
  
  
 
3 
 
Abstract 
 
Pancreatic cancer has historically been characterised by its poor prognosis, with 
very little increase in 5-year expectancy relative to other, comparable cancer-
types. This clinical observation is largely due to existing difficulties in identifying 
therapeutics effective in managing metastasised disease, a task compounded by 
the heterogeneity associated with pancreatic cancers. Concentrated efforts have 
been made in recent times to mitigate this issue, with the emergence of a range of 
subtyping strategies allowing for the stratification of patients. This categorisation 
of patients into workable groups thus serves to limit the degree of heterogeneity 
found within subgroups, with hypothetical, and otherwise unobservable, 
vulnerabilities shared between subtypes. This thesis aims to explore these 
potential therapeutically exploitable vulnerabilities by describing the extensive 
characterisation of pancreatic cancer subtypes via a diverse collection of patient 
derived cell-lines. This characterisation was achieved by profiling of the 
transcriptome via RNA-seq analyses, the proteome via mass-spectrometric 
approaches, and activation status of metabolic processes associated with 
oncogenesis in pancreatic cancer via functional assays. This work therefore 
facilitates the identification of vulnerabilities by utilising the profiles of subtypes 
generated in this manner and devising therapeutic strategies effective in treating 
the disease by interrogating dysregulated pathways. 
 
Within PDCLs, two pancreatic cancer subtypes were first identified which aligned 
with those described in patients: the squamous and classical subtypes. Preliminary 
profiling efforts highlighted a dysregulation of genes involved in metabolism across 
these subtypes in vitro, with active glycolysis associated with the aggressive 
squamous subtype and fatty acid biosynthesis and metabolism upregulated in the 
classical subtype. Further proteomic characterisation then validated this 
observation, providing further evidence for the existence of distinct metabolic 
profiles associated with these subgroups. Follow-up experimentation which 
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focused on metabolic outputs then generated metabolic profiles for each subtype, 
with in vitro phenotypes reflecting findings at the transcriptome and proteome 
level and demonstrating enhanced glycolysis and fatty acid oxidation in the 
squamous and classical subtypes respectively. 
 
Subsequent attempts to target arms within those subtype-associated metabolic 
pathways yielded mixed results. Inhibiting glycolysis via targeting of ALDOA 
successfully mediated a selective response in cell-lines associated with the 
squamous subtype, while classical cell-lines required a combination therapy to 
suppress metabolic flexibility to induce sensitivity to inhibition of fatty acid 
synthesis via targeting of FASN. 
 
An adjacent and complementary arm of research involved collaborative high-
throughput drug repurposing screens to identify additional targets for follow-up. 
This involved an initial screen of ~600 compounds in 8 PDCLs. Results generated as 
part of this screening approach highlighted the potency of statins in effecting a 
significant response selectively in squamous cell-lines. Research probing the 
mechanism by which statins induce this selective inhibition suggested that 
differences in degradation of the statin target HMGCR and cholesterol homeostasis 
may confer resistance to cell-lines classified as squamous, with findings 
demonstrating the potential of dietary components found in commonly ingested 
foodstuffs to mitigate the effects of statins in the otherwise sensitive, squamous 
subtype. 
 
This thesis therefore identified a range of therapeutic strategies effective in 
mediating sensitivity in in vitro pancreatic subtypes, with mechanisms of actions 
determined for each strategy. Results have demonstrated that pancreatic cancer 
cells exhibit differential sensitivities to metabolic inhibition, with subtype 
classification found to act as a predictor of sensitivity. As these in vitro subtypes 
recapitulate stratifications described in patients, these therapeutic strategies are 
of clinical relevance in the treatment of pancreatic cancer. 
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1.1  Introduction 
 
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease notoriously 
resistant to treatment, with a 5-year survival rate of less than 8% for patients 
diagnosed with the disease (Siegel, Miller and Jemal, 2017). Currently, the only 
means of curing the disease is surgical resection, a measure available only to ~20% 
of patients, and even then, a patient can expect just a 25% chance of surviving five 
years after surgery (Gillen et al., 2010). Over the past two decades, the standard 
of care treatment given to non-resectable PDAC patients has been Gemcitabine 
(Burris et al., 1997), with FOLFIRINOX (Conroy et al., 2011) and gemcitabine with 
nab-paclitaxel (Von Hoff et al., 2013) emerging more recently as alternatives. 
Though they represent the most effective therapeutics currently available to 
clinicians, the median survival for metastatic patients receiving these regimens of 
chemotherapy falls short of a year (Kamisawa et al., 2016). This highlights a clear 
need for novel therapeutic avenues that may be effective in treating the majority 
of patients. 
 
1.2  General characteristics of pancreatic cancer 
 
1.2.1  Anatomy and development of the pancreas 
 
The pancreas consists of a combination of interspersed exocrine and endocrine 
tissue, and as an organ, acts as a secretory gland to regulate metabolism. Its 
primary functions are to provide enzymes to the duodenum necessary for 
digestion, as well as to generate regulatory hormones to enter the circulatory 
system, controlling systemic metabolism; these two functions are carried out by 
the exocrine and endocrine lineages respectively. The exocrine system is made up 
of acinar and duct cells, while the endocrine component is comprised of a 
combination of cell-types, α-, β- and δ-cells, which constitute the islets of 
Langerhans. In the context of pancreatic cancer, it is important to consider the 
molecular mechanisms that regulate pancreatic formation and cell differentiation 
  
 
19 
(Figure 1.1) in order to understand the pathological rewiring that leads to 
oncogenic transformation. 
 
In mice, both PDX1 and GATA6 are necessary for the development of pancreatic 
tissue (Ahlgren, Jonsson and Edlund, 1996; Decker et al., 2006), with PDX1 
expression driving the early development of cells of all lineages within the 
pancreas (Wilding and Gannon, no date; Hale et al., 2005). Beyond formation of 
the pancreas, PDX1 is associated with insulin-producing β-cells, which are 
instrumental in carrying out the endocrine function of the pancreas: regulating 
metabolism. The collective expression of Forkhead Box A family of transcription 
factors, FOXA1, FOXA2 and FOXA3, is also associated with the developing pancreas 
(Monaghan et al., 1993). 
 
 
 
 
 
Figure 1.1| Temporal expression of genes necessary for pancreatic differentiation. Schematic 
displaying different stages of development (circles) leading to terminal differentiation of 
pancreatic tissue of both endocrine (blue) and exocrine (red) lineages, along with genes that 
regulate function/differentiation. Adapted from (Beer and Gloyn, 2016) and (Hruban et al., 2006). 
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Mutations within the Hepatocyte Nuclear Factor (HNF) family of transcription 
factors have long been associated with maturity-onset diabetes of the young 
(MODY), implicating their involvement in the maturation and function of β-cells 
(Fajans, Bell and Polonsky, 2001). A range of genomic and chromatin-
immunoprecipitation (ChIP) assays have validated this observation, and reinforced 
the role of HNF1A, HNF1B and HNF4 in pancreatic formation (Shih et al., 2001; 
Odom et al., 2004; Edghill et al., 2006). 
 
1.2.2  Tumour initiation 
 
The long-standing model of cancer formation holds that pancreatic precursor 
lesions, such as pancreatic intraepithelial neoplasms (PanINs) or intraductal 
papillary mucinous neoplasms (IPMNs), acquire mutations associated with 
oncogenesis over time. In this fashion, it is a gradual, multi-step process leading to 
progression to invasive carcinoma (Moskaluk, Hruban and Kern, 1997; Basturk et 
al., 2015), the most common of which likely occurs in ductal tissue giving rise to 
PDAC, accounting for 85% of all pancreatic malignancies (Alexakis et al., 2004). 
 
There remain issues with this model to this day however, with current research 
suggesting that oncogenesis can initiate within a tight time-frame, with 
simultaneous mutations potentially occurring concomitantly (Notta et al., 2016). If 
this is indeed the case, with progression occurring rapidly in a significant 
population of patients, there is then an even greater need for therapeutics 
effective in the management of advanced disease alongside the development of 
methods to assist in early diagnosis. Even the tissue of origin is a point of 
contention in PDAC, with evidence suggesting the transformative potential of cells 
of various lineage (Kleeff et al., 2007; Yonezawa et al., 2008). As such, much 
remains to be done to increase our understanding of pancreatic cancer 
oncogenesis, particularly to facilitate and advance the range of clinical 
interventions available to treat the disease. 
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1.2.3  Epidemiology and aetiology 
 
PDAC tends to occur in older populations, with the majority of cases found in 
patients over 60 years of age (Raimondi et al., 2007). A number of factors are 
thought to contribute to the occurrence of PDAC beyond age, with smoking found 
to contribute to incidence most from a range of various factors (Vrieling et al., 
2010; Bosetti et al., 2012). Body mass index is another contributor (Aune et al., 
2012), along with, although to a lesser extent, diet (Li et al., 2007). A family 
history of pancreatic cancer, along with germ-line mutations in genes that have 
long been associated with cancer susceptibility, are also found to increase the 
chances of developing pancreatic cancer (Lal et al., 2000; Jacobs et al., 2010). 
Despite these various risk factors that associate with PDAC, there are currently 
very few indicators to confidently identify high risk individuals for PDAC screening 
efforts, compounding early diagnosis of the disease and again, highlighting the 
necessity for late-stage treatments. 
 
1.3  Molecular characteristics of pancreatic cancer 
 
1.3.1  Common driver mutations 
 
Although a high degree of heterogeneity exists within pancreatic cancer, as seen in 
the high number of low prevalence mutations identified, mutations in KRAS are 
present in ~90% of PDAC cases (Biankin et al., 2012; Witkiewicz et al., 2015). KRAS 
is a membrane-bound GTPase, a member of the Ras superfamily of small GTPases 
that, when active, regulate a variety of pathways associated with oncogenesis, 
including survival and cell cycle progression (Vigil et al., 2010). In PDAC, 98% of 
KRAS mutations occur at the 12th glycine residue, leading to a constitutively active 
form of KRAS. 
 
In mouse models, maintenance of PDAC is dependent on continuous expression of 
activated KRAS (Collins et al., 2012). KRAS has proven to be a largely undruggable 
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target up to now (Gysin et al., 2011), though some experimental, clinically 
relevant methods have shown promise in treating pancreatic cancer in a preclinical 
setting, including the use of exosomes loaded with small interfering RNA (siRNA) 
designed to target mutant KRAS (Kamerkar et al., 2017). In addition to this, some 
small inhibitory molecules have been developed against KRASG12C (Ostrem et al., 
2013), however this specific mutation is present only in a very small percentage 
(3%) of PDAC patients (Cox et al., 2014), meaning these compounds will likely be 
clinically viable in other cancer-types and not pancreatic cancer. Should drug 
discovery research efforts lead to the development of a KRAS inhibitor effective in 
the context of pancreatic cancer, there is evidence from knockdown/knockout 
assays that subsets of cancer cell populations may prove refractory to KRAS 
inhibition (Singh et al., 2009; Muzumdar et al., 2017), with additional studies 
showing the potential of acquired resistance to KRAS inhibition as a possible 
mitigator of clinical efficacy (Collins et al., 2012). These observations indicate 
that pathways downstream of KRAS mutation may provide more promising drug 
targets than the gene product itself. 
 
Beyond KRAS alterations, mutations are found at high frequency in CDKN2A, TP53, 
and SMAD4 (Jones et al., 2008). PDAC is additionally characterised by an 
abundance of low prevalence mutations (Waddell, Pajic, A.-M. Patch, et al., 
2015), with experimental evidence highlighting the range of genes capable of 
driving pancreatic cancer initiation upon mutation (Mann et al., 2012). Despite a 
clear diversity in driver genes, the majority of mutations tend to occur in a 
number of canonical pathways central to cancer development (Jones et al., 2008). 
These studies therefore indicate that approaches to identifying therapeutics 
effective in treatment of PDAC be focused on targeting these pathways in general, 
rather than one specific genetic target, while these common driver mutations are 
also found to activate pathways commonly associated with the development of 
pancreatic cancer. These include the PI3K/Akt pathway (Ng SSW et al., 2000; 
Perugini et al., 2000; Bondar et al., 2002) and the oncogene c-Myc (Asano et al., 
2004; Hessmann et al., 2016). 
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1.3.2  Genomic instability and mutation burden 
 
Previous research has investigated the degree of genomic instability found in 
PDAC, with results highlighting the presence of disrupting structural variants in 
previously mentioned driver genes (Waddell, Pajic, A.-M. Patch, et al., 2015). 
Additionally, a subset of 14% of pancreatic cancer patients exhibit highly unstable 
genomes, with a further 36% displaying scattered chromosomal rearrangements. 
Those patients with a high degree of chromosomal instability also score highly for a 
point-mutational signature associated with BRCA1 and BRCA2 mutation (Alexandrov 
et al., 2013). Additionally, concurrent mutations in KRAS and TP53 in mice models 
drive genomic instability in the context of PDAC (Hingorani et al., 2005), providing 
evidence for a single event leading to wide-spread alterations of the genome. 
 
1.3.3  Dysregulation of gene expression 
 
While cancer signatures based on mutations and genetic alterations have informed 
the development of therapeutics effective in the treatment of various cancer-
types in the past (Lynch et al., 2004; Druker et al., 2006), analyses into gene 
expression and regulation are likely to provide more in-depth insights into the arms 
of targetable pathways that will be susceptible to inhibition. With the wide-spread 
availability of next-generation sequencing platforms, a number of large-scale 
studies have been conducted utilising RNA-seq to compare the transcriptomes of 
tumour and paired benign tissue (Mao et al., 2017), which has revealed similar 
dysregulation within pathways observed to exhibit increased rates of mutations 
(Jones et al., 2008). 
 
1.3.4  Epigenetic perturbations in pancreatic cancer 
 
Epigenetics is a term that describes genetic regulation beyond the genome, 
initially defined in the context of developmental biology (Margueron, Trojer and 
Reinberg, 2005; Holliday, 2006). Though cancer is inherently a genetic disease, 
with mutations driving oncogenic progression, the prevalence of gene 
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dysregulation in cancers attests to the contribution of epigenetic factors. Over the 
past couple of decades, the extent to which various cancer-types are driven by 
epigenetic perturbations has been extensively interrogated (Nebbioso et al., 
2018), highlighting the involvement of histone modification (Martinez-Garcia et 
al., 2011; McCabe et al., 2012; Zhao et al., 2016) and DNA methylation (Cai et al., 
2017; Hao et al., 2017) events in multiple cancers.  
 
Heterogenous epigenomic landscapes have been observed within pancreatic 
cancer, with distinct chromatin states found to predict prognosis in patients 
(Lomberk et al., 2018), while sweeping changes in chromatin structure have been 
described in pancreatic cancer metastases (McDonald et al., 2017). These 
observations, coupled with the finding that cells across multiple cancer types 
undergo epigenetic changes underpinning drug tolerance (Sharma et al., 2010), 
highlight the potential of therapeutically targeting epigenetic players in pancreatic 
cancer. To this end, there have been a number of novel inhibitors tested in the 
context of pancreatic cancer targeted towards a variety of classes of epigenetic 
enzymes (Hessmann et al., 2016). This includes proteins that regulate histone 
acetylation, including histone acetyltransferases (Ono, Basson and Ito, 2016) and 
histone deacetetylases (Lee et al., 2017; Booth et al., 2019), histone methylation, 
such as polycomb proteins (Avan et al., 2012), and the reading of epigenetic 
marks, such as the bromodomain and extra terminal domain (BET) family (Mazur et 
al., 2015; Sherman et al., 2017). 
 
 
1.4  A need for defined subtypes in pancreatic cancer 
 
Preclinical research efforts to identify new treatments are compounded by the 
previously described genomic diversity that exists within pancreatic cancer. By 
their design, classical clinical trials generally fail to appropriately address 
heterogeneity as patients are, by necessity, grouped together in large numbers. 
For this reason, drugs that may have potential in treating smaller subsets of 
actionable groups of patients may be overlooked, with exceptional responders 
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being dismissed as outliers rather than meaningful results. This highlights a need to 
break down pancreatic cancers into subtypes, each with unique sets of 
characteristics including differential sensitivities. Previous research efforts have 
succeeded in identifying effective therapeutic strategies in the treatment of other 
cancer-types in this manner (Slamon et al., 2001; Davies et al., 2002; Druker et 
al., 2006; Chapman et al., 2011). 
 
1.4.1  Different approaches to defining subtypes 
 
In order to address this diversity and develop methods allowing for the 
stratification of patients, various studies have attempted to define subtypes within 
pancreatic cancer. These research efforts have employed a range of approaches, 
including attempts that recognised the need for subtypes in pancreatic cancer, and 
considered physical properties/tissue of origin as pertinent characteristics for 
classification (Cubilla and Fitzgerald, 1979). Additional examples are the 
previously described subtyping study that looked at variability in genomic 
instability (Waddell, Pajic, A.-M. Patch, et al., 2015). Several successful attempts 
have also involved microarray assays, applied directly to multiple sources of 
tumour tissue (Collisson et al., 2011), and cells from metastatic sites and the 
surrounding microenvironment (Moffitt et al., 2015). 
 
With the advent of next-generation sequencing, transcriptome-based subtyping 
methodologies can be extended beyond microarrays, overcoming the limitation of 
quantifying expression within a pre-specified collection of genes. A recent 
research project characterised subtypes within PDAC via publicly available 
transcriptome databases within an entirely metabolic context. This study defined 
subtypes according to expression patterns of genes involved in glycolysis (Follia et 
al., 2019). Beyond the transcriptome, subtyping efforts have probed chromatin 
accessibility and DNA methylation profiles to describe the existence of epigenetic 
subtypes (Lomberk et al., 2018). 
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1.4.2  A multi-omics characterisation of pancreatic cancer subtypes 
 
This project will focus on a subtype classification system that employs a multi-
omics approach, taking into account the transcriptome, genome and epigenome to 
analyse a cohort of 457 patients, resulting in a descriptor of four distinct subtypes 
within PDAC (Bailey et al., 2016). These subtypes have recently been characterised 
taking into account previously mentioned subtyping efforts (Collisson et al., 2019) 
and are presented correspondingly as follows: the squamous subtype, 
characterised by poor prognosis and an upregulation of genes associated with 
“squamous-like” cancers (Hoadley et al., 2014); the pure classical progenitor 
subtype, associated with an upregulation of transcription factors involved in 
endoderm cell-fate determination; exocrine-like, a subtype defined by increased 
expression of transcriptional networks involved in later stage pancreas 
development, of both endocrine and exocrine lineages; and the immunogenic 
progenitor subtype, which shares a transcriptomic profile similar to the pure 
classical progenitor subtype, but with an additional upregulation of genes 
suggestive of immune infiltration. Based on their transcriptomic profiles, patients 
can be classed as belonging to one of the four subtypes (Figure 1.2). 
 
Enrichment analysis to characterise gene programmes (GPs) that define these 
subtypes facilitates the identification of pathways that may be involved in the 
initiation, progression or maintenance of tumours belonging to each subtype. When 
applied to GPs, enrichment analysis reveals the association of a diverse range of 
pathways with each of the four subtypes. One recurring observation is the 
enrichment of different pathways involving metabolism, particularly with GPs 
associated with squamous and pure classical progenitor subtypes (Figure 1.2). 
Gene programme 1 (GP1), the largest of the gene-sets whose collective expression 
is associated with both the pure classical progenitor and immunogenic progenitor 
subtypes, shows a marked enrichment for a broad range of pathways, many of 
which are associated with the biosynthesis and catabolism of various lipid 
metabolites. In contrast to this, the squamous subtype exhibits an upregulation of 
four separate gene programs, each defined by an enrichment for a distinct set of 
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pathways covering a diverse range of cellular functions. GP2 is the primary 
program enriched for genes associated with the “squamous-like” cancers and is 
also the most significantly associated with a worse prognosis, accounting for the 
poor clinical performance observed in the squamous subtype. Gene members of a 
range of pathways involving metabolism are enriched within this gene programme, 
including hypoxia which has long been associated with glycolytic activation 
(Semenza et al., 1994), as well as canonical glycolysis and glycolytic process 
pathways. 
 
More recent projects carrying out similar multi-omics analyses have validated and 
refined these findings, resulting in the description of two clearly distinct subtypes 
of pancreatic cancer (Cancer Genome Atlas Research Network., 2017). These two 
subtypes, squamous/basal-like and progenitor/classical, are reflective of the 
previously discussed attempts to define pancreatic cancer subtypes. 
 
1.5  Metabolism in cancer cells 
 
Metabolism is the process by which cells break down nutrients and generate energy 
to fuel biological functions. Metabolism in the context of cancer has been studied 
more and more extensively in recent years, with clear potential recognised in the 
identification of therapeutic targets that can be exploited after metabolic 
transformation in tumour cells. Such metabolic inhibitors would have the 
advantage of selectively killing cancer tissue, having no detrimental effect on 
normal cells, thus limiting deleterious side-effects associated with systemic 
chemotherapy (Vander Heiden, 2011). 
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Figure 1.2| Gene programmes constituting pancreatic cancer subtypes reveal metabolic 
dysregulation. Heatmap showing the collective expression of GPs that define the four subtypes, 
with black circles denoting GPs that are correlate best to specific subtypes. Pathways significantly 
enriched in those correlated GPs are shown to right, with those pathways related to metabolic 
function highlighted in red. Adapted from (Bailey et al., 2016). As can be seen, several metabolic 
pathways are found to be enriched in programmes associated with the squamous and pure classical 
progenitor subtypes. 
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1.5.1  Cancer cells and glucose 
 
One hallmark of transformation is the reliance of cancer cells on glycolysis as a 
primary source of energy production. This metabolic process, which involves 
breaking down glucose into pyruvate and then subsequently lactate (or ethanol in 
unicellular organisms, through the process of fermentation), was originally 
associated with cells grown in conditions of hypoxia. It is a mechanism less 
efficient at generating ATP from glucose than oxidative phosphorylation (OXPHOS), 
the primary means of energy production in most cells and which is reliant upon the 
tricarboxylic acid (TCA) cycle in mitochondria. Hypoxic cells are dependent on 
glycolysis as oxidative phosphorylation requires oxygen, as well as NADH and FADH2 
generated via the TCA cycle, to fuel the electron transport chain (ETC) that 
generates ATP (Figure 1.3).  
 
Aerobic glycolysis, or glycolysis conducted in normoxia, has also been associated 
with cell-types that exhibit rapid-proliferation. This includes single-cell organisms 
characterised by rapid growth (Bryant, Voller and Smith, 1964; Rolland, Winderickx 
and Thevelein, 2002), proliferating fibroblasts (Munyon and Merchant, 1959), stem 
cells, both induced and embryonic (Folmes et al., 2011), and transformed cells 
(Warburg, 1956), with cancer-associated aerobic glycolysis frequently termed as 
the “Warburg Effect” after Otto Warburg, the researcher credited with its 
discovery. While the reasons that a cell in an oxygen-limiting environment would 
utilise glycolysis as an energy source are apparent, the advantage of aerobic 
glycolysis is not immediately obvious, with the observed association between 
proliferation and glycolysis suggestive of a rapid production of cellular energy to 
fuel biosynthetic demands made possible by glycolysis. Alternative theories suggest 
that it may be due to metabolic reprogramming as a result of intermittent 
exposure to hypoxic conditions associated with the tumour micro-environment 
(Gatenby and Gillies, 2004). 
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Since its inception, much work has both reinforced and been influenced by 
Warburg’s theory, with one commonly-used and historically successful diagnostic 
tool in many cancer-types, FDG-PET, having been developed to detect the Warburg 
Effect in patients (Adams et al., 1998; Burt et al., 2001; van Tinteren et al., 
2002). This test functions via imaging of the radiotracer fluorodeoxyglucose (FDG), 
a fluorinated glucose analogue that is readily taken up by glycolytic tumour cells 
and can be detected via positron emission tomography (PET) imaging (Adams et 
al., 1998). Despite this, research throughout the years has cast doubt as to the 
veracity of the theory (Weinhouse, 1956), and one meta-analysis demonstrated 
that higher glycolytic ATP production is not a consistent characteristic of cancer 
cells on the whole relative to normal tissue (Zu and Guppy, 2004). However, these 
results highlight a metabolic heterogeneity found within cancer-associated cellular 
metabolism and suggests that a sub-category of cancer cells likely exhibit the 
highly glycolytic phenotype described by Warburg. This may also, in part, explain 
the inconsistency in the success rates of FDG-PET, with some population of cancer-
cells utilising glucose to fuel the TCA cycle, and potentially harnessing metabolic 
intermediates generated in this manner to support anabolic pathways (Lunt and 
Vander Heiden, 2011). 
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Figure 1.3| Overview of metabolic pathways dysregulated in cancers. Schematic outlining the various processes and metabolites that contribute to 
cancer progression. The glycolysis pathway is shown in red, with pyruvate converted to lactate in conditions of aerobic glycolysis and shuttled into 
mitochondria to fuel the TCA Cycle in most, non-cancerous cell-types. FAO is shown in green, with the end-product of β-oxidation (acetyl-CoA) also acting 
as a fuel source for the TCA cycle. NADH generated via this cycle acts as an electron carrier, driving the electron transport chain, and allowing the 
controlled transfer of protons (red circles) from the mitochondrial matrix (yellow) to the intermembrane space (pink). This interaction allows the 
maintenance of the proton gradient across the inner mitochondrial membrane, and the controlled generation of ATP via ATP synthase. 
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1.5.2  Lipid and fatty acid biosynthesis in cancer 
 
Lipogenesis is initiated utilising cytoplasmic pools of acetyl-CoA, which are 
predominantly produced by the breakdown of citrate by ATP citrate lyase (ACLY) 
within the cytoplasm. This citrate supply originates from within the TCA cycle, and 
its export from mitochondria is facilitated by the citrate transport protein 
(SLC25A1). Acetyl-CoA can then be converted to malonyl-CoA by the family of 
acetyl-CoA carboxylase family, consisting of an alpha and beta subunit (ACACA or 
ACC1 and ACACB or ACC2). The subsequent step in fatty acid synthesis (FAS) is 
mediated by fatty acid synthase (FASN), an enzyme integral for fatty 
acid/cholesterol biosynthesis, which acts to generate palmitate and saturated 
fatty acids from both acetyl-CoA and malonyl-CoA. This conversion is mediated by 
multiple reactions, all of which are catalysed by FASN, resulting in elongation 
cycles iteratively leading to the generation of 16-carbon palmitate (Lomakin, Xiong 
and Steitz, 2007). FASN has long been associated with cancer, with inhibition 
associated with an inhibition of growth in tumour cells (Kuhajda et al., 1994). As 
such, FASN has been considered as a possible target for anti-cancer therapeutics 
(Menendez and Lupu, 2007). 
 
In cancer cells, lipid biosynthesis is generally primed for the production of 
membranes and signalling molecules which are required for rapid proliferation 
(Currie et al., 2013). Cell membranes are primarily composed of phospholipids, 
and the generation of phosphatidylcholine, the primary phospholipid constituent of 
membranes, has been shown to promote oncogenesis in vivo (Gallego-Ortega et 
al., 2009), highlighting the link between transformation and lipid synthesis. 
 
Where fatty acid precursors are not synthesised into phospholipids, triacylglycerols 
(TAGs) are formed instead. These act as stores of cellular energy, and are 
maintained in the form of lipid droplets (Walther and Farese, 2009). Various 
families of enzymes are involved in TAG generation, including lipins (Csaki and 
Reue, 2010). The family of lysophosphatidylcholine acyltransferases (LPCATs) have 
been shown to localise to lipid droplets, and are thought to assist in LD formation 
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by providing phosphatidylcholine (Moessinger et al., 2011). Phosphatidylcholine is 
integral for LD structure, as it is the most abundant component in the polar lipid 
monolayer encompassing the neutral lipids and TAGs at the core (Bartz et al., 
2007). 
 
Transformation induced by KRAS mutation, present in the majority of pancreatic 
cancer, has been linked to a decrease in de novo lipid synthesis (Kamphorst et al., 
2013). Cells having been affected by such transformation are observed to scavenge 
exogenous lipids to compensate for the lack of endogenously produced fatty acids, 
in order to fuel the anabolic pathways rapidly proliferating cells are dependent on. 
 
1.5.3  The mevalonate pathway and cholesterol synthesis in cancer 
 
Beyond conversion to malonyl-CoA, acetyl-CoA may be converted to acetoacetyl-
CoA. This step is a necessary precursor for the mevalonate pathway, which is 
responsible for the generation of cholesterol, alongside a variety of sterol 
intermediates. The mevalonate pathway is initiated by the conversion of 
acetoacetyl-CoA to HMG-CoA and subsequently, to mevalonate, a metabolite which 
has been found to promote tumour progression in a xenograft mouse model 
utilising MDA-MB-435 (Duncan, El-Sohemy and Archer, 2004), a cell-line most likely 
of melanoma origin (Prasad and Gopalan, 2015). This discovery points to the 
involvement of downstream components of the mevalonate pathway on cancer 
development, the most well-characterised of which being cholesterol. 
 
Cholesterol has been shown to be instrumental in regulating a number of signalling 
pathways, with a variety of signalling receptors found to be recruited to lipid rafts 
(Mollinedo and Gajate, 2015), cholesterol-rich membrane microdomains (Brown 
and London, 1998, 2000). A number of these signalling receptors associated with 
lipid rafts are known to be involved in pancreatic cancer development, including 
insulin-like growth factor I receptor (IGF-IR), which is dependent upon lipid rafts 
for downstream signalling (Huo et al., 2003). IGF-I, the ligand of IGF-IR, has long 
been known to be overexpressed in PDAC (Bergmann et al., 1995), while 
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therapeutic inhibition of IGF-IR has been shown to inhibit PC growth in in vivo 
models (Moser et al., 2008), thus demonstrating the indirect involvement of lipid 
rafts in pancreatic cancer. This relationship is reinforced by the observation that 
markers involved in lipid raft formation are found to upregulated in a range of 
cancer-types, particularly breast and colon cancers (Staubach and Hanisch, 2011). 
 
Upstream of sterol synthesis, there are a number of alternative metabolites within 
the mevalonate pathway associated with cancer development and progression. 
This includes farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate 
(GGPP), two metabolites required for the transfer of farnesyl and geranylgeranyl 
moieties, constituting a post-translational modification known as prenylation. This 
modification is of particular relevance in PDAC as KRAS has long been known to be 
farnesylated (Hancock et al., 1989), while inhibition of KRAS prenylation has been 
shown to prevent tumour growth both in vitro and in vivo models of PC 
(Zimmermann et al., 2013; Jansen et al., 2017). Beyond KRAS, the Rho family of 
GTPases are also known to be prenylated (Clarke, 1992), while RhoA, a member of 
this family of small GTPases, has been shown to regulate the activity of YAP (Yu et 
al., 2012). This is of importance as YAP is inactivated by the tumour suppressor 
Hippo signalling pathway, a pathway known to be repressed in PDAC (Zhang et al., 
2014; Wang et al., 2020). These findings collectively highlight the mevalonate 
pathway’s involvement in driving cancer progression in general, with evidence that 
targeting the mevalonate pathway can disrupt the localisation and function of a 
range of GTPases (Ali et al., 2010), clearly demonstrating its relevance to PDAC. 
 
1.5.4  Fatty acid oxidation in cancer 
 
Fatty acid oxidations (FAO) is the process by which cells break down reserves of 
fatty acids, generating NADH and FADH2 to fuel the ETC. The initial stage of the 
process is β-oxidation, which occurs primarily within mitochondria and less 
commonly in peroxisomes. This process involves the recurrent break-down of fatty 
acids (FAs) to generate stores of acetyl-CoA, which can subsequently be utilised as 
fuel for the TCA cycle. Long chain FAs, which serve as a common substrate for β-
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oxidation, must be shuttled into mitochondria via the carnitine shuttle before they 
can be broken down (Fritz and Yue, 1963). 
 
Under conditions of metabolic stress, reflected by high AMP/ATP and ADP/ATP 
ratios, AMP-activated protein kinase (AMPK) modulates a number of signalling 
pathways that regulate cellular metabolic function. In this manner, AMPK acts as a 
key regulator of the balance between lipogenesis and FAO, increasing transcription 
of carnitine transporters, which drive FAO by facilitating the transfer of palmitate 
across mitochondrial membranes, in colorectal cell-lines and cardiac myocytes 
(Zaugg et al., 2011; Pfleger, He and Abdellatif, 2015), while directly 
phosphorylating and inhibiting the acetyl-CoA carboxylase (ACAC) family of 
enzymes. These enzymes, as described previously in chapter 1.5.2 , are necessary 
for the production of malonyl-CoA, which is essential for fatty acid biosynthesis 
(Hardie and Pan, 2002). This balance between FA catabolism and anabolism is then 
influenced by the metabolite malonyl-CoA, which is capable of both driving FAS 
and inhibiting FAO. The differential compartmentalisation of malonyl-CoA 
production, as determined by localisation of ACACA and ACACB, decides which 
pathway is effected, with cytosolic malonyl-CoA produced by ACACA activating 
lipogenesis, while mitochondrial malonyl-CoA produced by ACACB inhibits FAO in 
various experimental models (Abu-Elheiga et al., 2000, 2001; Hardie and Pan, 
2002). The observation that FAS and FAO are regulated by distinct enzymes 
challenges the historic assumption that the two pathways are mutually exclusive to 
one another (Jeon, Chandel and Hay, 2012; Carracedo, Cantley and Pandolfi, 
2013). 
 
Beyond the balance between lipogenesis and FAO, AMPK has also been found to 
regulate lipolysis, the process by which hydrolysis of TAGs induces the liberation of 
FAs, which can be utilised via FAO to generate cellular energy. In the past, 
conflicting results demonstrated that AMPK could both promote and inhibit 
lipolysis in adipocytes (Yin, Mu and Birnbaum, 2003; Daval et al., 2005). However, 
more recent research has highlighted the complex interplay of this regulatory 
cycle, with AMPK activation associated with upregulated lipolysis (Gauthier et al., 
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2008), hypothesised to act to offset the high energy consumption resultant from 
increased re-esterification of free FAs to TAGs (Ceddia, 2013). 
 
1.5.5  Autophagy in cancer 
 
Beyond regulation of the balance between FAS and FAO, AMPK also activates 
autophagy, the process by which cellular components such as organelles and 
cytoplasmic constituents are degraded, allowing for the recycling of energy and 
molecules required for biosynthesis. The initiation of autophagy facilitates 
homeostasis and the mitigation mitochondrial stress, which in the context of 
cancer, promotes cell survival by preventing DNA damage (Karantza-Wadsworth et 
al., 2007) and necrosis/inflammation (Degenhardt et al., 2006). As these processes 
are associated with tumorigenesis, the protective role of autophagy is thought to 
be tumour suppressive, an observation further validated by the enhanced initiation 
of tumour formation in autophagy-deficient mice (Yue et al., 2003; Takahashi et 
al., 2007). Despite this, autophagy inhibition has been shown to inhibit tumour 
growth in PDAC mouse-models (Yang et al., 2011), highlighting the complex 
interplay between autophagy driven tumour survival and suppression. 
 
1.5.6  Metabolic perturbations as a result of pancreatic cancer 
drivers 
 
Historic experiments performed in mice showed that transfection of ras oncogenes 
induced an increase in glucose uptake and expression of glucose transporters in rat 
fibroblasts (Racker, Resnick and Feldman, 1985; Flier et al., 1987). As further 
validation of the involvement of KRAS in driving glycolysis, previous research has 
shown that tumours initiated via inducible mutant KRAS expression in in vivo 
models regress upon loss of KRAS expression, leading to a reduction in glucose 
uptake and glycolysis (Ying et al., 2012). Building on these findings, work involving 
a similar inducible model assessing KRAS oncogene withdrawal also showed tumour 
regression, with those cells that survive withdrawal exhibiting decreased 
glycolysis, as observed in (Ying et al., 2012), as well as enhanced OXPHOS, which 
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was found to be necessary for the survival of these cells (Viale et al., 2014). In 
addition to inducing activation of glycolysis in PDAC, oncogenic KRAS has also been 
shown to drive non-canonical glutamine dependency (Son et al., 2013) and lipid 
uptake (Kamphorst et al., 2013) in in vitro models of pancreatic cancer, while 
signalling pathways downstream of mutant KRAS, such as mTOR (Kong et al., 2016; 
Zeitouni et al., 2016), also mediate metabolic dysregulation (Laplante and 
Sabatini, 2009). 
 
c-Myc, commonly activated in pancreatic cancer (Asano et al., 2004; Hessmann et 
al., 2016) and associated with the squamous, GP5 in PDAC patients (Figure 1.2), 
has been shown to act as a driver of a variety of metabolic pathways. For example, 
evidence proves that c-Myc mediates a switching from oxidative to glycolytic 
phenotypes in pancreatic cancer cell-lines (Sancho et al., 2015), an observation 
supported by past research demonstrating the ability of c-Myc to induce expression 
of lactate dehydrogenase (Shim et al., 1997) required for aerobic glycolysis. 
Conversely, c-Myc has also been shown to induce transcription of a number of 
genes involved in mitochondrial biogenesis in a range of cell-lines (Li et al., 2005; 
Kim, Lee and Iyer, 2008) and can mediate glutamine addiction in glioma cell-lines 
(Wise et al., 2008), indicating its ability to drive metabolic processes involving 
OXPHOS. In addition to this, interplay between mutant KRAS and c-Myc effects 
changes within cellular metabolism, with KRASG12D induced glycolysis shown to be 
dependent on c-Myc (Ying et al., 2012). These studies highlight the complex 
contribution of c-Myc to metabolic reprogramming in oncogenesis, as well as its 
ability to drive both glycolysis and OXPHOS (Dang, Le and Gao, 2009). 
 
Conversely, the hepatocyte nuclear factors (HNFs) are associated with pancreatic 
development, as described in chapter 1.2.1 , and have been found to act as 
tumour suppressors in pancreatic cancer (Hoskins et al., 2014; Luo et al., 2015), 
while HNF loss is associated with the aggressive squamous subtype in PDAC 
subtypes (Bailey et al., 2016). In the context of metabolism, this family of 
transcription factors have been linked to lipid homeostasis (Hayhurst et al., 2001) 
and are found to induce expression of genes involved in lipid biosynthesis (Odom et 
al., 2004).  
  
 
38 
Table 1.1| PDAC drivers are associated with metabolic reprogramming. Table showing 
perturbations commonly associated with PDAC oncogenesis and their demonstrated impacts on 
metabolism. A variety of molecular drivers of pancreatic cancer have been implicated in 
modulating metabolism, including KRAS mutation, which occurs in ~90% of PC. These are found 
affect a number of metabolic processes associated with cancer, including glycolysis, OXPHOS and 
lipogenesis. 
 
Collectively, these findings highlight the close association between drivers of 
pancreatic cancer formation and metabolic reprogramming (Table 1.1). This 
therefore highlights the integral part metabolism likely plays in PC development. 
 
1.6  Thesis aims and objectives 
 
Taking these collective findings into account, it was decided to focus on metabolic 
perturbations in those clearly defined subtypes of PDAC, with the end goal of 
selecting therapeutic interventions with clinical potential for subpopulations of 
patients. In order to enhance the possibility of identifying novel and effective 
therapeutic interventions, this thesis describes a multi-step approach which 
included the following specific aims: 
 
• Characterise and validate subtype-associated metabolism in a clinically 
relevant model of PDAC. 
• Identify therapeutics with potential to inhibit metabolic pathways found to 
associate with subtypes. 
Gene Perturbation in PDAC Effect on Metabolism Reference 
KRAS Mutation • Enhances glycolysis • Inhibits OXPHOS 
(Ying et al., 2012) 
(Viale et al., 2014) 
c-Myc Activation • Enhances glycolysis • Associated with OXPHOS 
(Sancho et al., 2015) 
(Li et al., 2005; Wise et al., 2008) 
HNFs Tumour Suppressor Enhances lipogenesis (Odom et al., 2004) 
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• Perform simultaneous, high-throughput drug repurposing screening to 
identify metabolism modulating therapeutics that effect a subtype-selective 
response. 
 
These efforts validated observations of metabolic dysregulation observed within 
patient subtype groups, confirming the upregulation of glycolysis associated with 
the aggressive, squamous subtype and FAO with the pure classical progenitor 
subtype in in vitro models of PDAC. Attempts to target these metabolic processes 
were met with success, with squamous PDCLs determined to exhibit sensitivity to 
inhibition of glycolysis. In contrast to this, PDCLs classified as pure classical 
progenitor were found to be resistant to attempts to target stores of FAs, with 
metabolic flexibility identified as the potential mechanism by with which PDCLs 
effect this mechanism of escape. 
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Materials and Methods 
 
2.1  General reagents 
 
Reagents used throughout the project are listed in table 2.1. 
 
Table 2.1| Table listing materials used throughout project. 
General Use 
Product Supplier Cat # 
AffinityScript cDNA Synthesis Kit Agilent 200436 
Bovine Serum Albumin (BSA) 
Fisher 
Bioreagents 
BP9702 
CellTiter 96® Aqueous Non-Radioactive Cell 
Proliferation Assay (MTS) 
Promega G5430 
Cholera Toxin Subunit B (Recombinant), Alexa 
Fluor™ 594 Conjugate 
Thermo 
Scientific 
C34777 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D4540 
Filipin III Sigma-Aldrich F4767 
Formaldehyde 
Fisher 
Bioreagents 
F/1501/PB17 
Fumed Silica Sigma-Aldrich S5130-100G 
2X Laemmli Sample Buffer  Bio-Rad 1610737 
4-20% Mini-PROTEAN® TGX™ gel, 10-well, 50 µL Bio-Rad 4561094 
4-20% Mini-PROTEAN® TGX™ gel, 12-well, 20 µL Bio-Rad 4561095 
Mini-PROTEAN® Tetra Cell system Bio-Rad 1658004edu 
Phosphate Buffered Saline (PBS) Sigma-Aldrich P4417 
Pierce™ BCA Protein Assay Kit 
Thermo 
Scientific 
23227 
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Pierce™ ECL Western Blotting Substrate 
Thermo 
Scientific 
32106 
Precision Plus Protein™ Dual Xtra Prestained 
Protein Standards 
Bio-Rad 1610377 
RIPA Buffer Sigma-Aldrich R0278 
RnaseZap™ RNase Decontamination Solution Invitrogen AM9780 
RNeasy Mini Kit Qiagen 74106 
Seahorse XF Palmitate-BSA FAO Substrate Agilent 102720-100 
SYBR™ Select Master Mix 
Applied 
Biosystems 
4472908 
Trans-Blot® Turbo™ Midi Nitrocellulose 
Transfer Packs 
Bio-Rad 1704159 
Trizma® Base Sigma-Aldrich T1503 
10X Tris/Glycine/SDS (TGS) Bio-Rad 1610732 
TWEEN® 20 Sigma-Aldrich P7949 
Triton X-100 Sigma-Aldrich T8787 
VECTASHIELD Antifade Mounting Medium Vector Labs H-1000 
VECTASHILED with DAPI Vector Labs H-1200 
Tissue Culture 
13C6-D-Glucose Sigma-Aldrich 389374 
13C5-L-Glutamine Sigma-Aldrich 605166 
60 mm TC-treated Culture Dish VWR 734-1699 
6-well plates, TC treated VWR 734-1599 
96-well plates, TC treated VWR 734-1794 
Apo-Transferrin Sigma-Aldrich T1147 
D-(+)-Glucose Solution Sigma-Aldrich G8644 
DMEM Gibco 41965039 
DMEM/F12 Gibco 11320-033 
DMEM, no glucose, no glutamine, no phenol red Gibco A1443001 
Dulbecco’s PBS Gibco 14190094 
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EGF Recombinant Human Protein Gibco PHG0311L 
Fetal Bovine Serum (FBS) Gibco 10270106 
Ham’s F12 Nutrient Mixture Gibco 21765-029 
HEPES Buffer Solution Gibco 15630-049 
Hydrocortisone Sigma-Aldrich H0888 
IMDM Gibco 21980-065 
Insulin, Human Recombinant Gibco 12585014 
KSFM Gibco 17005042 
L-Glutamine Gibco 25030024 
Medium M199 Gibco 31150-022 
MEM Vitamins Gibco 11120037 
Mevalonic acid 5-phosphate, lithium salt hydrate Sigma-Aldrich 79849 
MycoAlert™ Mycoplasma Detection Kit Lonza LT07-318 
O-phosphorylethanolamine Sigma-Aldrich P0503 
RPMI 1640 Medium Gibco 21875034 
3,3’,5-Triiodo-L-thyronine Sigma-Aldrich T6397 
0.5% Trypsin (10X) Gibco 15400054 
Versene Gibco 15040033 
siRNA 
ON-TARGETplus Non-targeting Pool/siRNA #1 Dharmacon D-001810 
ON-TARGETplus HMGCR individual siRNA Dharmacon J-009811-08 
ON-TARGETplus HNF4A SMARTpool siRNA Dharmacon L-003406-00 
Primers/qPCR 
Hs_GAPDH_1_SG QuantiTect Primer Qiagen QT00079247 
Hs_HMGCR_1_SG QuantiTect Primer Qiagen QT00004081 
Drugs 
2-Deoxy-D-Glucose Sigma-Aldrich D8375 
Antimycin Sigma-Aldrich A8674 
Carbonyl Cyanide 3-chlorophenylhydrazone Sigma-Aldrich C2759 
Etomoxir Sigma-Aldrich E1905 
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FDA Approved Drug Library Selleckchem L1300 
L-Carnitine Sigma-Aldrich C0283 
Oligomycin Sigma-Aldrich O4876 
Rotenone Sigma-Aldrich R8875 
Antibodies 
Target Protein Species/Isotype Supplier Cat # 
ACLY Rabbit IgG NEB 13390 
Akt (pan) Rabbit IgG NEB 4691 
Β-Actin Mouse IgG2b NEB 3700 
pan-Akt Rabbit IgG NEB 4691 
AMPKα Rabbit IgG NEB 5831 
Phospho-AMPKα (T172) Rabbit IgG NEB 2531 
CAV1 Rabbit IgG NEB 3238 
Cleaved Caspase-3 
(D175) 
Rabbit IgG NEB 9661 
Cleaved PARP (D214) Rabbit IgG NEB 5625 
FASN    
GAPDH Mouse IgG1 NEB 97166 
HMGCR Rabbit IgG Abcam ab174830 
P62-lck Mouse IgG1 BD Biosciences 610832 
Peroxidase Anti-
mouse IgG 
Donkey IgG Stratech 
715-035-150-
JIR 
Peroxidase Anti-rabbit 
IgG 
Donkey IgG Stratech 
711-035-152-
JIR 
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2.2  Cell culture methods 
 
All methods involving the handling of cell tissue requiring aseptic technique were 
performed under sterile conditions in class II biological safety cabinets. 70% 
ethanol was used to sterilise all work surfaces and equipment before use. 
 
2.2.1  Cell-lines 
 
Patient derived cell-lines used throughout the project are characterised briefly in 
Table 2.2. Principle components analysis of gene expression in PDCLs highlights 
grouping of cell-lines into subtypes (Figure 2.1). 
 
Table 2.2| PDCLs and general characteristics. Table showing names of all PDCLs included in 
project, along with corresponding subtype classification and source of cell-line. 
Name Subtype Source Reference 
TKCC-02 Squamous The Kinghorn Cancer Centre (Hardie et al., 2017) 
TKCC-02-LO Squamous The Kinghorn Cancer Centre (Hardie et al., 2017) 
TKCC-10 Squamous The Kinghorn Cancer Centre (Hardie et al., 2017) 
TKCC-18 Squamous The Kinghorn Cancer Centre (Hardie et al., 2017) 
TKCC-19 Squamous The Kinghorn Cancer Centre (Hardie et al., 2017) 
TKCC-26 Squamous The Kinghorn Cancer Centre (Hardie et al., 2017) 
Mayo-4636 Classical The Mayo Clinic, Rochester (Pal et al., 2014) 
Mayo-5289 Classical The Mayo Clinic, Rochester (Pal et al., 2014) 
TKCC-22 Classical The Kinghorn Cancer Centre (Hardie et al., 2017) 
PaCaDD137 Classical Technische Universität Dresden (Rückert et al., 2012) 
TKCC-17 Borderline The Kinghorn Cancer Centre (Hardie et al., 2017) 
TKCC-09 Undefined The Kinghorn Cancer Centre (Hardie et al., 2017) 
 
Cell-lines established from KPC mouse models, originating from c57Bl/6 mice, 
were generously donated from the Owen Sansom, Beatson Institute. 
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Figure 2.1| Principle components analysis highlighting PDCL subtyping. PCA plot of gene 
expression within PDCLs showing principle component 1 (x-axis) plotted against principle 
component 2 (y-axis). Cells are coloured according to subtype. Arrows show directionality of gene-
sets consisting of genes found to be differentially expressed between PDCL subtypes. 
Data provided by Peter Bailey (unpublished) 
 
2.2.2  Culture maintenance 
  
TKCC-02-LO, TKCC-09, TKCC-10, TKCC-17 and TKCC-26-LO PDCLs were cultured in 
a 1:1 mixture of Medium M199 (Gibco) and Ham’s F12 nutrient mixture (Gibco) 
supplemented with 15 mM HEPES Buffer solution (Gibco), 2 mM L-Glutamine 
(Gibco), 20 ng/mL EGF (Gibco), 40 ng/mL Hydrocortisone (Sigma-Aldrich), 5 µg/mL 
apo-Transferrin (Sigma-Aldrich), 0.2 IU/mL Insulin (Gibco), 0.06% Glucose Solution 
(Sigma-Aldrich), 7.5% FBS (Gibco), 0.5 pg/mL Triiodothyrinine (Sigma-Aldrich), 1X 
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MEM vitamins (Gibco) and 2 µg/mL O-phosphoryl ethanolamine (Sigma-Aldrich), 
referred to as M199/F12 medium. TKCC-18, TKCC-19 and TKCC-22-LO were 
cultured in IMDM (Gibco) supplemented with 20% FBS, 20 ng/mL EGF, 2.5 µg/mL 
apo-Transferrin, 0.2 IU/mL Insulin and 0.5X MEM Vitamins, referred to as IMDM 
Rich medium. Mayo-4636 and Mayo-5289 were cultured in DMEM/F12 (Gibco) 
supplemented with 10% FBS and 15 mM HEPES Buffer solution, referred to as Mayo 
medium. TKCC-02 was cultured in RPMI 1640 (Gibco) supplemented with 10% FBS 
and 20 ng/ml EGF. PaCaDD137 was cultured in  DMEM (Gibco) supplemented with 
27% KSFM (Gibco) and 10% FBS (Table 2.3). All cell-lines were incubated at 37°C 
and TKCC-02-LO, TKCC-22-LO and TKCC-26-LO were grown in hypoxia (5% O2) while 
TKCC-10, Mayo-4636 and Mayo-5289 was grown in normoxia (20% O2). Cells were 
routinely cultured in T75 flasks, with 10 mL appropriate medium. All cells were 
subject to routine checks for mycoplasma using a MycoAlert™ Mycoplasma 
Detection Kit (Lonza), with tests conducted by the WWCRC Reagent Services. 
 
2.2.3  Splitting cells 
 
Cells were split at or nearing confluence by aspirating spent medium and adding 10 
mL DPBS (Gibco) supplemented with 0.1 mM Versene (Gibco). Cells were incubated 
at 37°C for 10 minutes in order to detach loosely attached cells, which were then 
transferred to a 15 mL Falcon tube. In order to dislodge those more strongly 
adhered cells, 3 mL Trypsin (Gibco) was then added to flasks and incubated at 
37°C for no more than 15 minutes, or until total detachment of cells. Detached 
cells were pooled in Falcon tubes and centrifuged at 1,000 RPM for 5 minutes, with 
cell pellets subsequently resuspended in fresh, pre-warmed media to be put into 
new flasks or used for experiments. Cells were then counted using a Nexcelom 
Cellometer 2000 cell counter. 
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Table 2.3| Media formulations for tissue culture. Table showing the complete make-up of all 
media types used throughout the project upon addition of all base media and supplements. Unless 
specified otherwise, concentrations are provided in mM. 
 
 
2.2.4  Freezing/thawing cells 
 
To store in liquid nitrogen at -196°C, cells were split as previously described. Cell 
pellets were resuspended in FBS supplemented with 10% DMSO (Sigma-Aldrich) to 
prevent ice crystal formation and stored overnight in a -80°C freezer. To thaw, 
cells were incubated in a water bath at 37°C for one minute before transfer into a 
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flask containing the appropriate, pre-warmed medium. Cells were incubated 
overnight to allow for adherence before replacing media containing DMSO. 
 
2.3  Protein handling methods 
 
2.3.1  Cell lysate preparation 
 
Cells were seeded at an appropriate density on a 6-well plate or 60 mm dish (VWR) 
and incubated overnight at minimum to allow for adherence, with incubation 
periods extend where required for experimental protocol. When ready for 
harvesting, spent medium was aspirated and cells were washed once with PBS 
(Sigma-Aldrich). After washing, cells were scraped on ice in PBS, then centrifuged 
at 13,300 RPM for 3 minutes at 4°C. The cell pellet was washed in PBS before 
resuspending 1:5 in cold RIPA buffer (Sigma-Aldrich), and this cell suspension was 
left on ice for 30 minutes to allow for complete lysis. In order to remove any 
remaining cell debris, lysates were centrifuged as before, and the resulting pellet 
was discarded. 
 
2.3.2  Quantifying lysate protein concentration 
 
Lysates were incubated on ice for a minimum of 30 minutes before quantification 
with a Pierce™ BCA Protein Assay kit (Thermo Scientific) according to the 
Bicinchoninic Acid assay (Smith et al., 1985). The assay was conducted according 
to manufacturer’s specifications, with known concentrations of albumin used to 
create a standard-curve. Absorbance values corresponding to each tested sample 
were subsequently read at 562 nm using a Tecan Infinite 200 plate-reader and 
converted to protein concentration (µg/mL) using standard-curves. 
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2.3.3  Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Electrophoresis was carried out using 20-40 µg of total protein from each cell 
lysate, diluted 1:1 in 2X Laemmli Buffer (Bio-Rad). Samples were heated at 95°C 
for 10 minutes before loading onto precast 4-20% Mini-PROTEAN® TGX™ gels (Bio-
Rad). Electrophoresis was run in a Mini-PROTEAN® Tetra Cell system (Bio-Rad) at a 
constant voltage of 120V for ~1.5 hours in 10X TGS running buffer (Bio-Rad). 10 µL 
Precision Plus Protein™ Dual Xtra standards (Bio-Rad) was run alongside samples to 
provide a scale for protein size. 
 
2.3.4  Western blotting 
 
Separated proteins were then transferred from the gel to a nitrocellulose 
membrane using a Trans-Blot® Turbo™ Midi Nitrocellulose Transfer Pack (Bio-Rad) 
run on the Trans-Blot® Turbo™ transfer system. After transfer, the membrane was 
blocked in 5% milk in TBS-T (150 mM NaCl, 20 mM Tris, 0.1% TWEEN® 20) for 1 
hour. Membranes were washed twice with TBS-T for 15 minutes before incubation 
with primary antibodies, diluted according to manufacturer’s specifications, for 
one hour in TBS-T supplemented with 2% BSA (Fisher Bioreagents). The membranes 
were washed as before and then incubated for an hour with secondary antibodies 
specific to the primary antibody isotype, conjugated to Horseradish Peroxidase 
(HRP). Finally, Pierce™ Enhanced Chemiluminescence (ECL) Western Blotting 
Substrate (Thermo Scientific) was used to produce a visible signal from HRP, which 
was subsequently imaged using the ChemiDoc MP system (Bio-Rad). Image Lab 
software was used to process all generated images, as well as for the identification 
and quantification of bands. 
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2.4  RNA handling methods 
 
2.4.1  RNA isolation from PDCLs 
 
Cells were seeded at an appropriate density on a 6-well plate and allowed to 
adhere overnight. RNA was harvested from plates and purified using an RNeasy 
Mini Kit (Qiagen) according to manufacturer’s specification. The workspace used 
for harvesting was pre-treated with RnaseZap™ (Invitrogen) in order to prevent 
contamination with RNase. Purified RNA was quantified via NanoDrop™ 2000 
spectrophotometer and kept frozen at -80°C until needed. 
 
2.4.2  cDNA synthesis 
 
In order to generate cDNA necessary to perform quantitative PCR (qPCR), 1 µg of 
RNA isolated as described previously was subjected to reverse transcription. This 
was achieved via an AffinityScript cDNA synthesis kit (Qiagen), with the reaction 
carried out according to all manufacturer’s instructions. Any cDNA created in this 
manner was diluted 1:3 in RNase-free water and frozen at -20°C until required for 
qPCR. 
 
2.4.3  qPCR assays 
 
qPCR assays were carried out using 2X SYBR™ Select master mix (Applied 
Biosystems) and 10X QuantiTect primers (Qiagen), all according to manufacturer’s 
directions. Assays were performed on a QuantStudio 7 Flex Real-Time PCR System, 
with data processed and analysed using R statistical software. 
 
2.4.4  siRNA transfections 
 
Cells were transfected using RNAiMAX (13778-075, Invitrogen), a Lipofectamine-
based transfection reagent. Transfections were carried out with 10 nM appropriate 
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siRNA, with non-targeting siRNAs (Dharmacon), single or pooled, depending on 
experimental set-up, as a control. 
 
2.4.5  RNA-seq 
Sequencing was carried out on the Illumina HiSeq 2000/2500, generating paired-
end reads. These reads were then aligned to the GRCh37 reference genome via 
STAR (Dobin et al., 2013), with count data subsequently obtained using the 
featureCounts function of the “Rsubread” package (Liao, Smyth and Shi, 2014). 
Count data were subsequently normalised across samples and log transformed 
using the DESeq2 package (Love, Huber and Anders, 2014), generating log counts 
per million (LogCPM) values. 
 
2.5  Drug treatments 
 
2.5.1  Generating dose-response curves. 
 
Drugs were dissolved in appropriate solvent as instructed by manufacturers, where 
possible, creating 10mM working stocks. Cells were split, plated in a 96-well 
format and left in incubation for 24 hours to attach. After this attachment period, 
cells were dosed in 6 replicates with drug concentrations according to a 1:3 serial 
dilution. Additional wells containing the appropriate maximum percentage DMSO 
and 0.007% Triton-X100 (T8787, Sigma-Aldrich) were used as drug vehicle controls 
and 100% kill controls respectively. Viability was measured using an MTS assay kit 
(G5430, Promega), which acts to provide a quantification of viability via lactate 
dehydrogenase (LDH) mediated conversion of tetrazolium salt to formazan 
(Mosmann, 1983). GraphPad Prism version 7 was used to generate and analyse 
dose-response curves, with error bars shown across three replicates for each cell-
line tested. 
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2.6  Metabolic assays 
 
2.6.1  Extracellular metabolic flux assays 
 
Measurements of extracellular acidification rate (ECAR) and oxygen consumption 
rate (OCR) were obtained utilizing the Seahorse Xfe96 Analyser (Seahorse 
Biosciences) as previously described(Wu et al., 2006; Pike Winer and Wu, 2014). In 
brief, cells were seeded in their respective, fully supplemented medium at a range 
of densities optimized for each PDCL. 45 minutes prior to starting the assay, cells 
were equilibrated in basal media with minimal supplementation at 37°C in a non-
CO2 incubator. During the assay, indicated compounds were injected into wells at 
18-minute intervals. All results were normalized to total cellular protein content 
per well by RIPA extraction followed quantification with BCA protein assay kit 
(ThermoFisher Scientific, #23227) in a 96-well format, with absorbance measured 
using a Tecan Infinite 200 plate-reader. 
 
Table 2.4| Seahorse media formulations. Composition of media types used to culture cell-lines 
during extracellular flux assays. Red shading indicates addition of a supplement, while orange 
indicates addition conditional upon cell-line requirements. 
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2.6.2  Glycolytic stress test 
 
This extracellular flux assay, performed on the Seahorse platform, was initiated in 
the absence of glucose, with 10 mM glucose, a PDCL-dependent concentration of 
oligomycin and 50 mM 2-DG sequentially added to generate a profile of glycolysis 
under various conditions, as described previously (Pike et al., 2011; Pike Winer and 
Wu, 2014). TKCC-10 and TKCC-22-LO both required 1 µM while TKCC-02-LO, TKCC-
26-LO, Mayo-4636 and Mayo-5289 all required 2.5 µM oligomycin to achieve a 
maximal shift in ECAR. 
 
2.6.3  FAO assay 
 
This assay functions as an extension to the Mitochondrial Stress Test described by 
Seahorse Biosciences. 4-hours prior to beginning this assay, cells were cultured in 
substrate limited media supplemented with L-carnitine in order to stimulate 
consumption of endogenous fatty acid (FA) reserves. FAO was then subsequently 
quantified as a measurement of OCR upon treatment of subsets of cells with either 
40 µM FAO inhibitor Etomoxir or the FA palmitate, purchased as Seahorse XF 
Palmitate-BSA FAO Substrate, as described previously (Pike et al., 2011; Pike 
Winer and Wu, 2014). Initial OCR readings of the assay represent basal levels of 
respiration in the PDCLs, with sequential additions of PDCL-dependent 
concentrations of oligomycin, 1.6 µM CCP and a 1 µM combination of Antimycin and 
Rotenone providing a profile of OCR under different metabolic conditions. PDCLs 
were cultured in serum-free Krebs-Henseleit buffer supplemented with all 
necessary cell-line specific supplements excluding glutamine during the course of 
OCR recording. 
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2.6.4  Mito Fuel Flex Test 
 
The Mito Fuel Flex Test assay is designed to quantify the dependency, capacity and 
flexibility of cells to utilise three the major contributors to oxidative 
phosphorylation, glucose, glutamine and fatty acids. This is achieved by measuring 
changes in OCR upon treatment of cells with inhibitors of the metabolic arms 
corresponding to those three metabolites: UK5099, which inhibits the import of 
pyruvate into the mitochondria, halting glucose-driven OXPHOS; BPTES, an 
inhibitor of glutamine hydrolysis; and etomoxir, which inhibits CPT1A transfer of 
long-chain FAs into mitochondria. 
 
2.6.5  Lactate production and glucose consumption assays 
 
The L-Lactate content of culture media was measured using the colorimetric-based 
L-Lactate Assay Kit (Abcam, #ab56331) according to manufacturer’s specifications. 
3 x 104 cells were plated in their respective, fully supplemented medium and 24 
hours after seeding, this medium was replaced. Cells were cultured for a further 
48 hours before medium was taken for analysis and samples were subsequently 
deproteinated via PCA/KOH. Lactate levels in spent media were quantified by 
harnessing NADH generated from the conversion of lactate to pyruvate in order to 
reduce WST. This reaction yields formazan, which can be quantified 
spectrophotometrically, allowing a direct measurement of lactate levels. Each test 
was performed in duplicate, with output adjusted to background lactate levels in 
medium and normalised to total cell count. 
 
Glucose consumption was quantified via the colorimetric-based Glucose Uptake 
Assay Kit (Abcam, #ab136955) as per the manufacturer’s protocol. The assay 
functions by exposing cells to 2-DG, a glucose analogue that is taken up alongside 
glucose, but cannot be broken down beyond the initial step of glycolysis. This 
leads to accumulation of 2-DG-6-phosphate in cells proportionate to rate of 
glucose uptake, which can be oxidised to form NADPH. The resultant NADPH is 
then utilised as a reducing agent to convert glutathione disulphide to glutathione, 
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which can then be reacted with DTNB to produce a quantifiable colorimetric 
output. Each test was performed in triplicate and normalized to cellular protein 
content. 
 
2.6.6  Generating delipidated serum for metabolic studies 
 
Serum was delipidated with fumed silica (Sigma-Aldrich) according to 
manufacturer’s specifications. Briefly, 1 g of fumed silica was added to 50 mL FBS 
and left rotating overnight at 4°C. The resultant mixture was centrifuged at 2000 g 
for 15 minutes, and the supernatant filtered through. This method has been 
determined to most effectively deplete cholesterol, triglycerides and lipoproteins 
from serum as compared to other, commonly used approaches (Agnese, Spierto 
and Hannon, 1983), while preserving protein content (Ferraz et al., 2004).  
 
2.6.7  Stable isotope tracer metabolomics 
 
Cells were cultured in DMEM with no glucose, glutamine or phenol red, 
supplemented with all appropriate additives, replacing glucose and glutamine with 
isotopically labelled equivalents consisting of 13C. After 72 hours, cells were 
washed in PBS and collected in chilled 90% methanol. Cholesterol was then 
extracted after saponification with KOH in hexane. MSTFA was added to silylate 
samples, allowing for analysis via gas chromatography-mass spectrometry (GC-MS). 
 
2.7  Immunofluorescence and confocal microscopy 
 
2.7.1  Preparing cells for staining 
 
In preparation for microscopy work, cells were grown on coverslips, sterilised via 
autoclaving, placed in 6-well plates. Cells were incubated overnight to allow for 
adherence before harvesting for imaging or experimental treatment followed by 
harvesting. To prepare cells for staining, wells containing coverslips were washed 
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with PBS and fixed at room temperature with 4% formaldehyde in PBS for 10 
minutes. Formaldehyde was then removed, and cells were washed before being 
permeabilised for 3 minutes in 0.2% Triton X-100 (Sigma-Aldrich) in PBS. Where 
cells were stained for cholesterol imaging, permeabilization and staining steps 
were carried out concomitantly as described in the following section. 
 
2.7.2  Staining cells for imaging 
 
Cells were washed x3 with PBS between each described step and all plates were 
kept from direct light for the duration of staining upon addition of any 
fluorophore. Firstly, if staining for cholesterol, 100 µL of 50 µg/mL Filipin III 
(Sigma-Aldrich) in PBS was added to each coverslip and incubated at room 
temperature for 30 minutes. Next, if performing immunofluorescence, primary 
antibodies were diluted according to manufacturer’s specifications in 2% BSA in 
PBS and added to coverslips. After one-hour incubation at room temperature, 
coverslips were washed with PBS before the addition of secondary antibody for 
another hour incubation. Finally, if neutral lipid staining was carried out, 1 µg/mL 
BODIPY 493/503 was added to coverslips and incubated at room temperature for 
30 minutes. Coverslips were then washed in PBS and mounted on slides in 
VECTASHIELD, with or without DAPI depending on whether nuclear staining was 
required. 
 
2.7.3  Image acquisition 
 
All images were captured using a Zeiss LSM 780 confocal microscope system, with 
preliminary processing carried out using ZEN Black software. Immunofluorescence 
experiments were carried out with a minimum of 4 positions analysed for each 
condition, with imaging conducted at either 20X or 40X magnification. Z-stacks 
were acquired at each position, with sufficient depth to capture the entirety of all 
cells. Image sequences were then output as TIFFs for downstream analysis. 
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2.8  Data analysis 
 
2.8.1  General statistical analysis 
All statistical processing was carried out in R, while subsequent figure generation 
was performed using GraphPad Prism. Linear regression was performed using the 
least squares method of line fitting and was executed using the lm function of the 
“stats” package, which functions via QR decomposition (Goodall, 1993). 
 
2.8.2  Drug screening analysis 
 
Drug target data were obtained from the DrugBank database (Wishart et al., 2018), 
downloaded in the XML format. Clinical trials data were obtained from the 
Aggregate Analysis of ClinicalTrials.gov (AACT) database (Clinical Trials 
Transformation Initiative), downloaded in pipe-delimited format and processed in 
R. 
 
 
2.8.3  Immunofluorescence image analysis 
 
Images generated via confocal imaging were further processed using FIJI 
(Schindelin et al., 2012), allowing for the re-arranging of channels and the 
generation of maximum intensity Z-projections from a sequence of images 
representing a Z-stack. Feature detection and quantification was subsequently 
performed on Z-projections using CellProfiler (Carpenter et al., 2006) utilising the 
various functions to identify and enhance various features such as nuclei, lipid 
droplets, cleaved PARP and cleaved Caspase-3. Where necessary, additional 
processing allowed for the expansion of features and assessment of overlap of 
objects. 
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Defining Candidate Metabolic Vulnerabilities 
 
3.1  Introduction 
 
In order to identify therapeutics potentially effective in treating pancreatic 
cancer, studies concentrated on characterising subtypes previously found to exist 
within patients (Bailey et al., 2016). To this end, a diverse collection of patient 
derived cell-lines (PDCLs) generated directly from tumour tissue was used as a 
potential model for subtype-specific therapeutic development for pancreatic 
cancer. To first validate their application to this end, extensive transcriptomic 
profiling of PDCLs via RNA-seq was performed. To act as further verification of the 
robustness of the approach and model, subtyping of cell-lines was performed 
independently of the patient from which they were derived. 
 
Though the central dogma of genetics holds that translation of proteins is 
dependent on transcription of RNA, the relationship between mRNA and protein 
abundances are not directly proportionate, largely in part due to regulation at the 
post-transcriptional level (Lai, 2002; Thomson et al., 2006). Though previous 
evidence shows that gene expression in pancreatic tissue is closely correlated with 
protein abundance, more so than in a number of other tissue-types (Kosti et al., 
2016), proteomic characterisation was performed to confirm clinical relevance of 
dysregulation observed at the transcriptome level. 
 
Simultaneous characterisation of both transcriptomes and proteomes within PDCLs 
enabled the interrogation of both datasets to quantify dysregulation of pathways 
associated with oncogenesis and subtype differentiation in PDAC (Jones et al., 
2008; Bailey et al., 2016). This approach was intended to further reinforce the 
validity of the PDCL model, while allowing focus to be directed to pathways which 
represent potential for subtype-specific vulnerabilities. 
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In line with recent research that ties metabolic perturbations to pancreatic cancer 
development and progression (Ying et al., 2012; Kamphorst et al., 2013; Son et 
al., 2013), PDCLs were additionally subject to a range of assays assessing 
metabolic outputs. Specifically, rates at which cells utilised both glucose and fatty 
acids as energy sources were interrogated, which were then compared to findings 
at the transcriptomic and proteomic level. These analyses collectively revealed 
differential metabolic profiles that exist between subtypes, with subsequent 
research efforts aimed at identifying vulnerabilities within these metabolic arms. 
 
3.2  Transcriptomic profiling of PDCLs reveals subtype-
specific metabolic dysregulation 
 
3.2.1  Analysis of PDCL transcriptomes identifies in vitro subtypes  
 
In order to determine potential subtypes in PDCLs, RNA-seq was performed on a 
set of 48 novel, patient derived cell-lines (PDCLs), provided by the Australian 
Pancreatic Cancer Genome Initiative (for details on origin, see Table 2.2). This 
provided a comprehensive profile of PDCL transcriptomes, with subsequent 
hierarchical clustering of RNA-seq data revealing the existence of two broad 
subtype groups (Figure 3.1a) (Peter Bailey, unpublished data). These two subtypes 
were classified as squamous and classical. As was seen within bulk tumour and 
described in chapter 1.2.1 , the PDCL squamous subtype was characterised by the 
loss in expression of a number of genes associated with pancreatic identity 
determination, including PDX1 and HNFs (Figure 3.2). Clustering did reveal the 
existence of three PDCLs that could be classed as exocrine-like, which displayed 
expression of genes associated with terminally differentiated pancreatic epithelia 
such as CPA1, INS and GCG. Beyond those perturbations, these exocrine-like PDCLs 
showed similar transcriptional patterns as 17 PDCLS determined to belong to the 
pure classical progenitor subtype, and as such, these subtypes were grouped and 
referred to as classical, representative of the classical-pancreatic subgroup 
described in patients (Collisson et al., 2019).  
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Weighted Gene Co-expression Network Analysis (WGCNA) was then performed on 
transcriptome data to identify co-ordinately regulated gene programmes across 
the subtypes (Langfelder and Horvath, 2008), as previously conducted in bulk 
tumour data (Bailey et al., 2016). This analysis was conducted independently of 
that performed in patient samples, similarly generating gene networks assigned 
colour identifiers to facilitate the plotting of data. By comparing the composition 
and connectivity patterns of gene programmes between PDCL and patient data, it 
was possible to quantify conservation between tumour and cell-line gene 
networks, as previously described in literature (Langfelder et al., 2011). One 
major observation from this assessment of conservation was the recapitulation of a 
majority of gene programmes identified in bulk tumours, in particular those 
associated with the squamous and pancreatic progenitor subtypes, and those found 
in PDCLs. This can be seen in the high Zsummary measures obtained for gene 
programmes 1-5, which constitute all GPs that define squamous and pancreatic 
progenitor subtypes. Conservation scores are all greater than 10 in these GPs 
(Figure 3.1b), suggesting a preservation across these modules. Additionally, gene 
networks within cell-lines that share a high degree of similarity to subtype-
associated bulk tumour GPs are associated with subtype specification in cell-lines. 
This is seen in the module eigengene (ME) values, or values of expression that 
typify the collective expression of gene networks (Langfelder and Horvath, 2007), 
in those conserved modules. When plotting ME values of PDCL modules in cell-
lines, cell-lines are shown to cluster according to subtype (Figure 3.1c). An 
example of this can be seen within the turquoise GP in PDCLs, which has 
significant overlap with GP1, the GP most associated with the pancreatic 
progenitor subtype in patients. The ME values of this module are consistently 
higher across cell-lines grouped as classical. These observations collectively point 
to the existence of patterns which define patient subtypes in an in vitro context, 
thus highlighting the potential of cell-lines as a model of patient subtypes. 
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Figure 3.1| RNA-seq reveals two distinct subtypes in PDCLs. a Heatmap displaying hierarchical, unsupervised clustering of PDCL RNA-seq data. This 
analysis yields a clear, binary subtyping (squamous blue, classical orange). b Plot highlighting conservation between GPs previously described in patient 
tumour (y-axis, colour identifiers and GP numbers shown) and GPs identified in PDCLs (x-axis). Preservation scoring was achieved by computing Zsummary 
statistics (Langfelder et al., 2011) for bulk tumour GPs and shown along the y-axis (module preservation), with scores of >10 indicating preservation across 
modules, 2-10 suggesting weak preservation and scores <2 indicating no preservation. c Module eigengene values of PDCL modules for each cell-line, with 
subtyping shown along top. A number of modules are seen to associate with each of the two subtypes. Data provided by Peter Bailey (unpublished). 
b c 
a 
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The mirroring of subtypes observed is a positive indicator of sample purity and 
suggests there was little to no stromal contamination of cancer epithelia while 
generating PDCLs. Though there may be strength in modelling interactions 
between stroma and tumour tissue, particularly as evidence shows cross-talk 
between the dense stroma associated with PDAC and tumour promotes cancer 
progression (Hwang et al., 2008), monocultures were studied to reduce 
complexity, thus facilitating the primary goal of identifying therapeutics that 
selectively target tumour cells. The immunogenic subtype, which is defined by 
gene programmes suggestive of significant immune infiltration, was not identified 
within PDCLs. This observation is expected as the immune component is naturally 
absent in monoculture systems derived from tumour epithelia. Reinforcing this, it 
was found that 74% (86 out of 116) of genes determined to be differentially up-
regulated in the immunogenic subtype in patient transcriptomes, as determined 
via Voom package (Law et al., 2014), were not found to be expressed in any PDCL. 
In comparison, when looking at each of the gene-sets significantly up-regulated in 
the three other subtypes, <10% were not found to be expressed within PDCLs. 
Interestingly though, gene programmes were found that were enriched for genes 
involved in immune regulation, likely resulting from cell autonomous signalling 
pathways previously described as being associated with the squamous subtype 
(Bailey et al., 2016).  
 
In summary, by comparing the co-ordinately regulated gene modules that exist in 
both patient and PDCL transcriptomes, the potential in harnessing PDCLs as a 
model of clinically relevant pancreatic cancer subtypes is evident. This then 
justified subsequent interrogation of the transcriptomes and proteomes of the two 
subtypes in PDCLs to search for therapeutic vulnerabilities. RNA-seq data were 
obtained and processed by Peter Bailey and Rosanna Upstill-Goddard. 
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Figure 3.2| Genes associated with pancreatic identity are downregulated in squamous PDCLs. 
Bar-plots showing the expression of (a) HNF1A, (b) HNF4A, and (c) PDX1 across PDCLs, coloured 
according to subtype and ordered from highest to lowest in terms of expression. As can been seen, 
expression is generally selectively found within classical (brown) rather than squamous (blue) 
PDCLs. The protein products of these three genes are all associated with pancreatic differentiation 
and identity, and the observation that their expression is lost in squamous PDCLs is in-line with 
observations within bulk tumour. All data are presented in LogCPM (log-transformed counts per 
million). 
c 
b 
a 
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3.2.2  Subtype-associated metabolic signatures within PDCL 
transcriptomes 
 
In order to identify pathways enriched for in subtype-associated gene modules and 
to quantify the collective expression of these functional biological pathways in 
PDCLs, the dnet R package (Fang and Gough, 2014) was implemented, allowing for 
enrichment analysis of pathways described in Gene Ontology (GO) (Ashburner et 
al., 2000), KEGG (Kanehisa and Goto, 2000) and Reactome (Fabregat et al., 2018)   
 
databases, and Gene-Set Variation Analysis (GSVA) was employed (Hänzelmann, 
Castelo and Guinney, 2013). GSVA analysis revealed that differences in expression 
of genes associated with metabolism are a key feature that defines the two 
subtypes in PDCLs, with a range of molecular processes involving fatty acid and 
glucose biosynthesis/metabolism differentially co-ordinately regulated between 
subtypes (Figure 3.3a). Upregulation of fatty acid biosynthesis in classical PDCLs 
can be demonstrated through highlighting the expression of genes involved in lipid 
anabolism in the turquoise GP, the module described previously as being most 
closely associated with the classical subtype (Figure 3.3b). Of note is the 
conservation of this transcriptional upregulation between PDCLs and bulk tumour, 
as a similar enrichment of genes involved in lipid anabolism, such as Peroxisomal 
Trans-2-Enoyl-CoA Reductase (PECR), which acts to elongate FAs during the 
biosynthetic process, and Malonyl-CoA Decarboxylase (MLYCD), which regulates 
levels of malonyl-CoA, the key determinant in rates of biosynthesis, can be seen 
within the pancreatic progenitor subtype in patients. This serves to further 
validate this observation within the PDCL model. 
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Figure 3.3| Metabolic genes are dysregulated between subtypes. a Heatmap showing 
coordinated dysregulation of metabolic gene-sets highlighting the transcriptional distinction 
between PDAC subtypes. Analysis performed and data provided by Peter Bailey (unpublished). b 
Heatmap showing the expression of genes from the turquoise gene programme associated with the 
fatty acid biosynthetic process according to the GO database. Rows and columns were clustered 
according to Ward hierarchical clustering. 
 
 
 
 
Metabolic Cassettes 
Fatty Acid Biosynthesis b 
a 
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When assessing differences in expression of genes involved in glycolysis, isoform 
ratios are seen to inform subtype classification, with the aldolase family of 
enzymes best representing this phenomenon. The aldolases are essential enzymes 
for early glycolysis, catalysing the cleavage of fructose 1,6 bisphosphate into 
glyceraldehyde-3-phosphate. Early enzyme kinetic assays determined that Aldolase 
A (ALDOA) has the greatest cleavage efficiency for fructose 1,6 bisphosphate 
among the isoforms (Penhoet and Rutter, 1971), implicating it as the major 
aldolase driving glycolysis within cells (Chang et al., 2018). Its expression is 
predominantly associated with energy-consuming muscle cells (Lebherz and Rutter, 
1969), and loss of ALDOA has previously been linked to fatal rhabdomyolysis (Yao 
et al., 2004). Additionally, increased levels of ALDOA have long been observed in 
patients with cancer (Asaka et al., 1994; Li et al., 2019). Within PDCLs, 
ALDOA:ALDOB expression ratios are found to be dysregulated across subtypes, with 
squamous cell-lines displaying greater levels of ALDOA transcript and classical cell-
lines, ALDOB (Figure 3.4a-b). This association corresponds to a poorer prognosis in 
patients with a high ALDOA:ALDOB ratio (Figure 3.4c). 
 
These observations work to collectively highlight the coordinated dysregulation of 
genes involved in metabolism between the subtypes and suggest a transcriptome-
driven regulation of general metabolism in PDCLs. These findings were then 
validated at the proteomic level to ensure an association between abundance of 
metabolic enzymes and subtypes before confirming the effect on metabolic 
phenotypes. 
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Figure 3.4| Impact of metabolic isoform ratio on subtype and outcome. a Scatter-plot showing 
the expression of ALDOA plotted against expression of ALDOB, highlighting association between 
ALDOA:ALDOB ratio and subtype, as well as the significant negative correlation in expression 
between the two isoforms. High ALDOA/low ALDOB expression is associated with the squamous 
subtype (blue triangles) while the opposite is true for classical (brown circles). Test statistics 
correspond to the Pearson correlation coefficient, with linear regression (grey, dotted line) 
highlighting negative correlation. b Boxplot displaying the ALDOA:ALDOB ratios grouped according 
to subtype. As observed in (a), a high ALDOA:ALDOB ratio is highly significantly associated with the 
squamous subtype, as determined via Mann-Whitney U test. c Kaplan-Meier curve showing the 
significantly improved disease-specific survival prognosis in PDAC patients with low ALDOA:ALDOB 
ratio relative to those with high. Low/high patient classification was achieved by splitting the 
cohort in two across the median ratio and p-value calculated via logrank test. 
c 
a b 
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3.3  Proteomic profiling validates and expands on 
transcriptomic analysis 
 
In order to ensure that the observed dysregulation of genes involved in metabolism 
translated to differences in protein quantities between subtypes, PDCL proteomes 
were quantified via mass-spectrometry. This analysis was performed within a 
selection of cell-lines representative of the two distinct subtypes. This analysis 
firstly demonstrated that there was a strong correlation (r = 0.78; p = 2.2 x 10-16) 
between mRNA and protein abundances when considering genes/gene products 
involved in lipid biosynthesis and glycolysis, as defined by the canonical glycolysis 
and fatty acid biosynthetic processes specified in the GO database (Ashburner et 
al., 2000) (Figure 3.5). These pathways consist of a variety of genes integral to 
both glycolysis and lipogenesis, including the aldolases, whose role in glycolysis is 
described in chapter 3.2.2 , acetyl-CoA carboxylases and FASN, both catalysing 
intermediate reactions in FA biosynthesis, described in chapter 1.5.2 , and AMPK 
subunits, which mediate the metabolic stress response described in 1.5.4 , 
suggesting that transcriptomic analysis which demonstrates a dysregulation of 
metabolic cassettes (Figure 3.3a) should directly inform downstream proteomic 
data. 
 
In order to investigate the extent to which pathways are affected by this 
dysregulation at the protein level, a subset of PDCLs most reflective of the subtype 
extremes were analysed, considering only proteins present in classical and absent 
in squamous. This validated the association between lipid biosynthesis and 
metabolism pathways and the classical subtype observed within the transcriptome 
(Figure 3.6). The findings that proteins involved in lipid biosynthesis and 
metabolism are more abundant in classical cell-lines, in conjunction with the 
previously described results obtained from RNA-seq analysis that corroborate the 
upregulation of genes associated with lipogenesis in classical PDCLs and suggest 
the more widespread dysregulation of metabolic cassettes between subtypes 
(Figure 3.3a), provide compelling evidence that different metabolic pathways are 
activated between the subtypes. These observations are consistent with the 
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research described in chapter 1.5.6 , which details the association of drivers of 
pancreatic cancer with upregulation of glycolysis, FA biosynthesis and FAO (Table 
1.1). Before interrogating these pathways to identify potential susceptibilities, it 
was necessary to first validate these findings via functional assays.  
 
Figure 3.5| Expression of metabolic genes correlates strongly to protein abundances in PDCLs. 
Scatter-plot showing correlation between the expression of genes as determined by RNA-seq in a 
selection of subtyped PDCLs (x-axis) and abundance of their corresponding gene product as 
determined by mass-spectrometry (y-axis). Genes were selected to display from the “canonical 
glycolysis” and “fatty acid biosynthetic process” pathways as defined by the GO database. 
Spearman’s rank correlation coefficient was calculated at 0.782, p = 2.2 x 10-16, with linear 
regression highlighting the positive correlation between transcript and protein abundances (dotted 
grey line). 
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Figure 3.6| Classical subtype PDCLs are defined by the presence of metabolic networks of 
proteins. Network plot displaying metabolic pathways enriched for proteins selectively found in 
classical cell-lines. Each red ellipse represents a protein associated with the classical subtype, 
associations between biological processes and proteins are highlighted in grey, and druggable 
targets are shown in yellow. Transcriptome analysis had previously highlighted upregulation of lipid 
biosynthesis within this subtype, with network analysis validating this phenomenon at the protein 
level. An association was also found between the classical subtype and metabolism of both lipids 
and amino acids. Analysis and data provided by Bryan Serrels (unpublished). 
 
3.4  Metabolic characterisation reveals distinct metabolic 
phenotypic differences between subtypes 
 
In order to characterise metabolism in PDCLs and validate results from RNA-seq 
and proteomics, the Seahorse XFe96 analyser was employed for quantification of 
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extracellular bioenergetics. This system functions through the quantification of 
oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) within 
wells containing cells, as determined by shifts in oxygen and pH levels recorded by 
fluorescent biosensors (Wu et al., 2006). OCR acts as a measure of oxidative 
phosphorylation as cellular oxygen consumption is coupled with the electron 
transport chain (ETC) and ATP production through the progression of the TCA 
cycle. ECAR is similarly linked to aerobic glycolysis due to the resultant lactate 
production and efflux of protons. 
 
To generate a comprehensive profile in real-time, metabolic stress tests were 
performed. By measuring changes in extracellular flux in real-time upon the 
injection of various compounds into wells over the course of each assay, these 
protocols allow for basal and maximal read-outs for a range of metabolic 
functions. 
 
3.4.1  Determining optimal conditions for bioenergetics assays 
 
Before proceeding with extracellular flux assays, it was necessary to first 
determine the optimal seeding densities for each cell-line, as well as the minimum 
concentrations of injected compounds required to achieve maximal effects on 
metabolic pathways. These steps were required to avoid recording metabolic 
artefacts in response to over- or under-confluence, as well as to limit the 
possibility of off-target effects that might result from injecting high concentrations 
of compounds. 
 
To ascertain the ideal plating conditions, cells were seeded at a range of densities, 
allowed 24 hours to attach, and viewed under a microscope. According to 
manufacturer’s specifications, optimal confluency was determined to be 50-90% at 
the time of assay, with seeding densities selected to satisfy this criterion. Upon 
determining this, the optimal concentrations of oligomycin and FCCP were 
deduced in each cell-line by assaying shifts in ECAR and OCR respectively in 
response to increasing concentrations of each compound. As oligomycin/FCCP 
concentrations increase, ECAR/OCR rise until they reach a maximal level, with 
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final concentrations selected by determining the lowest concentration at which 
these maximal levels were recorded Table 3.1. 
 
Table 3.1| Cell-line optimisations determined for bioenergetic stress tests on Seahorse 
platform. Optimal overnight seeding densities and minimum oligomycin concentrations required to 
affect maximal metabolic response listed for each PDCL tested. 
 
 
3.4.2  Rates of glycolysis differ between subtypes in PDCLs 
 
Rates of both basal and maximal glycolysis were recorded according to the 
glycolytic stress test (Figure 3.7). This experiment functions by first recording 
background levels of ECAR while cells are cultured in full media lacking glucose 
and serum (Table 2.4). This then acts as a measurement of non-glycolytic ECAR, 
and when glucose is subsequently injected into cell-plates followed by a rise in 
ECAR, this background level of acidification can be subtracted from recorded ECAR 
values to provide a quantification of basal glycolysis. 
 
In order to measure glycolytic capacity, or maximal rates of glycolysis, oligomycin 
is subsequently injected into cells. This compound acts as an inhibitor of ATP 
Synthase (Symersky et al., 2012), rapidly reducing levels of OXPHOS and leading to 
an increase in ADP/ATP ratios (Slater and Welle, 1969), which in turn drives 
anaerobic metabolism in the form of glycolysis. 2-DG, a glucose analogue that is 
taken up by glucose transporters in cells (Hansen et al., 1995) but cannot be 
metabolised further, is lastly injected into cells, acting as an inhibitor of key 
glycolytic enzymes (Wick et al., 1957). ECAR levels are then expected to drop, 
with this final measurement acting as a secondary measure of non-glycolytic ECAR. 
 
PDCL TKCC-22 PaCaDD137 Mayo-5289 Mayo-4636 TKCC-18 TKCC-26 TKCC-10 TKCC-02 
Oligomycin 
Concentration 
1 µM 2.5 µM 2.5 µM 2.5 µM 1 µM 2.5 µM 1 µM 2.5 µM 
Cell Density 
(cells/well) 
2.2 x 104 2.5 x 104 3.5 x 104 1.5 x 104 2 x 104 1.85 x 104 1.75 x 104 1.3 x 104 
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Figure 3.7| Conducting glycolytic stress tests in PDCLs. Rates of basal and maximal glycolysis 
were determined in real-time via glycolytic stress test. Background, non-glycolytic acidification 
rates were measured in cells before addition of glucose. Basal rates of glycolysis (green) were 
subsequently obtained after injection of 10 mM glucose, with maximal rates, or glycolytic capacity, 
(red) next achieved via injection of a PDCL-dependent concentration of oligomycin. Finally, 50 mM 
2-DG was injected in order to suppress glycolysis, providing a secondary measure of background 
acidification rates. Data presented as mean, with error bars representing SD, n=5. 
 
The results of the glycolytic stress test determined that rates of basal glycolysis 
were significantly higher across all squamous PDCLs as compared to classical cells 
(Figure 3.8a) with a modest but significant, increase in maximal rates of glycolysis 
also observed in squamous PDCLs (Figure 3.8b). The greater increase in levels of 
basal glycolysis relative to maximal glycolysis in squamous PDCLs translated to 
lower rates of glycolytic reserve within this subtype (Figure 3.8c). This suggests 
that glycolysis within squamous PDCLs is, in general, operating at rates closer to 
maximum in the absence of a source of metabolic stress. These data collectively 
indicate a dependency on glycolysis and is suggestive of a potential sensitivity to 
therapeutic inhibition of this pathway (Issaq, Teicher and Monks, 2014). 
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3.4.3  Functional metabolic outputs validate subtype aligned-
glycolytic phenotypes 
 
In order to validate the findings determined via bioenergetic stress tests, 
additional colorimetric kits were implemented to directly quantify the 
consumption of glucose and production of lactate across PDCLs. Two assays were 
employed: 
 
1. Abcam glucose uptake assay: this assay functions as outlined in (Saito et al., 
2011). Briefly, cells are exposed to the previously described glucose 
analogue 2-DG, which is taken up by cells at rates equivalent to glucose 
(Hansen, Gulve and Holloszy, 1994). Upon uptake, 2-DG is phosphorylated by 
hexokinases within cells, generating 2-DG-6-phosphate which cannot be 
metabolised further. The resultant 2-DG-6-phosphate is then exposed to 
high concentrations of glucose-6-phosphate dehydrogenase, leading to 
oxidation and the concurrent generation of NADPH. This NADPH is then 
harnessed via a recycling amplification reaction alongside glutathione and 
DTNB, allowing for colorimetric detection (Ellman, 1959). The production of 
NADPH, and hence signal, is directly proportionate to 2-DG uptake. 
2. Abcam L-lactate assay: this assay functions similarly to the glucose uptake 
assay, with lactate dehydrogenase (LDH) utilised to convert L-lactate to 
pyruvate, producing NADH. NADH production is then quantified by exposure 
to tetrazolium salts, as in MTS/MTT assays, providing a colorimetric output 
which corresponds to starting quantities of lactate. As small quantities of 
LDH inherent to metabolically active cells are capable of influencing results, 
all samples were deproteinized using perchloric acid (Neuberg, Strauss and 
Lipkin, 1944) and subsequently neutralised using potassium hydroxide. 
 
Results from colorimetric assays validated the previous Seahorse experiments, and 
found that squamous cells consistently consume more glucose (Figure 3.9a) and 
subsequently produce more lactate (Figure 3.9b) than compared to classical 
PDCLs. Furthermore, the results of the glucose uptake assay account for the 
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latency between addition of 2-DG and cessation of glycolysis observed in classical 
PDCLs during the glycolytic stress test (Figure 3.7), with squamous cell-lines taking 
up 2-DG at quicker rates, resulting in a more immediate inhibition of glycolytic 
enzymes. 
 
Insulin has long been associated with stimulating the uptake of glucose (Park and 
Johnson, 1955; Levine and Goldstein, 1958). In order to quantify its possible 
influence as a supplement on the rate of glucose consumption, the glucose uptake 
assay was conducted in the presence and absence of insulin. Insulin was found to 
slightly increase glucose uptake, though not significantly, selectively in squamous 
cell-lines, but even in the absence of insulin, basal levels of glucose consumption 
were higher in all tested squamous PDCLs relative to classical. As such, insulin 
supplementation is not considered a likely contributor to described metabolic 
phenotypes. Though more data would be required to determine conclusively, the 
insulin-mediated increase in glycolysis associated with squamous PDCLs may be 
due to the secondary, noncatalytic function of the aldolase family of enzymes as 
modifiers of cell structure and endo/exocytosis (Volker and Knull, 1997; Merkulova 
et al., 2011). In this role, aldolases have been shown to act as a scaffolding 
protein for the insulin-responsive glucose transporter, GLUT4 (SLC2A4), facilitating 
insulin-driven exocytosis of GLUT4 (Kao et al., 1999). This interaction has been 
described as potential facilitator of a negative feedback system, wherein high 
levels of aldolase substrates, indicative of active glycolysis, inhibit the scaffolding 
function of aldolases and limit insulin-driven glucose transport. Within the context 
of the PDCLs, the more active aldolase isoform is associated with squamous PDCLs 
(Figure 3.4), which would allow this subtype to clear aldolase substrates quicker, 
liberating a greater proportion of aldolase to facilitate the translocation of GLUT4 
to the cell membrane, enhancing insulin sensitivity.  
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Figure 3.8| Distinct glycolytic signatures define PDCL subtypes. a Boxplot displaying rates of 
basal glycolysis determined via glycolytic stress test across PDCLs. Data is presented as Individual 
cell-lines (left) and cell-lines grouped according to subtype (right). Subtypes are indicated by 
colouring, with squamous PDCLs (blue) displaying significantly higher rates of glycolysis than 
classical (brown). b Boxplot showing rates of glycolytic reserve, or the difference between basal 
and maximal observed rates of glycolysis, as in (a). c Boxplots of glycolytic capacity, or rate of 
maximal glycolysis, as in (a). Data presented with boxes indicating 25th to 75th percentiles, with 
lines representing median values and whiskers showing minima and maxima, n=5. P-values were 
determined according to a Mann-Whitney U test. 
a 
b 
c 
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Figure 3.9| Validating PDCL metabolic signature. a Bar-plot showing rates of glucose consumption 
in individual PDCLs ordered according to subtype. Measurements were recorded with cells cultured 
in medium without insulin (blue) and with insulin (red). b Bar-plots showing lactate production 
across PDCLs, with data presented according as in figure 3.7. All experiments were performed in 
duplicate mean and presented as mean with error bars representing SD. P-values were determined 
according to a Mann-Whitney U test. 
a 
b 
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3.4.4  Rates of Fatty Acid Oxidation co-segregate with PDCL subtypes 
 
Basal and maximal Fatty acid oxidation (FAO) processes depend on the utilisation 
of both endogenous and exogenous fatty acids as fuel to drive the TCA cycle, and 
rates were determined in PDCLs using a modified version of the mitochondrial 
stress test (Figure 3.10), as described previously (Pike et al., 2011). 
 
 
Figure 3.10| Measuring rates of fatty acid oxidation in PDCLs. The FAO profile corresponding to 
the Mayo-4636 cell-line, representative of the classical subtype and selected for descriptive 
purposes. Basal exogenous FAO levels (time-point 6-18 mins, green box within cyan area) are 
measured by recording the natural rate of respiration in the absence of exogenous FAs (control, red 
curve) and then quantifying the increase in OCR recorded in the presence of the FA palmitate (dark 
red). Endogenous FAO (blue box) is similarly measured by quantifying the decrease in OCR induced 
by the drug Etomoxir (yellow curve), which prevents the metabolism of endogenous FAs. Maximal 
respiration (time-point 42-52 mins, red) is then calculated with the same conditions as basal rates 
after treating cells with the uncoupling agent FCCP, which drives oxidative respiration. Respiration 
is measured as the oxygen consumption rate (OCR) as normalised to total protein content of wells. 
Data presented as mean, with error bars representing SD, n=4. 
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Briefly, cells were cultured in glucose and glutamine-limited media (Table 2.4) for 
4 hours in advance of the assay in order to promote the metabolism of surplus 
endogenous FAs and to encourage uptake of exogenous FAs during the course of 
the experiment. Cells were treated with either DMSO (control), an exogenous 
source of FA (palmitate), or an inhibitor of FA uptake across the mitochondria 
(etomoxir), which prevents FAO entirely. Oxygen consumption was then measured 
in real-time across a range of treatments affecting metabolism, with an initial 
injection of oligomycin, preventing TCA cycle driven ATP synthesis, and providing a 
measurement of ATP production (statistics not shown as ATP synthesis aligned 
closely with basal respiration, indicating no differential proton leak between PDCL 
subtypes). FCCP, an uncoupling agent which uncouples ETC from ATP synthesis, is 
subsequently added into wells, facilitating the efflux of protons across the 
mitochondrial membrane, disrupting the proton gradient and generating heat 
energy that is lost instead of cellular energy captured in ATP production. This 
results in an upregulation of ETC to offset the flooding of protons back into the 
inner mitochondrial matrix, leading to the oxidation of all substrates available to 
the cell to fuel the TCA cycle, and allowing a measurement of maximal rates of 
respiration. Finally, antimycin A and rotenone are injected, both acting as 
inhibitors of ETC complexes, preventing all oxygen consumption linked to 
respiration, allowing for the resolution of background OCR. 
 
FAO assays revealed that the classical PDCLs use a significantly higher rate of 
exogenous FAs as a fuel source compared to squamous PDCLs (Figure 3.11a), 
though due to technical issues with their general growth properties and 
adherence, alongside additional washing steps necessary for this protocol, the 
squamous PDCL TKCC-02 were determined to be incompatible with this assay.  In 
contrast, endogenous FAs are preferentially utilised to fuel basal respiration in a 
selection of classical PDCLs as compared to squamous, but no significant 
association exists between subtype and endogenous FA usage at maximal levels, 
when cells are placed under metabolic stress (Figure 3.11b). This observed 
increase in FAO in classical PDCLs thus validates the previously described findings 
at the transcriptomic and proteomic levels, which had collectively suggested an   
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Figure 3.11| Rates of FAO differ across PDCL subtypes. a Boxplots showing the rates of fatty acid 
oxidation fuelled by exogenous fatty acids. Data is presented as in figure 3.7. Classical PDCLs 
(brown) exhibit significantly higher rates of both basal (top) and maximal (bottom) exogenous FAO 
than squamous (blue).  b Boxplots showing rates of FAO fuelled by endogenous fatty acids, as in 
(a). P-values were determined according to a Mann-Whitney U test. Data presented with boxes 
indicating 25th to 75th percentiles, with lines representing median values and whiskers showing 
minima and maxima, n=4. 
a 
b 
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upregulation of metabolic players involved in lipid and FA metabolism within this 
subtype. The increase in rates of exogenous FA supports the association between 
proteins involved in FA catabolism, such as acyl-CoA dehydrogenase 
short/branched chain (ACADSB), which oxidizes acyl-CoA derivatives as part of the 
FAO process (Rozen et al., 1994), malonyl-CoA decarboxylase (MLYCD), which 
mediates the degradation of malonyl-CoA to acetyl-CoA, thus preventing the 
inhibition of FAO associated with malonyl-CoA described in chapter 1.5.4 , and 
SLC27A3, a fatty acid transporter associated with FA uptake into cells (Maekawa et 
al., 2015), and the classical subtype. Additionally, the upregulation of genes 
involved in lipid biosynthesis in classical PDCLs may be linked to the increased 
rates of basal endogenous FAO in this subtype, as in the absence of metabolic 
stress, it is possible that a balance between catabolism and anabolism persists, as 
has been suggested in literature (Carracedo, Cantley and Pandolfi, 2013), 
described in greater detail in chapter 1.5.4 . As such, active FA synthesis within 
this subtype would produce FA stores which may be utilised to fuel FAO, reflected 
in increased rates of endogenous FAO. 
 
3.4.5  Metabolic flexibility is associated with classical PDCLs 
 
Emergence of resistance to therapeutic intervention is a common phenomenon in 
cancer (Holohan et al., 2013) mediated by a variety of mechanisms including the 
emergence of drug-target mutations conferring resistance via tumour evolution 
(Gorre et al., 2001; Pao et al., 2005) or the activation of redundant, compensatory 
pathways (Wheeler et al., 2008; Mao et al., 2013), and therefore requires careful 
consideration in a preclinical setting. Flexibility in metabolism has previously been 
shown to mitigate sensitivity to otherwise effective therapies over time, with 
imatinib resistance in chronic myeloid leukaemia having been linked to enhanced 
glycolysis (F. Zhao et al., 2010) and OXPHOS activation found to confer resistance 
to BRAF inhibition in melanoma (Haq et al., 2013). In the context of pancreatic 
cancer, in vitro models have demonstrated that upregulation of glucose uptake 
and glycolysis (Shukla et al., 2017; Zhao et al., 2017), as well as lipid synthesis 
(Tadros et al., 2017), may contribute to resistance to the standard of care 
therapeutic, gemcitabine. 
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Multiple research projects have also identified the potential of cancer cells to 
adapt to metabolic inhibition via various mechanisms, for example, inhibition of 
OXPHOS can be overcome across a range of cancer-types via upregulation of 
glycolysis (Zhong et al., 2015; Nagana Gowda et al., 2018). Similar phenomena 
have also been described within pancreatic cancer, with attempts to block 
glutamine dependency associated with PDAC (Son et al., 2013) in cell-line models 
found to induce concerted compensatory changes, including a metabolic shift to 
FAO, which facilitates resistance to inhibition (Biancur et al., 2017). Additionally, 
therapeutic inhibition of lactate dehydrogenase (LDH) in pancreatic cancer cells 
revealed an upregulation of OXPHOS via AMPK activation, conferring resistance to 
LDH inhibition (Boudreau et al., 2016). Given these findings, as well as the close 
association between molecular drivers of pancreatic cancer and metabolic 
reprogramming (Table 1.1), there is a clear potential of therapeutic resistance 
emerging as a result of metabolic flexibility in PDAC which must therefore be 
addressed (Kimmelman, 2015). 
 
In order to measure potential for metabolic flexibility within PDCLs, an assay 
designed according to the Mito Fuel Flex Test was conducted. This experiment 
allowed for the quantification of a cell-line’s dependency on the three major 
metabolites responsible for driving mitochondrial respiration: glucose, glutamine, 
and fatty acids. Dependency scores were calculated for each of the three 
metabolites via treatment with inhibitors of key players in their respective 
metabolism, such as: UK5099, an inhibitor of the mitochondrial pyruvate carrier 
(Hildyard et al., 2005) which prevents the utilisation of pyruvate, a primary 
product of glycolysis, to fuel OXPHOS; BPTES, a glutaminase inhibitor (Shukla et 
al., 2012), prevents the hydrolysis of glutamine, disrupting its introduction to the 
TCA cycle; etomoxir, an inhibitor of CPT1A (Kruszynska, Stanley and Sherratt, 
1987), as mentioned previously prevents the carnitine-dependent transfer of FAO 
intermediates into the mitochondria, inhibiting FAO. Capacity scores were 
subsequently calculated by employing combinations of these metabolic inhibitors, 
allowing a read-out of a cell’s ability to compensate for the loss of various fuel 
sources with one of the three metabolites of interest. Flexibility was then 
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calculated by subtracting dependency scores from capacity scores. This analysis 
revealed that metabolic flexibility existed only within PDCLs classified as classical 
(Figure 3.12), with low dependencies and high flexibility seen particularly within 
Mayo-5289. Some negligible flexibility in glutamine metabolism was observed 
within TKCC-10 (squamous), but in general, squamous PDCLs displayed no 
flexibility and greater dependency than classical cell-lines. 
 
 
Figure 3.12| Classical PDCLs display greater metabolic flexibility than squamous. Bar-plots 
showing metabolic dependency (dark grey) and flexibility (light grey) for glucose (a), glutamine (b) 
and fatty acids (c) across PDCLs representative of the squamous and classical subtypes. As can be 
seen, flexibility is observed only in classical cell-lines. Data are presented as mean, with error bars 
representing SD, n=5. 
 
a b 
c 
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3.5  KRAS and mitochondrial gene mutation status do not 
account for subtype-associated metabolic dysregulation 
 
As described in chapter 1.5.6 , KRAS mutation status has been implicated as a 
driver of glycolysis, with previous research additionally indicating an association 
exists between KRAS mutation copy number and metabolic reprogramming towards 
glycolytic activation (Kerr et al., 2016). Similarly, the presence of mutations in 
mitochondrial DNA suggestive of mitochondrial dysfunction have been found to 
contribute to a more glycolytic, less oxidative phenotype in a collection of TKCC 
pancreatic cancer cell-lines (Hardie et al., 2017). In order to assess this 
relationship within PDCLs, the mutation status of both KRAS and all genes 
expressed in PDCLs found within mitochondrial DNA, as determined by the Genome 
Reference Consortium Human (GRCh) genome, build 38 (Schneider et al., 2017), 
was overlaid onto subtype. This revealed that, although there did appear to be a 
slightly higher frequency in both mitochondrial and homozygous KRAS mutations in 
squamous PDCLs (Table 3.2), neither association was significant according to a chi-
squared test. These findings therefore suggest that neither mutant KRAS copy 
number, nor mitochondrial DNA mutation are major contributors to subtype-
associated metabolism, thus justifying an approach that prioritises focus on those 
distinct biological processes associated with the two subtypes. 
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Table 3.2| There is no apparent association between KRAS mutation copy number, 
mitochondrial mutations and PDCL subtype. Chart displaying mutation rates across KRAS and 
mitochondrial genes, with colouring to indicate nature of mutation. No significant association was 
found to exist between KRAS mutation status or mitochondrial mutation-load and subtype, 
according to chi-squared test. 
 
 
 
 
3.1  Association of KRAS amino acid substitution and 
subtype specification 
 
Though KRAS mutations most commonly affect codon 12 (Miglio et al., 2014), 
previous research has shown that the exact amino acid substituted for the glycine 
residue at this position may act as a prognostic factor in PDAC (Bournet et al., 
2016), while mutations at codon 61 have been linked to a favourable outcome in 
patients (Witkiewicz et al., 2015). As PDAC subtype is also a predictor of 
prognosis, it was decided to investigate any potential association between subtype 
and KRAS mutation type. As described in literature, most mutations within cell-
lines were found in codon 12 (Table 3.3), however there was no correlation found 
between subtype and any specific KRAS mutation.  
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Table 3.3| Within PDCLs, mutations in KRAS do not show association between codon specificity or residue change and subtype. Chart displaying 
mutations within KRAS in PDCLs, with mutations (red shading) categorised according to codon affected and amino acid substitution. PDCL subtypes are 
indicated by colour, with blue representing the squamous and brown representing classical subtypes. As can be seen, there is no association between the 
various KRAS mutations and subtypes. 
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3.2  Discussion 
 
This chapter aimed firstly to assess the relevance of PDCLs as an in vitro model of 
PDAC subtypes and secondly to identify vulnerabilities associated with subtypes via 
transcriptomic and proteomic analyses, with validation by functional assays. The 
first aim was achieved via analysis of RNA-seq data, which highlighted the 
conservation in co-ordinately expressed gene programmes between patients and 
cell-lines. Pathway analyses involving these gene programmes then revealed a 
dysregulation of genes involved in metabolism between the two identified in vitro 
subtypes, with both proteomics analysis and assays probing metabolic outputs 
pointing to an association between glycolysis and the squamous subtype, as well as 
FA synthesis and FAO with the classical subtype. This finding is particularly 
significant given that glycolysis, which is associated with the aggressive, squamous 
subtype, has been linked with a worse prognosis in PDAC (Baek et al., 2014; Xiang 
et al., 2018), echoed by previous findings that a poor prognosis glycolytic subtype 
exists in PDAC(Follia et al., 2019)  and that metabolic reprogramming has been 
long been described in PDAC, as described in chapter 1.5.6 . 
 
The results outlined within this chapter collectively point to the existence of 
distinct metabolic subtypes in PDCLs which correlate with subtypes previously 
described in pancreatic cancer patients (Bailey et al., 2016). This work therefore 
validates and expands on previous efforts to subtype pancreatic cancer via 
metabolite profiling, which demonstrated that cells subtyped into two divergent 
groups according to an alternative subtyping approach, as described in chapter 
1.4.1 (Collisson et al., 2011), exhibited distinct glycolytic and lipogenic 
dependencies (Daemen et al., 2015). This study demonstrated that cell-lines 
classed as quasi-mesenchymal, analogous to the squamous subtype described 
within this work (Collisson et al., 2019), displayed elevated levels of metabolites 
involved in glycolysis, such as glyceraldehyde-3-phosphate and lactate, while 
classical cell-lines exhibited upregulated long-chain FAs, such as oleic and 
palmitate. The findings described within this chapter therefore provide additional 
evidence for the existence of these subtypes, while suggesting the origins of such 
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are choreographed at the level of the transcriptome (Figure 3.1). Within PDCLs, 
initial analyses failed to narrow targets to a single driver accounting for the 
metabolic divergence observed between subtypes, although there is a clear and 
co-ordinately regulated shift in metabolic players at both the transcript and 
protein levels that aligns with subtype specification. Interrogating this metabolic 
dysregulation further therefore holds potential for identifying novel, subtype-
associated vulnerabilities.  
 
In order to facilitate the identification of novel therapeutic targets and maximise 
the possibility of identifying an effective treatment strategy, two separate 
approaches were taken at this point in the project (Figure 3.13). Firstly, 
transcriptome and proteome data were split by subtype and interrogated to 
highlight pathways that represent possible vulnerabilities, allowing for direct 
selection of key enzymes targetable through therapeutic modulation. This 
approach is supported by the previous successes of in vitro attempts to target both 
glycolysis (Maftouh et al., 2014; Anderson et al., 2017) and FA biosynthesis 
(Rajeshkumar et al., 2015; Ventura et al., 2015; Brandi et al., 2017), while 
differences in subtype vulnerabilities may provide further explanation for instances 
whereby cells exhibited resistance to these therapeutic interventions (Kamphorst 
et al., 2013; Boudreau et al., 2016). Secondly, high-throughput screening was 
performed to select a broader set of compounds that can be subsequently 
narrowed according to stratifications described within this chapter. This strategy 
allows the potential to select for inhibitors that indirectly modulate metabolic 
pathways associated with the subtypes, while drug repurposing allows the 
possibility for expediting prospective clinical tests (Bertolini, Sukhatme and 
Bouche, 2015; Würth et al., 2016). 
 
The following chapter describes the identification of pathways found to 
functionally contribute to subtype-specific phenotypes in in vitro models, allowing 
the identification of key players within these pathways that can be inhibited via 
clinically relevant compounds. The additional observation that these subtype-
associated pathways in cell-line models are reflective of dysregulation observed in 
patients reinforces the clinical potential of follow-up work to identify drug 
treatments following this approach. 
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Figure 3.13| Two concurrent approaches taken to identify novel therapeutics. Flowchart outlining approaches described as part of project to dissect 
metabolic dysregulation and identification of therapeutics. Research described in chapter 3 (blue boxes) revealed metabolic distinctions between 
subtypes, with later chapters designated to discuss the two arms to achieve the end goal of identifying compounds effective in treating pancreatic cancer 
in vitro. The first, to be described in chapter 4 (green boxes), focused on key players within metabolic processes identified as being subtype-associated, 
while the second, to be described in chapter 5 (orange boxes), relied on high-throughput screening to identify novel therapeutics that may induce 
sensitivity in cells via metabolic inhibition.
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Targeting Subtype-associated Metabolic 
Processes 
 
4.1  Introduction 
 
Evidence points to the existence of a variety of potentially targetable metabolic 
alterations across a range of cancer-types (Martinez-Outschoorn et al., 2017), as 
discussed in chapter 1.5 , with many pre-clinical research projects focused on 
exploiting these therapeutically, as described briefly in chapter 3.1 . In-line with 
these efforts, and guided by the distinct metabolic phenotypes identified within 
the PDCLs as described in the previous chapter, as defined by a dysregulation of 
metabolic players at the transcriptome and proteome levels, translating to 
differential activation of glycolysis and FA metabolism between subtypes, we 
sought to investigate potential individual targets within these pathways. As 
discussed in greater detail in chapter 1.5.1 , a major metabolic pathway long 
associated with oncogenesis is glycolysis, which is hyperactive in squamous PDCLs.  
Alongside this upregulation of glycolysis, aldolase isoform ration is skewed towards 
expression of ALDOA (Figure 3.4), a highly active form of this enzyme which is 
involved in early-stage glycolysis. As such, this presented an ideal potential target 
to modulate therapeutically and it was decided to assess the ability of ALDOA 
inhibition in suppression of squamous-associated glycolysis, alongside any impact in 
cell viability.  
 
Beyond inhibition of glycolysis, the potential of targeting fatty acid biosynthesis, 
another important metabolic process linked to cancer generation (Menendez and 
Lupu, 2007) and upregulated in classical PDCLs, was investigated. FA biosynthesis 
was targeted via inhibition of FASN, an enzyme necessary for lipogenesis and with 
previously described links to cancer progression, as discussed in chapter 1.5.2 . 
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Despite the potential of these approaches that target metabolism, as indicated by 
the dysregulation of various metabolic pathways between subtypes, it is expected 
that metabolic flexibility may prove a challenge when devising treatment 
strategies involving metabolic vulnerabilities. This is of particular concern as, 
beyond its identification in classical PDCLs (Figure 3.12), it has been described 
previously as a general feature of pancreatic cancer (Boudreau et al., 2016; 
Biancur et al., 2017). In order to account for any resistance to treatments 
potentially resulting from metabolic flexibility, compensatory activation of 
alternative metabolic pathways may be quantified on exposure to therapeutics. 
Should flexibility be identified within PDCLs, combinatorial approaches may be 
considered to suppress the upregulation of compensatory metabolism. 
 
4.2  Inhibiting squamous-associated glycolysis limits viability 
in PDCLs 
 
4.2.1  Identifying ALDOA as a potential target for inhibition of 
glycolysis in squamous subtype 
 
As described in chapter 3.2.2 , aldolase A (ALDOA) is the major functional isoform 
in a family of enzymes that catabolise one of the initial steps in glycolysis, and its 
expression is strongly associated with the squamous subtype. An siRNA screen 
conducted on a select number of PDCLs in the Institute of Cancer Research (ICR), 
London, showed that knockdown (KD) of ALDOA induced a significant  loss of 
viability across 5 out of 9 cell-lines tested (Figure 4.1). The majority of the PDCLs 
included in this screen were classified as squamous, a subtype found to display 
high levels of glycolysis (Figure 3.8), with only one classical PDCL, TKCC-22, 
included in siRNA screening, which may be considered an outlier relative to other 
classical PDCLs, exhibiting the highest levels of ALDOA expression amongst all 
PDCLs. The observation that many squamous PDCLs are sensitive to ALDOA KD, 
alongside the expression pattern of aldolase isoforms within PDCLs, suggests that 
the squamous subtype utilises the highly active ALDOA isoform (Chang et al., 2018) 
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to drive glycolysis and may be dependent on this for survival. This possibility was 
reinforced by previous research showing that the silencing of ALDOA inhibited 
glycolysis in two commercially available pancreatic cancer cell-lines and improved 
prognosis in vivo according to a xenograft model of breast cancer (Grandjean, de 
Jong, B. P. James, et al., 2016). The same body of work that described this 
research employed a drug repurposing screen, which identified TDZD-8, an 
inhibitor of GSK-3β (Martinez et al., 2002), to act as a small-molecule inhibitor of 
ALDOA. This inhibition was resolved to be likely due to interaction between TDZD-
8 and cysteine 289 of ALDOA, leading to conformational changes affecting the C-
terminal tail of the protein, a site that has long been recognised as a regulator of 
ALDOA activity (Gamblin et al., 1991), TDZD-8 was then found to mediate an anti-
cancer effect in the same mouse model and, based on these collective findings, 
TDZD-8 was selected to test as an inhibitor of squamous-associated glycolysis. 
  
 
Figure 4.1| ALDOA identified as possible target via siRNA-mediated KD. Barplot showing 
sensitivity of PDCLs to ALDOA KD, with cell-lines ordered according to sensitivity. As can be seen, a 
number of cell lines (5 out of 9) were found to be significantly sensitive. Significance was defined 
as a Z-score < -1.96, equivalent to p < 0.05, represented by the dashed, red line. 
 
In order to first validate ALDOA as a driver of glycolysis in squamous cells, the 
effect of TDZD-8 on glycolytic rates were assessed across PDCLs at a 4 hour time-
point, in line with previous publications (Grandjean, de Jong, B. P. James, et al., 
2016). This assay revealed that glycolysis was inhibited dramatically with TDZD-8 
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treatment, selectively in squamous PDCLs (Figure 4.2). This observation was dose-
dependent, with rates of glycolysis tending to 0% at higher concentrations of TDZD-
8, highlighting the importance of ALDOA in glucose metabolism. 
 
 
 
Figure 4.2| ALDOA inhibition selectively reduces rates of glycolysis in Squamous PDCLs. 
Scatter-plot showing inhibition of glycolysis, as determined via glycolytic stress test, in PDCLs after 
four hours treatment with TDZD-8, an inhibitor of ALDOA. As can be seen, inhibition of ALDOA leads 
to a reduction in glycolysis specifically in squamous cell-lines (blue), while classical PDCLs (brown) 
are largely unaffected. Glycolysis is presented as a percentage relative to glycolysis in DMSO-
treated control cells. Data presented as mean, with error bars representing SD, n=4. 
 
 
4.2.2  Inhibiting glycolysis via TDZD-8 treatment is effective in 
squamous PDCLs 
 
Upon determining that TDZD-8 inhibited glycolysis specifically in squamous cell-
lines, it was decided to assess the effect of the compound on cell viability. In 
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preparation for dose-response curve, it was first necessary to optimise 
concentrations and timeframes for testing. Firstly, it was found that TDZD-8 can 
maximally suppress glycolysis in a representative squamous cell-line within an hour 
after treatment, with high concentrations completely inhibiting glycolysis (Figure 
4.3a). Subsequent assays showed that lower concentrations require a longer 
treatment time, up to 72-hours, before a response is seen (Figure 4.3b). The 
observation that TDZD-8 can induce a response within this short timeframe 
suggests a direct mechanism of inhibition, supporting the likelihood that TDZD-8 
mediates its inhibition of glycolysis via on-target effects. Despite the rapid 
response, it was decided to allow 72 hours for dose-response curves, to maintain  
consistency with field standards. 
 
 
 
Figure 4.3| Determining optimal conditions for TDZD-8 treatment. a Curve showing rapid 
response of a squamous cell-line, TKCC-10, to 15 µM TDZD-8 treatment. Within an hour, glycolysis is 
almost completely inhibited. Data presented as mean, with error bars representing SD, n=8. b Box-
plot showing changes in glycolysis after treatment with 2 µM (blue) and 4 µM (dark blue) relative to 
DMSO control (cyan). At 24-hours, no response in glycolysis is apparent, but at 48- and 72-hour 
time-points, a clear and significant decrease is observed. Data presented with boxes indicating 25th 
to 75th percentiles, with lines representing median values and whiskers showing minima and 
maxima, n=6. 
 
a b 
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Efforts to assess the sensitivities of six cell-lines, three representative of the each 
subtype, to TDZD-8 at a 72-hour time-point determined that squamous cell-lines 
were more sensitive to TDZD-8 (Figure 4.4) (Holly Brunton, unpublished data), with 
lower observed IC50 values obtained for all squamous PDCLs tested. Reduction in 
viability in squamous cells was found to correspond closely with decreased rates of 
glycolysis, suggesting that abrogation of ALDOA-driven glycolysis may be 
responsible for inhibition of growth in these cells. These results were not wholly 
consistent with siRNA screening (Figure 4.1), with PDCLs displaying different 
sensitivities to ALDOA KD as compared to TDZD-8 treatment. This may indicate a 
lack of specificity of TDZD-8, though it would be necessary to validate results from 
high-throughput siRNA screening before any conclusions could be made. However, 
due to time limitations, this was not possible within this project. 
 
 
Figure 4.4| Squamous PDCLs are selectively sensitive to ALDOA inhibition. Dose-response curve 
showing impact of 72 hours TDZD-8 treatment on cell viability. As can be seen, squamous PDCLs 
(blue) were found to be considerably more sensitive than classical (brown) PDCLs. Cell viability was 
determined via MTS assay, with values presented adjusted according to readings obtained from 
DMSO controls. Data provided by Dr Holly Brunton (unpublished) and are presented as the mean of 
three biological replicates, with error bars representing SD.  
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Despite squamous cell-lines having been previously found to display no metabolic 
flexibility to fuel mitochondrial respiration (Figure 3.12), it was necessary to assess 
whether inhibition of glycolysis was maintainable over time, with no escape 
mechanism to overcome sensitivity as previously described in chapter 3.4.5 and 
commonly seen when targeting other metabolic vulnerabilities in pancreatic 
cancer (Ying et al., 2012; Son et al., 2013; Boudreau et al., 2016; Biancur et al., 
2017). As such resistance may arise in PDCLs upon ALDOA inhibition, glycolysis was 
recorded after 7 days of treatment with TDZD-8. Reduction in glycolysis was found 
to persist in the small population of cells still viable after a week of treatment 
without drug replenishment at IC50 concentrations (15 µM) in TKCC-26 (Figure 4.5), 
thus demonstrating that inhibition of glycolysis is sustainable in squamous cell-
lines. 
 
4.1  Inhibition of fatty acid metabolism in classical subtype 
reveals metabolic flexibility 
 
4.1.1  Inhibiting general oxidative phosphorylation in classical cells 
limits viability 
 
As described in chapter 1.5.4 , AMPK is a key regulator of cellular metabolic stress 
and is activated when cellular energy is depleted (Jeon, Chandel and Hay, 2012). 
Upon activation, AMPK phosphorylates and inactivates key anabolic enzymes, such 
as acetyl-CoA carboxylases (Buzzai et al., 2005), upregulates carnitine transporters 
(Zaugg et al., 2011), and facilitates lipolysis (Gauthier et al., 2008), leading to an 
initiation of FAO, while concurrently activating autophagy (Egan et al., 2011; Kim 
et al., 2011). Both processes allow for the recycling of a variety of cellular 
components and lipids, facilitating re-introduction into the TCA cycle, which in the 
context of cellular energetics would therefore promote OXPHOS. Within the PDCLs, 
it was demonstrated that phosphorylation of the functional, catalytic alpha subunit 
of AMPK is found to be associated PDCLs belonging to the classical subtype relative 
to squamous (Figure 4.6) (Holly Brunton, unpublished data). This observation,  
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Figure 4.5| Inhibition of glycolysis by TDZD-8 is sustained at extended time-points. Box-plot 
showing glycolysis rates after 7 days treatment with 15 µM TDZD-8 in TKCC-26, a cell-line 
representative of the squamous subtype. As can be seen, rates of glycolysis are decreased on 
treatment with TDZD-8, relative to DMSO control. Glycolysis was recorded via glycolytic stress test, 
and results are shown as percentage basal glycolysis, adjusted according to cell number, as 
determined via glycolytic stress test. Data presented with boxes indicating 25th to 75th percentiles, 
with lines representing median values and whiskers showing minima and maxima, n=8. 
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when considered alongside the role of AMPK as an activator of FAO, may in part 
explain the increased rates of FAO in classical cell-lines, and points to AMPK as a 
potential target to suppress classical-associated metabolic pathways.  
 
Compound C was selected to test as an inhibitor of AMPK in the PDCLs. This 
compound was initially identified by a high-throughput screen designed to identify 
AMPK inhibitors (Zhou et al., 2001), which demonstrated its action as a reversible 
competitor of ATP capable of reversing the effects of the AMPK activator AICAR 
(Sun, Connors and Yang, 2007). Compound C has been widely used as an inhibitor 
of AMPK in cancer (Vucicevic et al., 2011; Yang et al., 2012; Garulli et al., 2014).  
 
 
 
Figure 4.6| AMPK is activated in classical PDCLs. a Reverse-phase protein array (RPPA) results, 
showing greater levels of phosphorylated AMPKα in classical cell-lines (brown), as compared to 
squamous (blue). b Results of western blot validating levels of phospho-AMPKα in PDCLs. 
Unphosphorylated AMPKα is also included, and levels of both active and inactive forms are seen to 
be higher in classical PDCLs. Data provided by Dr Holly Brunton (unpublished). 
 
Dose-response curves demonstrated that classical PDCLs were more sensitive to 
treatment with compound C than squamous cell-lines (Figure 4.7) (Holly Brunton, 
unpublished data). Initial tests with compound C determined that rates of 
oxidative phosphorylation were decreased on treatment (Figure 4.8). This 
b a 
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observation was found only to be significant at maximal rates, under conditions of 
metabolic stress, which when taken into consideration alongside AMPK’s role in 
regulating metabolic stress response as well as its inherent activation in classical 
PDCLs, implicates its involvement in driving the stress response, and hence 
OXPHOS, in classical PDCLs. This is in-line with previous research which 
demonstrated that compound C acts as an inhibitor of AMPK-associated respiratory 
capacity in cardiac myocytes (Pfleger, He and Abdellatif, 2015). 
 
 
 
Figure 4.7| Classical cell-lines exhibit increased sensitivity to compound C. Dose-response curve 
showing response of PDCLs to 72 hours treatment of the AMPK inhibitor compound C. As can be 
seen, classical PDCLs (brown) were found to be more sensitive than squamous (blue). This result 
suggests that activated AMPK may be promoting the increased mitochondrial respiration associated 
with classical PDCLs, rendering this subtype sensitive to AMPK inhibition. Cell viability was 
determined via MTS assay, with values presented adjusted according to readings obtained from 
DMSO controls. Data provided by Dr Holly Brunton (unpublished) and are presented as the mean of 
three biological replicates, with error bars representing SD. 
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Figure 4.8| AMPK inhibition decreases rates of stress-induced oxidative phosphorylation in 
classical PDCLs. Bar-plots showing rates of OXPHOS in two PDCLs representative of the classical 
subtype after 96 hours treatment with AMPK inhibitor compound C. As can be seen, compound C 
significantly reduces OXPHOS at maximal levels, which are induced by stimulators of mitochondrial 
stress. This highlights AMPK’s role in activating metabolic stress in classical PDCLs. Both basal and 
maximal rates are shown. Data presented as mean, with error bars representing SD, n=8. 
 
As metabolic flexibility was determined to be a feature associated with the 
classical subtype, it was necessary to ensure that alternative sources of cellular 
energy production were not activated in response to loss in OXPHOS observed with 
compound C treatment. To this end, glycolytic stress tests were performed, which 
found glycolytic rates to decrease upon treatment with compound C (Figure 4.9), 
with rates of glycolysis dropping by 54% and 46% in TKCC-22 and Mayo-5289 
respectively. This result indicates that glycolysis is not activated as a response to 
OXPHOS suppression upon inhibition of AMPK. 
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Figure 4.9| AMPK inhibition decreases glycolysis in classical PDCLs. Box-plot showing rates of 
glycolysis in PDCLs representative of the classical subtype after 96 hours treatment with compound 
C. As can be seen, rates of glycolysis ten to decrease on treatment in a dose-dependent manner. 
This indicates that compensatory, glycolytic pathways are not activated upon inhibition of AMPK. 
Data presented with boxes indicating 25th to 75th percentiles, with lines representing median values 
and whiskers showing minima and maxima, n=6. 
 
 
4.1.2  Inhibiting fatty acid biosynthesis in classical PDCLs induces 
increased glycolysis 
 
FASN, a key enzyme in lipogenesis, has been implicated as a key driver pathologic 
lipid biosynthesis in tumour cells in multiple cancer-types (Chajès et al., 2006; 
Fiorentino et al., 2008). Consequently, efforts have been made to formulate  
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inhibitors of FASN in the treatment of cancer (Menendez and Lupu, 2007), with 
GSK2194069 an example of a potent and selective inhibitor of FASN identified 
specifically to this end (Hardwicke et al., 2014). Though FASN is involved in 
catalysing multiple reactions necessary in the generation of saturated FAs, 
GSK2194069 was found to act via inhibition of FASN’s β-ketoacyl reductase 
activity, similar to other previously described inhibitors (Vázquez et al., 2008). As 
an increase in genes and proteins involved in lipid biosynthesis, such as HMG-CoA 
reductase (HMGCR), a key enzyme in cholesterol biosynthesis, and acyl-CoA 
synthetase medium chain member 3 (ACSM3), a member of the acyl-CoA 
synthetases which regulate the balance between FA synthesis and FAO (Ellis, 
Bowman and Wolfgang, 2015), is associated with the classical subtype (Figure 3.3b 
and Figure 3.6) and previous work has indicated an increased dependence of 
classical PDCLs on FA biosynthesis (Daemen et al., 2015), we assessed the 
differential efficacy of GSK2194069 between PDCL subtypes. 
 
Firstly, it was necessary to validate that inhibition of FASN via GSK2194069 
treatment induced a cessation of lipid biosynthesis. To this end, lipid droplets, 
which act as units of storage for the end product of lipid synthesis (TAGs), were 
quantified in cells treated with GSK2194069. Results showed that lipid droplet 
count was drastically reduced upon inhibition of FASN (Figure 4.10), suggesting 
that FASN is necessary for the synthesis of fatty acids required to produce TAGs, 
and hence lipid droplets. These results therefore justified the use of GSK2194069 
as an inhibitor of lipid biosynthesis and provided evidence of on-target effects. 
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Figure 4.10| FASN inhibition reduces rates of 
triglyceride/lipid droplet production in classical 
PDCLs. a Representative images showing lipid droplets, 
fluorescently labelled with BODIPY 493/503 (green), in 
Mayo-5289. A clear reduction in lipid droplet number 
can be seen after treatment with GSK2194069 (bottom), 
an inhibitor of FASN, relative to DMSO control (top). 
Image acquired at 63X magnification. b Bar-plot showing 
total quantities of lipid droplets per counted nuclei in 
Mayo-5289 after treatment with GSK2194069. Data 
presented as mean across three biological replicates, 
with error bars representing SD. 
b 
a 
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Figure 4.11| GSK2194069-mediated FASN inhibition leads to increase in glycolysis in classical 
PDCLs. a Box-plot highlighting impact of 20 µM GSK2194069 on glycolysis in classical cell-lines. As 
can be seen, 72-hour treatment was not sufficient to yield a significant response in any PDCL, while 
96-hours elicited an increase in glycolysis in both Mayo-5289 and TKCC-22 cells. At 120-hours 
treatment, this response persists in TKCC-22, while it is lost in Mayo-5289. b Box-plot highlighting 
impact of 40 µM GSK2194069 on glycolysis in classical cell-lines. As with 20 µM, 72-hours was an 
insufficient time point to see a significant response, but at longer time-points, a response is seen 
across all PDCLs. At both concentrations, the effect on glycolysis within Mayo-5289 is alleviated at 
120-hours, suggesting that this cell-line may break the drug down quicker than the others. This set 
of experiments revealed that the optimal treatment time/dose to yield the greatest response in 
glycolysis across all classical cell-lines was 40 µM at 96-hours. Additionally, it was seen that 
inhibition of FASN induced a compensatory resistance mechanism in classical PDCLs. Data presented 
with boxes indicating 25th to 75th percentiles, with lines representing median values and whiskers 
showing minima and maxima, n=6. 
40 μM 
a 
b 
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Despite this impact on fatty acid biosynthesis, work performed by Holly Brunton 
showed no observable difference in impact on cell viability between subtypes upon 
GSK2194069 treatment. By quantifying rates in glycolysis after GSK2194069 
treatment over concentrations of 20-40 µM between 72-120 hours, it was 
subsequently determined that FASN inhibition increased glycolysis in three PDCLs 
representative of the classical subtype (Figure 4.11). This finding suggests that 
classical cell-lines may utilise previously described metabolic flexibility as 
mechanism to escape inhibition of FA biosynthesis; by targeting the stores of fatty 
acids required for FAO via inhibition of FASN, these cells can utilise glucose and 
glycolysis as an alternative source to generate required cellular energy. 
 
4.2  Modulating metabolic flexibility in classical subtype 
PDAC 
 
4.2.1  JQ1 treatment enhances subtype-associated metabolism in 
PDCLs 
 
The bromodomain and extra terminal domain (BET) family of proteins coordinate 
gene expression through the binding of acetylated histones and recruit 
transcription factors and other regulators of transcription (Belkina and Denis, 
2012). Due to their involvement in the regulation of genes involved in replication, 
including cyclin dependent kinases 6 and 9 (CDK6 and CDK9) (Dawson et al., 2011), 
as well as the BET family protein BRD4’s role in orchestrating mitotic transcription 
(Dey et al., 2009), these epigenetic readers have presented as attractive targets in 
cancer research (Dawson, Kouzarides and Huntly, 2012). In order to target this 
family therapeutically, an inhibitor, JQ1, was designed to competetively bind to 
acetyl-lysine binding cavities within this family of BET proteins, thus preventing 
their pattern recognition and hence, function (Filippakopoulos et al., 2010). JQ1 
has previously demonstrated anti-cancer potential, with research showing JQ1 
inhibits acinar-to-ductal metaplasia, which is an initial step in PDAC 
transformation, in explants from KRAS mutant mice (Mazur et al., 2015), while it 
has also been proposed as one of very few therapeutic approaches available to 
  
 
109 
target c-Myc (Delmore et al., 2011; Chen, Liu and Qing, 2018). Due to the role of 
c-Myc in metabolic reprogramming of pancreatic cancer discussed in chapter 1.5.6 
JQ1’s inhibition of c-Myc informs its potential as a modulator of metabolism, with 
previous research efforts demonstrating its ability to reverse c-Myc associated 
glycolysis in patient-derived xenograft models of pancreatic cancer (Sancho et al., 
2015). In addition to this, BRD4 has been shown to act as an inhibitor of 
autophagy, described in chapter 1.5.5 , with JQ1 disrupting this function and 
facilitating the AMPK-mediated stress response (Sakamaki et al., 2017), while JQ1 
has also been shown to act more generally to inhibit mitochondrial activity, 
leading to a deficit in ATP production and activation of mitochondrial stress 
respose via AMPK in leukemia and breast cancer cell-lines (Wang et al., 2015). 
Beyond this, JQ1 mediated inhibiton of BET-family proteins has also been shown to 
abrogate the transcription of a variety of genes associated with stroma-driven 
metabolism in pancreatic cancer cells, such as HMG-CoA reductase (HMGCR), a key 
driver of cholesterol biosynthesis, and glycine decarboxylase (GLDC) (Sherman et 
al., 2017). This collection of findings highlights the diverse effects JQ1 has been 
demonstrated to mediate on cancer cell metabolism, and as these metabolic 
pathways align with those found to be assoicated with PDAC subtypes in vitro, 
encompassing aerobic glycolysis and AMPK stress-response, it was decided to 
investigate effects of JQ1 on metabolism within PDCLs. 
 
Initial experiments were performed utilising the glycolytic stress test upon 
treatment of cells with JQ1, in order to assess the impact of BET inhibition on 
glycolytic profiles. Analysis revealed that JQ1 exposure enhanced the glycolytic 
characteristics indicative of subtype, with rates of glycolysis decreasing in classical 
PDCLs and increasing in squamous (Figure 4.12). These observed phenomena were 
particularly noticeable when considering basal rates of glycolysis in the classical 
subtype (Figure 4.12a), which when considered alongside current literature 
pointing to JQ1 as an activator of cellular stress response, suggests that JQ1 may 
promote AMPK activation in classical PDCLs, leading to a decrease in glycolysis and 
enhanced dependence on OXPHOS. This possibility is supported by the observation 
that phosphorylation of AMPK, as determined via western blotting, was selectively  
  
 
Figure 4.12| JQ1 treatment differentially affects glycolysis across subtypes. a Box-plot highlighting changes in rates of basal glycolysis induced by 
treatment with JQ1. As can be seen, glycolysis is universally, significantly decreased across all classical PDCLs after 3 days exposure, while squamous cell-
lines are largely unaffected. b Box-plot showing changes in maximal rates of glycolysis, with conditions as in a. Squamous cell-lines tend to exhibit an 
increase in glycolysis, in contrast to classical PDCLs. Taken together, these findings suggest that JQ1 drives cells towards a more extreme metabolic 
phenotype, reinforcing those traits in metabolism associated with subtype. Data presented with boxes indicating 25th to 75th percentiles, with lines 
representing median values and whiskers showing minima and maxima, n=4.
a b 
increased in classical PDCLs upon exposure to JQ1 (Figure 4.13). Western blotting 
in this instance showed inconsistencies with previous results, which indicated that 
Mayo-4636 has higher levels of phospho-AMPK than squamous PDCLs (Figure 4.6b). 
This may be due to passaging of Mayo-4636, a PDCL that has been demonstrated to 
incrementally shift from classical to squamous temporally, as determined via 
presence of HNF markers of the classical subtype (data not shown). As a higher 
passage of Mayo-4636 were used to generate Figure 4.13a, this PDCL may be more 
of an intermediate subtype than pure classical. 
 
As additional evidence, JQ1 increased rates of exogenous FAO in a cell-line 
representative of the classical subtype (Figure 4.14). However, maximal rates of 
glycolysis are less impacted by JQ1 in classical PDCLs (Figure 4.12b), suggesting 
that BET inhibition does not reduce the metabolic flexibility associated with this 
subtype (Figure 3.12). In squamous PDCLs, the reverse is seen, with rates of 
glycolysis increased after treatment with JQ1 (Figure 4.12), which may 
demonstrate an inability to modulate a stress response via AMPK in this subtype 
(Figure 4.6). 
 
4.2.2  JQ1’s effect on metabolism is mediated by increased 
lipogenesis and associated stress response 
 
As discussed in chapter 4.2.1 JQ1 acts as an inhibitor of BET proteins, which 
orchestrate transcriptional regulation via recruitment of transcription factors. Due 
to this role, it was decided to quantify the broad effect of JQ1 treatment on 
transcription in order to ascertain the mechanism by which BET inhibition mediates 
its effect on metabolism. To this end, RNA-seq was performed, with thanks, by 
Giuseppina Caligiuri and Peter Bailey on PDCLs representative of the subtypes after 
exposure to JQ1. Analysis of RNA-seq results revealed the upregulation of a 
number of genes whose protein products are involved in lipogenesis (Figure 4.15), 
including the acetyl-CoA carboxylases, described in chapter 1.5.2 , lipins 1 and 2 
(LPIN1/2), which catalyse one of the final steps in TAG synthesis. This upregulation 
of genes was particularly pronounced within the PDCL classified as classical. This 
was found to translate to a corresponding increase of protein abundances within 
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two of these gene targets that are integral to lipogenesis: FASN, described in 
chapters 1.5.2 and 4.1.2 , and ATP citrate lyase (ACLY), described briefly in 1.5.2 
and a mediator of the initial step of lipid and FA biosynthesis, the degradation of 
cytosolic citrate (Figure 4.16). 
 
 
 
 
 
 
Figure 4.13| JQ1 selectively activates mitochondrial stress in classical PDCLs. a Western blot 
showing levels of phospho-AMPK in PDCLs classed as classical (left, brown) as compared to 
squamous (right, blue). Mayo-5289 were run separately to the other PDCLs due to limitations in 
well number per gel. b Quantification of western blots shown in (a), normalised to DMSO control. 
 
a 
b 
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Figure 4.14| JQ1 reduces overall levels of mitochondrial respiration in classical PDCL, while 
increasing FAO rates. Bar-plots showing levels of oxidative phosphorylation, as determined via 
mitochondrial stress-test, in Mayo-4636, a classical PDCL, upon JQ1 treatment. As can be seen, 
basal levels of respiration decrease on JQ1 treatment, with 1 µM sufficient to induce a significant 
response. This observation is abrogated upon addition of palmitate, an exogenous fatty acid, which 
is reflected by the significant increase in FAO observed after JQ1 treatment. These results suggest 
that FAO may be upregulated as a response to the observed decrease of overall mitochondrial 
respiration induced by JQ1 treatment. Data presented as mean, with error bars representing SD, 
n=8. 
 
 
Figure 4.15| JQ1 treatment increases transcription of genes involved in lipogenesis. Schematic showing 
lipogenesis pathway. Log fold-change of genes involved in the pathway, as determined via RNA-seq, is shown 
alongside the position of their respective protein products, with significant results highlighted by golden 
borders. As can be seen, JQ1 induces an upregulation of expression across a range of genes whose protein 
products contribute to lipid biosynthesis. This observation is particularly true within the more classical PDCL 
(Mayo-4636) relative to the more squamous (TKCC-10). These transcriptional changes are hypothesised to 
increase shuttling of citrate from mitochondria to fuel anabolism, resulting in a decrease in ATP generated 
via OXPHOS (blue-shaded rectangle). In classical cells, this is likely to activate the stress-response regulator, 
AMPK, allowing for an increase in compensatory metabolic pathways, including autophagy, which allows for 
recycling of metabolites through the TCA cycle (Guo et al., 2016). 
 
In order to verify that this dysregulation and downstream modulation of protein 
levels affected changes on a functional level, rates of lipid biosynthesis were 
inferred via staining and quantification of lipid droplets, an organelle whose 
production is associated with late-stage lipogenesis (Figure 4.15), by BODIPY 
493/503 upon treatment with JQ1. This revealed an increase in lipid droplets in 
two PDCLs representative of the classical subtype (Mayo-5289 and Mayo-4636) and 
a squamous cell-line (TKCC-10) (Figure 4.17a). As it has previously been observed 
that induction of apoptosis often leads to an increase in lipid droplet abundance in 
vitro (Boren and Brindle, 2012), it was necessary to assess whether lipid droplet 
production associated with JQ1 treatment was due to increased lipogenesis 
resulting from transcriptional regulation, or apoptosis as a result of JQ1 exposure. 
Immunofluorescence of two markers of apoptosis, cleaved PARP and cleaved 
Caspase-3, indicated that apoptosis was not directly initiated by JQ1 treatment, 
with no significant induction of apoptosis observed in PDCLs representative of 
either classical or squamous subtypes (Figure 4.17b-c). 
 
Collectively, these results show that JQ1 treatment leads to an upregulation of 
genes involved in lipogenesis, resulting in increased FA biosynthesis and generation 
of stores of lipid droplets. While the observation of increased LD count on 
exposure to JQ1 is consistent with previous research (Zirath et al., 2013; Wang et 
al., 2015), this has been proposed to be a result of FA uptake to offset 
mitochondrial dysfunction rather than biosynthesis. This hypothesis makes sense in 
light of the AMPK activation associated with JQ1 treatment (Sakamaki et al., 
2017), which would be expected to inhibit anabolic process such as lipogenesis 
(Hardie and Pan, 2002), and is corroborated by the finding that KD of c-Myc, which 
is a target of JQ1, leads to downregulation of genes central lipogenesis, including 
FASN, ACLY and ACACA, each described in chapter 1.5.2 , in fibroblasts, alongside 
a concurrent increase in LD quantity (Edmunds et al., 2014). The observation that 
these genes involved in lipid biosynthesis are upregulated in PDCLs after JQ1 
treatment therefore represents a potentially novel mechanism by which 
lipogenesis is maintained in spite of the upregulated stress response, with 
increased FAO allowing for a recycling of cellular energy committed to lipid 
biosynthesis. 
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Figure 4.16| JQ1 treatment leads to increased levels of proteins involved in lipogenesis. a 
Western blot showing levels of ACLY and FASN, two enzymes necessary for lipid biosynthesis. Upon 
treating PDCLs with JQ1 for 96 hours. Subsequent quantification of the bands corresponding to 
ACLY (b) and FASN (c) highlighted their upregulation upon treatment with JQ1. As both proteins are 
involved in the process of FAS, it is expected that JQ1 acts as a promotor of FA biosynthesis. 
 
a 
b 
c 
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Figure 4.17| JQ1 increases rates of lipid biosynthesis across both PDCL subtypes. a Bar-plot 
displaying the ratio of lipid droplets to nuclei across a selection of PDCLs representing both 
subtypes after 4 days treatment with JQ1, with DMSO representing a vehicle control. Results are 
shown as percentage relative to DMSO control, displayed on a log scale. As can be seen, increases 
lipid droplet production is associated with JQ1 treatment in a dose-dependent manner. b Bar-plot 
showing the percentage of cells determined to be positive for cleaved PARP via 
immunofluorescence upon JQ1 treatment. As can be seen, no increase in cleaved PARP was 
observed in either PDCL. c Bar-plot showing percentage cells positive for cleaved Caspase-3, as in 
(b). A slight increase in cleaved Caspase-3 was observed in TKCC-10 (squamous) at high 
concentrations of JQ1, however, this result was not found to be significant. This shows no 
significant correlation between apoptosis and lipid droplet formation. All data presented as mean 
across three biological replicates, with error bars representing SD. 
a 
b c 
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4.2.3  JQ1 treatment enhances sensitivity to inhibitors of 
lipogenesis, highlighting potential as a combination treatment 
 
As JQ1 acts to enhance both FAO and lipid biosynthesis in classical PDCLs, it was 
decided to assess the efficacy of combining JQ1 with the FA synthesis inhibitor, 
GSK2194069. By adding JQ1, it was possible to limit the increase in rates of 
glycolysis previously observed with FASN inhibition via GSK2194069 in classical 
PDCLs (Figure 4.11), with JQ1 exposure negating any observable increase in 
glycolysis (Figure 4.18a). This effect is thought to be due to the ability of JQ1 to 
activate the metabolic stress responder, AMPK, along with the associated 
downregulation of aerobic glycolysis (Faubert et al., 2013) and upregulation of FAO 
(Hardie and Pan, 2002). Additionally, as JQ1 has been found to suppresses overall 
mitochondrial respiration (Zirath et al., 2013), which in PDCLs results in an 
increased dependence on FAO (Figure 4.14), concurrent inhibition of FASN likely 
decreases the store of FAs available to fuel FAO. As such, this combination therapy 
is associated with decreased cell viability in classical PDCLs (Figure 4.18b) (Holly 
Brunton, unpublished data).  
 
4.1  Discussion 
 
By selecting potential targets within the metabolic pathways found to be 
functionally upregulated within the subtypes of PDAC, an inhibitor of squamous-
associated glycolysis, TDZD-8, was identified with potential to induce selective 
sensitivity in PDCLs classed as squamous. These results therefore validated findings 
that demonstrated the role of ALDOA as an activator of glycolysis in pancreatic 
cancer cells (Grandjean, de Jong, B. James, et al., 2016) and siRNA screening 
conducted within PDCLs (Figure 4.1), confirming ALDOA as a target for squamous-
associated glycolysis. These findings also build on work that have demonstrated 
the efficacy of therapeutic interventions that target glycolysis in pancreatic 
cancer, such as LDH inhibition in pancreatic cancer cells cultured under hypoxia, 
and thus under conditions of induced anaerobic glycolysis (Le et al., 2010; Maftouh 
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et al., 2014). It also supports observations that pancreatic cells exhibit differential 
sensitivities to LDH inhibition, with resistance dependent on AMPK-mediated 
activation of OXPHOS (Boudreau et al., 2016) and wild-type TP53 (Rajeshkumar et 
al., 2015), which is of relevance as the sensitive squamous subtype is associated 
with mutant TP53 in patients (Bailey et al., 2016), although there is no significant 
association between subtype and TP53 mutation status in PDCLs. 
 
 
  
Figure 4.18| JQ1 treatment suppresses induced metabolic plasticity in classical PDCL and 
increases sensitivity to FASN inhibition. a Box-plot showing basal rates of glycolysis in TKCC-22 
after 7 days treatment with JQ1 and GSK2194069. As can be seen, in the absence of JQ1, FASN 
inhibition leads to increased glycolysis. This is suppressed upon addition of JQ1. Data presented 
with boxes indicating 25th to 75th percentiles, with lines representing median values and whiskers 
showing minima and maxima, n=8. b Bar-plot showing synergistic effects of GSK2194069 and JQ1 on 
cell viability, as determined vai MTS, in PDCLs representative of the classical subtype at 30 µM and 
1 µM respectively. Data for (b) provided by Dr Holly Brunton (unpublished). 
 
 
a b 
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One issue that would need to be addressed in future experiments involving TDZD-8 
as a selective inhibitor of ALDOA is its lack of specificity: although TDZD-8 has 
been shown to potently inhibit ALDOA, it was initially described as an inhibitor of 
glycogen synthase kinase 3-β (GSK3β) (Martinez et al., 2002), which phosphorylates 
and inactivates glycogen synthase. GSK3β is a known inhibitor of glucose 
homeostasis (Cline et al., 2002; Patel et al., 2008) and has been proposed as a 
therapeutic target in PC (Garcea et al., 2007). For these reasons, it cannot be 
concluded with certainty from this work whether the anti-cancer and anti-
glycolytic effects mediated by TDZD-8 in PDCLs are dependent on ALDOA or GSK3β 
inhibition, with the possibility of both targets contributing to loss in viability 
observed on treatment. In order to validate which therapeutic target of TDZD-8 
mediates its anti-glycolytic effects in squamous PDCLs, additional assays would be 
required. This could involve knock-down experiments, assessing the effects of KD 
of both targets on cell viability and glycolysis in comparison to TDZD-8 exposure; 
unfortunately, due to time constraints, this was not possible to complete as part of 
this project. 
 
However, the same approach was met with less success when attempting to inhibit 
FAO in the pure classical progenitor subtype, with the targeting of stores of FAs via 
inhibition of FASN insufficient to induce a similar subtype-selective sensitivity. It 
was thought that metabolic flexibility inherent to this subtype (Figure 3.12) may 
have contributed to this observed resistance, a hypothesis supported by the 
observation that oncogenic KRAS can facilitate metabolic reprogramming 
conferring resistance to inhibition of FA synthesis in vitro (Kamphorst et al., 2013), 
as well as the sensitivity of pure classical progenitor PDCLs to inhibition of AMPK, a 
regulator of metabolic flexibility in many cell-types (Faubert et al., 2015). 
Concurrent treatment with the metabolic modulator JQ1 allowed for a mitigation 
of this sensitivity. It’s thought that JQ1 treatment enhances sensitivity to FASN 
inhibition via an upregulation of lipogenesis, which is offset by a simultaneous 
increase in FAO as cells recycle energy committed to anabolic processes via the 
degradation of newly synthesised FA. By targeting FASN therapeutically, it is 
possible to prevent lipid biosynthesis proceeding to generation of long-chain FAs 
such as palmitate (Ventura et al., 2015), which are shuttled into the mitochondria 
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to fuel FAO (Qu et al., 2016). As such, a combination of JQ1 and FASN inhibition 
may result in a build-up of intermediate metabolites, such as cytosolic acetyl-CoA 
and malonyl-CoA, acting as an energy sink that cells are unable to efficiently 
recycle. Excess malonyl-CoA synthesised in this fashion would additionally serve to 
further promote lipogenic processes and inhibit FAO (Abu-Elheiga et al., 2001), 
thus exacerbating limitations in available energy. Further work may be performed 
to confirm this hypothesis; for example, experiments assessing histone acetylation 
after JQ1 treatment could be implemented to infer levels of cytoplasmic acetyl-
CoA generated via ACLY, as the two have been found to be correlated (Wellen et 
al., 2009; Lee et al., 2014). 
 
As is the case with TDZD-8 as an inhibitor of ALDOA, lack of specificity may affect 
the validity of some findings described within this chapter. Previous work has 
found compound C, like many general purpose kinase inhibitors, to be lacking in 
specificity (Bain et al., 2007), with an independent screen identifying a 
structurally identical compound they named Dorsomorphin, as an inhibitor of bone 
morphogenetic protein signalling (Yu et al., 2008). Due to this lack of specificity, 
compound C’s impact in inhibiting stress induced OXPHOS cannot be entirely 
ascribed with certainty to inhibition of AMPK. In order to further validate this, 
future work could include either AMPK knock-down or the testing of a second 
inhibitor, with one candidate being SBI-0206965. This compound was initially 
discovered as an inhibitor of ULK1 (Egan et al., 2015), but was subsequently found 
to have selective inhibitory activity against both AMPK and ULK1 (Dite et al., 
2018). However, this would not serve to completely address the issue of 
specificity, as this compound does target ULK1.  
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Chapter 5 High-Throughput Drug 
Screening Reveals potential of 
Statins in PC Treatment 
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5.1  Introduction 
 
De novo drug development is an intensive scientific procedure, requiring 
significant commitments of money, time and expertise to yield a product that can 
be considered for clinical use. Due to the restrictive nature of this kind of 
approach, there have been many studies in recent years aimed at assessing the 
efficacy of previously designed and publicly available compounds in a range of 
different cancer types via drug repurposing (Pollak, 2014; Würth et al., 2016). One 
example of such being the discovery that disulfiram, a therapeutic primarily and 
historically used to treat alcoholism (Chick et al., 1992), is effective in selectively 
inducing cell death in glioma cell-lines resistant to other lines of 
chemotherapeutics, identified via a drug repurposing screen (Triscott et al., 2012). 
This finding has been expanded on by multiple preclinical research projects (Liu et 
al., 2012; Lun et al., 2016), with phase II clinical trials initiated to test its efficacy 
in glioblastoma patients (Huang et al., 2018, 2019). 
 
Concurrent with work outlined in the previous chapter that sought to identify 
inhibitors of subtype-associated pathways, a high-throughput drug repurposing 
screen was conducted with selected PDCLs in collaboration with the Beatson 
Screening Facility. Cell viability was used as primary output from this project, 
though cell morphology data were also collected. This is of relevance as previous 
work has described the value in screening the impact of compounds on various 
adverse effects on cells beyond toxicity (Martin et al., 2014). However, analysis of 
morphology data is planned for the future and will be outwith the scope of this 
PhD project. 
 
Analysis of cell viability data resultant from drug repurposing screening 
determined that the statin family of therapeutics, originally designed to reduce 
cholesterol levels in patients, effectively reduced viability selectively in squamous 
PDCLs. This finding was in accordance with other preclinical research efforts that 
indicate that statins may exhibit anti-cancer potential. Efforts were then 
concentrated on elucidating the mechanism by which statin sensitivity was 
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mediated differentially between subtypes. This was performed with the end goal 
of identifying strategies allowing for enhancement of statin treatment by either 
overcoming mechanisms of resistance in classical PDCLs or synergising with 
mechanisms of sensitivity in squamous PDCLs. 
 
5.2  Identifying candidate metabolic targets via high-
throughput screening  
 
High-throughput screening within the Beatson Screening Facility was performed in 
a 384-well format, with cells seeded and drugs added 24 hours after seeding. 72 
hours after treating, cells were stained with DAPI and whole-cell stain and read on 
the Operetta (Figure 5.1a), with screening conducted to allow for two runs per 
week (Figure 5.1b). Screening in the Beatson Screening Facility consisted of a 
single round of primary screening involving multiple drug concentrations. 
 
5.2.1  Optimising PDCLs for High-Throughput Screening 
 
5.2.1.1 Selecting PDCLs for screening 
 
PDCLs were selected to best represent the diversity of a variety of features found 
across cell-lines (Table 5.1). This led to the inclusion of a range of PDCLs that can 
be characterised according to subtype as classical or squamous, with some PDCLs 
included representative of a less well defined, borderline phenotype. Additional 
subtyping metrics were assessed allowing for cell-lines to be considered in terms of 
structural variant features (Waddell, Pajic, A.-M. Patch, et al., 2015) and DNA-
damage response elements (Alexandrov et al., 2013), providing a quantification of 
nuclear stability. Metabolic profile was also considered, with a mixture of PDCLs 
displaying active glycolysis and oxidative phosphorylation, as described throughout 
chapter 3.4 , included in screening, though this expectedly correlated closely with 
the subtype grouping.
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Table 5.1| Selecting PDCLs for inclusion in screening project. Table showing characterization of PDCLs included in high-throughput screening. 
Characteristics pertaining to subtype, DNA-repair defects, and metabolism quantified across PDCLs, with cell-lines selected to represent the full spectrum 
of the set of PDCLs. The classical metric shows the collective expression of the classical-associated, turquoise gene programme. As no single gene 
programme is representative of the squamous subtype, the squamous metric shows the collective expression of genes determined to be upregulated in 
patients categorised as squamous. Subtype shows a categorical labelling summarising the classical and squamous measurements. Stability shows PDCLs 
subtyped according to structural variants, as in (Waddell, Pajic, A.-M. Patch, et al., 2015), while BRCA score describes the COSMIC BRCA mutational 
signature (signature 3), as in (Alexandrov et al., 2013). The metabolic metric shows which descriptor best reflects metabolic phenotype, with PDCLs 
described as glycolytic, high levels of aerobic glycolysis, or oxidative, high levels of oxidative phosphorylation.  
 
 
  
 
126 
5.2.1.2 DMSO and Staurosporine Concentration 
 
The primary endpoint of screening was percentage inhibition as determined via 
nuclear count. A variety of approaches can be implemented to identify significant 
hits, depending on the design of the assay, with Z-scores often employed for hit 
selection in post-screening analyses. This method depends on assigning Z-scores as 
determined relative to the standard deviation across a plate and assumes that  
 
 
 
 
 
Figure 5.1|Workflow of high-throughput screening with Beatson Screening Facility. a Schematic 
detailing high-throughput drug-screen, with details of drug libraries included and outputs of screen. 
b Scheduling of plates over the course of the screen, allowing for two runs per week. 
a 
b 
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most compounds will yield negative results (Malo et al., 2006). As the libraries 
included in this screen contain a large number of potent active compounds with 
known anti-cancer properties, as will be discussed in chapter 5.2.2.1, this method 
was not applicable, and as such, precise neutral and inhibitor controls were 
required to ascertain percentage inhibition. To this end, DMSO was utilised as a 
neutral control, while staurosporine, commonly used to initiate apoptosis in cells 
(Frankfurt and Krishan, 2001; Herrmann et al., 2007), acted as an inhibitor 
control. 
 
5.2.2  High-Throughput Screening of PDCLs 
 
5.2.2.1 Primary Screening 
 
Primary screening was carried out with a variety of drug libraries, with in-house 
screening in collaboration with the Beatson Screening Facility including two 
libraries of clinically approved and well characterised compounds: one consisting 
of 119 approved oncology drugs assembled by the Developmental Therapeutics 
Program (Institute National Cancer), as well as a larger set of 420 more general 
purpose, FDA approved compounds, distributed by Selleckchem (Table 2.1). Both 
these libraries were screened at four concentrations, ranging from 10 nM to 10 µM 
(Figure 5.1a). A smaller library of 35 epigenetic chemical probes, available from 
the structural genomics consortium (SGC) (Brown and Müller, 2015), was 
additionally included in this screen. Two rounds of screening were performed each 
week, allowing 24 hours for cells to attach and 72 hours for drug treatments 
(Figure 5.1b). 
 
In anticipation of the in-house screening project, an extensive list of targets was 
generated for the compounds within the two large drug libraries. This was 
achieved by incorporating data downloaded in the XML format, with subsequent 
formatting, from the DrugBank database (Wishart et al., 2018). This data provided 
annotations for targets alongside each drug, as well as associated gene targets, 
which informed later pathway analyses. 
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5.2.3  Analysis of Results from In-house Screening 
 
Results were processed by the Beatson Screening Facility, with cell loss of viability 
(LOV) quantified via nuclear count acting as the primary output. Morphological 
data was also generated via whole-cell staining, although this was treated as a 
secondary output with results planned for more detailed analysis at a later time-
point by the Beatson Screening Facility. 
 
In order to first identify compounds acting selectively in one subtype relative to 
the other, compounds were scored according to mean LOV difference between 
PDCLs classed as extremely squamous (TKCC-02, TKCC-10) and extremely classical 
(TKCC-22, PaCaDD137) (Table 5.2). One primary observation made while analysing 
results from drug-screening was the subtype-selective response of PDCLs to 
treatment with a number of compounds that target elements within the DNA-
damage response (DDR) and DNA replication, including irinotecan and etoposide, 
which inhibit topoisomerases and affect DNA structure through facilitating strand 
breaks in DNA (Champoux, 2001; Wood et al., 2015), and fluorouracil, which 
inhibits thymidine synthesis, leading to an imbalance of deoxynucleotides and DNA 
damage (Yoshioka et al., 1987; Longley, Harkin and Johnston, 2003). This 
squamous-associated effect was most apparent in the drug bleomycin, an inhibitor 
of DNA ligase, likely through DNA binding (Ono et al., 1976), which is commonly 
used as part of the chemotherapeutic regimen to treat testicular cancer (Einhorn 
and Williams, 1980) and functions to kill cells via induction of single- and double-
stranded breaks in DNA (Tounekti et al., 2001). Though these responses were 
subtype selective, with squamous PDCLs exhibiting greater sensitivities than 
classical PDCLs, nuclear stability phenotypes (as specified in Table 5.1) were not 
predictive of sensitivities to these DDR modulating agents, with TKCC-10, TKCC-02 
and TKCC-22 all classified as unstable (Waddell, Pajic, A. M. Patch, et al., 2015), 
exhibiting high BRCA scores (Alexandrov et al., 2013). As work involving DNA 
damage initiating agents was the research focus of others within the group, it was 
decided to investigate alternative hits. 
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Beyond compounds with known targets in the DDR pathway, two statins were found 
to induce loss of viability in a distinctly subtype selective fashion, specifically 
effecting a response in squamous PDCLs: pitavastatin and fluvastatin. This finding 
was of particular note as these two therapeutics have never been tested in clinical 
trials involving pancreatic cancer, according to the Aggregate Analysis of 
ClinicalTrials.gov (AACT) database (Clinical Trials Transformation Initiative), thus 
indicating the clinical novelty of such a therapeutic strategy in the context of 
PDAC. The statin family of therapeutics were originally designed to manage 
hypercholesteremia via competitive inhibition of HMGCR and have historically been 
successfully employed to reduce LDL cholesterol in patients (Baigent et al., 2005; 
LaRosa et al., 2005). Within the context of cancer, multiple research projects have 
highlighted the statins family’s ability to induce cell death across a range of 
 
Table 5.2| Identifying subtype-selective, metabolically active compounds. Table showing those 
compounds included in drug screening with significantly different responses between squamous and 
classical subtype PDCLs at 1 or 10 µM. Compounds were ordered according to absolute mean 
difference in percentage loss of viability (LOV) between the two subtypes (red/green shading), 
taken as a mean of 1 and 10 µM, with only compounds with mean LOV > 25% shown. Positive scores 
(red) indicate greater sensitivity in squamous cell-lines, while negative scores (green) indicate 
classical sensitivity. Selected gene product targets are shown to the right in blue, with genes 
grouped according to target proteins/pathways. As can be seen, two statins, pitavastatin and 
fluvastatin, were found to induce a highly subtype-selective response. The number of clinical trials 
relating to pancreatic cancer each compound was involved in is shown on the right. 
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cancer-types in vitro (Dimitroulakos et al., 1999, 2002; Mueck, Seeger and 
Wallwiener, 2003; Seeger, Wallwiener and Mueck, 2003), including in models of 
pancreatic cancer (Gbelcová et al., 2008; Fendrich et al., 2013), with the finding 
that PC cells are dependent on cholesterol uptake (Guillaumond et al., 2015) 
providing additional rationale for targeting cholesterol synthesis in PDAC. 
 
Despite these observations, clinical efforts to treat pancreatic cancer with statins 
has been met with mixed results: while some retrospective analyses of clinical 
trials have shown statin exposure to positively influence survival (Lee et al., 2016; 
Moon et al., 2016), randomised prospective trials indicate that addition of statin to 
standard of care treatment alone is not sufficient to benefit pancreatic cancer 
patients (Hong et al., 2014). To further complicate statins’ ability to treat 
pancreatic cancer, a meta-analysis found that cholesterol intake was correlated 
with an increased incidence of pancreatic cancer (Chen et al., 2015), while more 
recent analysis has cast some doubt on this, indicating that patient LDL levels do 
not account for the relationship between statin exposure and survival (Huang et 
al., 2017); however, there is insufficient clinical data to draw any firm conclusion 
from this study (Liu et al., 2017). Recently, various preclinical research projects 
investigating the repurposing of statins for use in cancer management have 
focused on the observation that the anti-cancer effects associated with this family 
of therapeutics are observed in sub-populations of cell-lines (Clendening et al., 
2010; Goard et al., 2014; Warita et al., 2014). As these findings align with the 
results from screening, it was decided to pursue statins as a hit, with the potential 
to explore the mechanism of subtype-specific sensitivity. 
  
5.2.4  Validating statins as major hit from screening 
 
In order to ensure definitively that those statins identified via screening affected 
PDCLs in a subtype-selective manner, dose-response curves were generated to 
include supplementary PDCLs that best represent the two subtypes. As pitavastatin 
elicited a more potent response than fluvastatin (Table 5.2), this therapeutic was 
selected for further testing. Dose-response curves assessing pitavastatin’s efficacy 
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validated the findings of high-throughput screening, highlighting the increased 
levels of sensitivity to statins within squamous PDCLs (Figure 5.2). As further 
validation, siRNA mediated KD of HMG-CoA Reductase (HMGCR), the primary target 
of pitavastatin, was shown to activate apoptosis, as determined via PARP cleavage, 
a commonly used marker of apoptosis (Boulares et al., 1999; Soldani and Scovassi, 
2002), as similarly observed on pitavastatin treatment in TKCC-02, the cell-line 
most sensitive to statin treatment (Figure 5.3). 
 
 
 
 
  
 
Figure 5.2| Pitavastatin selectively inhibits squamous subtype PDCLs. a Dose-response curve 
showing effect of pitavastatin on PDCLs during high-throughput drug screening. Curves are coloured 
according to subtype, with squamous cell-lines (blue) displaying higher sensitivity than classical 
(yellow/brown). b Barplot showing the differences in IC50 of pitavastatin between PDCLs of classical 
(yellow) vs squamous (blue) subtypes. Results were obtained for an extended set of cell-lines which 
validated results generated via high-throughput screening.  
a b 
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Figure 5.3| Inhibition of HMGCR activity induces apoptosis in squamous PDCLs. Western blot 
showing induction of PARP cleavage on siRNA mediated silencing of HMGCR (left) and inhibition of 
HMGCR via pitavastatin treatment. As can be seen, HMGCR KD leads to a reduction in protein 
abundance, while both HMGCR KD and pitavastatin induce apoptosis, as denoted by PARP cleavage. 
 
5.3  Cholesterol synthesis and HMGCR degradation 
potentially contribute to statin resistance in classical 
PDCLs 
 
5.3.1  Quantifying anabolic processes reveals differences in 
cholesterol biosynthesis between subtypes 
 
In order to assess whether rates of cholesterol biosynthesis align with differential 
sensitivities observed in statin sensitivity described above (Figure 5.2), cholesterol 
biosynthesis rates were quantified via isotope labelling. This process involves 
feeding cells with 13C-labelled glucose and glutamine for 72 hours before 
metabolites are extracted and quantified via liquid or gas chromatography 
followed by mass-spectrophotometry. Both glucose and glutamine are taken up and 
catabolised to restore pools of cellular acetyl-CoA, an intermediate metabolite 
necessary for the synthesis of a range of biomolecules including fatty acids and 
sterols. By quantifying isotope ratios of metabolites downstream of acetyl-CoA in 
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this fashion, it’s possible to quantitively differentiate between newly synthesised 
and imported metabolites. 
 
As suggested by previous RNA-seq data, classical cell-lines display higher rates of 
cholesterol biosynthesis (Figure 5.4a-b), with a greater proportion of cholesterol 
labelled with 13C to unlabelled than squamous PDCLs. While the correlation 
between statin sensitivity and rates of cholesterol biosynthesis appears to be a 
novel finding in preclinical cancer research, work in breast cancer cells have 
shown that increased expression of genes involved in cholesterol synthesis 
corresponds to an enhanced resistance to treatment with atorvastatin (Kimbung et 
al., 2016). These results align with findings that protein products involved in  
 
 
Figure 5.4| Rates of cholesterol biosynthesis differ between subtypes. a Bar-plot showing 
distribution of cholesterol isotope labelling within PDCLs representative of the classical subtype. Up 
to 27 atoms of 13C may be incorporated into a single molecule of cholesterol, with partially labelled 
molecules containing 12 or more 13C atoms also resultant from de novo synthesis. b Bar-plots 
showing cholesterol synthesis in squamous PDCLs, as in (a). c Bar-plot showing ratios of synthesised 
cholesterol relative to unlabelled cholesterol taken-up by cells directly from media. As can be 
seen, rates of cholesterol synthesis are increased in classical PDCLs, with nearly no synthesis 
detected in the squamous TKCC-10 or TKCC-02 cell-lines. 
a 
b 
c 
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cholesterol biosynthesis, including HMGCR, are upregulated in classical PDCLs 
(Figure 3.6). Sample preparation and mass-spectrometry was performed with 
thanks by Grace McGregor. 
 
5.3.2  HMGCR degradation is found to be dysregulated between 
subtypes 
 
In order to understand the difference in sensitivity to statins observed between 
subtypes, it was firstly necessary to consider the protein target of the statin family 
of therapeutics, HMGCR. HMGCR is an endoplasmic reticulum (ER)-bound enzyme 
integral to the biosynthesis of cholesterol (Stevenson, Huang and Olzmann, 2016), 
functioning to convert HMG-CoA to mevalonate, a precursor to synthesised sterols. 
Western blots were conducted initially to test for differences between protein 
abundances, however this revealed a putative cleavage band that appeared 
specifically within the resistant, classical PDCLs (Figure 5.5a). This observed band 
suggests upregulated degradation within this subpopulation of cell-lines, which is 
of particular interest due to previous work that identified cleavage of HMGCR in 
response to downstream products of the mevalonate pathway, suggestive of a 
negative feedback loop (Inoue et al., 1991; Sever, Song, Yabe, Joseph L Goldstein, 
et al., 2003; DeBose-Boyd, 2008). One paper in particular points to degradation 
induced by a cysteine-protease, resulting in cleavage along a membrane-spanning 
domain of the protein existing between residues 314-340 (Moriyama et al., 1998). 
This sterol-dependent cleavage mirrors the ER-associated degradation of HMGCR, 
which is initiated via Insig-mediated ubiquitination of HMGCR’s transmembrane 
region (Sever, Song, Yabe, Joseph L. Goldstein, et al., 2003; Hartman et al., 
2010), though is induced independent of the proteasome and would likely mediate 
inactivation of HMGCR similarly via displacement from the ER. This event results in 
the generation of two cleavage products, one lighter (36 kDa) consisting of 
membrane-spanning domains, and another heavier (61 kDa) consisting of the 
catalytic domain. The observation of a putative cleavage product with the 
molecular weight of ~60 kDa is therefore in-line with these findings, as the 
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antibody used (ab174830, Abcam) was generated against an immunogen spanning 
400-500 aa residues (Figure 5.5b).  
 
Of additional note, no SNPs were found to occur within the HMGCR gene across all 
PDCLs included in analysis, ruling out the possibility of the band existing due to 
heterozygous mutation resulting in a truncated protein. This finding is of 
additional relevance as previous research has identified a genetic variation within 
the HMGCR gene that confers resistance to statins in colorectal cancer cells (Lipkin 
et al., 2010) and has been confirmed within a range of in vitro systems (Medina et 
al., 2008). This class of SNP is found within exon 13 in the catalytic region, 
encoding the statin-binding domain and is therefore distinct from the pattern of 
cleavage observed here. 
 
5.3.1  Proteasomal inhibition partially inhibits HMGCR cleavage in 
vitro 
 
To validate whether this observed band corresponds to HMGCR degradation, it was 
decided to assess the effect, if any, of protease inhibitors on band formation. 
ALLN, an inhibitor of cysteine-proteases including cathepsins and calpains (Sasaki 
et al., 1990), which are associated with lysosomal and non-lysosomal protein 
degradation respectively (Chondrogianni, Fragoulis and Gonos, 2002), was first 
tested to assess whether inhibition of proteasomal protein degradation prevented 
the generation of this cleavage band (Figure 5.6a). Treatment with 25 µM ALLN 
was seen to lead to an increase of overall HMGCR abundance, both intact protein 
and putative cleavage product (Figure 5.6b). This observation may be due to the 
inhibition of degradation of activated SREBP, an ER-localised transcriptomic 
activator of lipogenesis and promoter of HMGCR expression (Wang et al., 1994), 
resulting in increased transcription and translation of HMGCR. Despite this general 
increase in protein levels of both bands, the shift in abundance of the putative 
cleavage band was observed to be slightly less relative to full-length HMGCR, 
suggesting that inhibition of cysteine-proteases may mitigate degradation as 
previously documented (Moriyama et al., 1998), and that this band genuinely   
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Figure 5.5| HMGCR is potentially selectively cleaved in classical PDCLs. a Western blot showing 
the differential cleavage of HMGCR between PDCL subtypes. As can be seen, intact HMGCR was 
detected in all PDCLs tested, however, the putative cleavage product was found selectively in the 
three classical cell-lines (left, yellow) and was absent in squamous (right, blue). Labels for 
detected bands are shown to the right, alongside predicted molecular weights. Actin is shown as a 
loading control. b Schematic showing structure of the HMGCR protein. The cleavage site previously 
described (Moriyama et al., 1998) is highlighted, along with the region against which the antibody 
used in (a) was manufactured. 
 
a 
b 
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corresponds to HMGCR degradation. The partial inhibitory effect observed may be 
due to additional proteasomal mechanisms also contributing to HMGCR 
degradation, which is supported by evidence that HMGCR is also ubiquitinated and 
targeted for proteasomal degradation (Sever, Song, Yabe, Joseph L Goldstein, et 
al., 2003). 
 
5.3.2  Mevalonate induces negligible levels of cleavage of HMGCR in 
vitro 
 
As described in the previous section, it has been long established that downstream 
metabolites within the mevalonate pathway contribute to the degradation of 
HMGCR. Both sterol and non-sterol intermediates induce this degradation, 
including mevalonate itself (Roitelman and Simoni, 1992; Ravid et al., 2000). In 
order to determine the effect, if any, mevalonate has on the cleavage product 
observed in a representative classical PDCL, Mayo-5289 were supplemented with 
mevalonate 5-phosphate at a range of concentrations for 24 hours. Western 
blotting was then performed in order to quantify changes in the abundance of 
intact HMGCR and the putative cleavage product (Figure 5.7a). This determined an 
slight, incremental increase in HMCGR degradation, with increased abundances 
observed in both full-length and cleaved HMGCR. While the increase in intact 
HMGCR is unexpected, though potentially accounted for by compensatory 
fluctuations in levels of downstream metabolites which may occur within the 24-
hour time frame of the experiment, this increase is offset by the comparatively 
larger increase in abundance of the ~60 kDa cleavage band. 
 
This observed increase in the putative cleavage band of HMGCR upon exposure to 
mevalonate, though slight, reinforces the likelihood of this being a true indicator 
of degradation. If so, this suggests that internal levels of the metabolites within 
the mevalonate pathway may be increased within classical PDCLs, thus inducing 
the increased levels of HMGCR cleavage associated with this subtype. Additionally, 
the higher rates of cholesterol synthesis found in this subtype (Figure 5.4) may be 
a contributor to this phenomenon. Though speculative, it’s possible that increased  
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Figure 5.6| Treatment with protease inhibitor ALLN moderately inhibits HMGCR cleavage in 
vitro. a Western blot showing HMGCR levels in response to 25 µM ALLN treatment in Mayo-5289 
across a range of time-points. As can be seen, ALLN treatment does appear to increase the 
presence of cleaved HMGCR, however this is observed alongside in increase of intact HMGCR, 
indicating that cleavage is not enhanced in the presence of mevalonate. b Quantification of 
western blot results shown in (a), normalised to loading control (GAPDH). 
 
a 
b 
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Figure 5.7| Mevalonate exposure induces some HMGCR cleavage in vitro. a Western blot 
showing HMGCR levels in representative classical PDCL, Mayo-5289, exposed to increasing 
concentrations of mevalonate for 24 hours. As can be seen, exposure to high concentrations of 
mevalonate does appear to increase the presence of cleaved HMGCR, however this is observed 
alongside an increase of intact HMGCR. b Quantification of western blot results shown in (a), 
normalised to loading control (GAPDH). Results show that, although levels of both intact and 
cleaved forms of HMGCR increase upon mevalonate treatment, slightly more cleaved HMGCR is 
generated than whole, suggesting a slight increase in HMGCR degradation at higher mevalonate 
concentration. 
a 
b 
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levels of downstream metabolites in classical PDCLs induces cleavage of HMGCR, 
the effect of which is offset due to higher levels of HMGCR translation (as 
transcription is not significantly upregulated in either subtype), leading to roughly 
equivalent abundances of intact HMGCR across subtypes. This high level of 
turnover may allow classical PDCLs escape statin treatment, with pitavastatin 
unable to induce its inhibitory effect, allowing this subtype to overcome the 
sensitivity observed in squamous PDCLs. Due to time limitations, it was not 
possible to assess the impact of pitavastatin on rates of cholesterol synthesis via 
stable isotope tracing, which would be required to confirm this hypothesis. 
 
5.4  Cholesterol localisation and lipid raft formation are 
indicators of statin sensitivity 
 
5.4.1  Caveolin-1, a regulator of cholesterol homeostasis, is found 
selectively in squamous PDCLs 
 
Beyond the potential of statin resistance being modulated by differential 
degradation of HMGCR, it was decided to investigate additional regulators of the 
mevalonate pathway to identify other possible contributors to subtype-associated 
statin sensitivity. By interrogating transcriptomic and proteomic data for proteins 
involved in the regulation of cellular cholesterol, it was determined that Caveolin-
1 (CAV1) is selectively found in squamous PDCLS, which was validated by western 
blot (Figure 5.8). CAV1 is a cholesterol binding scaffolding protein (Murata et al., 
1995) and an integral constituent of caveolae (Rothberg et al., 1992), specialised 
lipid rafts found within cell membranes and enriched for cholesterol. CAV1 is 
necessary for the formation of caveolae (Drab et al., 2001) and its ectopic 
expression is also sufficient to lead to caveolae formation in CAV1 deficient cell-
lines (Fra et al., 1995). 
 
The absence of CAV1 in classical PDCLs may provide an insight into the mechanism 
of resistance to pitavastatin associated with this subtype as research has described  
  
 
141 
  
Figure 5.8| CAV1 protein and mRNA is upregulated in the statin-sensitive, squamous subtype. a 
Western blot highlighting dysregulation of CAV1 at the protein level (top) in PDCLs ordered 
according to subtype and bar-plot showing similar expression of CAV1 according to RNA-seq 
(bottom). b Box-plot showing expression of CAV1 in PDCLs grouped according to subtype. P-values 
were determined according to a Mann-Whitney U test. 
a 
b 
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CAV1 as a regulator of cholesterol efflux (Frank et al., 2001; Fu et al., 2004) and 
cholesterol as an instigator of caveolin trafficking (Pol et al., 2005). This complex 
interplay between localisation CAV1 and cholesterol homeostasis, though not 
completely elucidated, may modulate sensitivity due to the dependence of 
squamous PDCLs on caveolae and downstream signalling pathways (Anderson, 1998) 
or the inability of classical PDCLs to export and sequester cholesterol, driving the 
ER-localised HMGCR degradation previously described (Figure 5.6 and Figure 5.7). 
This possibility of CAV1 mediating sensitivity to pitavastatin is in-line with the 
finding that increased levels of caveolae are indicative of increased sensitivity to 
cholesterol depletion (Li et al., 2006). 
 
5.4.2  Cholesterol localisation differs between subtypes in vitro 
 
To assess the possible correlation between the absence/presence of CAV1 within 
PDCLs on cholesterol localisation, filipin III was used to stain and visualise 
cholesterol in cells representative of both subtypes. Typical imaging via confocal 
microscopy requires a permeabilization step to allow the passage of fluorophores 
across the plasma membrane, allowing for internalisation of staining materials and 
visualisation. However, detergents commonly used to permeabilise mammalian 
cells, such as Triton X-100 and saponin, function via the disruption or removal of 
cholesterol at the cell membrane (Ingelmo-Torres et al., 2009; Böttger and Melzig, 
2013). In order to avoid this effect, it was decided to permeabilise cells with filipin 
III, which is known to permeabilise membranes (Knopik-Skrocka and Bielawski, 
2002); it was first necessary to optimise the concentrations and time-points that 
would allow sufficient permeabilization for cholesterol visualisation (Figure 5.9). 
Recent publications describe using 50-100 µg/mL filipin III in combination with 
detergent-based permeabilization for cholesterol quantification (Hissa et al., 
2012; Warita et al., 2014), while higher concentrations ranging from 150-1000 
µg/mL were utilised in earlier studies which omitted additional permeabilization 
steps (Tillack and Kinsky, 1973; Milhaud, 1992). As such, it was decided to test 
concentrations between 100-500 µg. 
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Figure 5.9| Optimising filipin III concentrations in cholesterol visualisation reveals differential 
localisation between subtypes. Confocal images acquired at 40X magnification in TKCC-22 (top) 
and TKCC-02 PDCLs, representative of the classical and squamous subtypes respectively, treated for 
30 mins with increasing concentrations of filipin III. As can be seen in TKCC-22, lower 
concentrations of filipin III induce minimal cholesterol staining, with a disparate staining pattern, 
while exposure to increased concentration leads to greater signal and the emergence of patterns 
consistent with cell membrane. This is contrast to TKCC-02 which seems largely unaffected by 
filipin III concentration, with a consistent staining across all doses.  
 
It was observed that increasing concentrations of filipin III in PDCLs representative 
of the two subtypes had no visible effect on permeabilization within TKCC-02, a 
cell-line classed as squamous. This was found in contrast to the classical PDCL, 
TKCC-22, which required higher concentrations to effectively permeabilise cells, 
with staining patterns differing as filipin III concentrations increased. It was 
thought that this phenomenon may exist due to morphological distinctions 
between the two PDCLs, with TKCC-22 tending to grow in compact, epithelial-like 
layers, therefore requiring increased concentrations of filipin III to penetrate 
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clusters of cells, while TKCC-02 exhibit a more mesenchymal-like morphology, with 
individual cells growing disparately. Taking into account the stoichiometry of the 
binding of filipin with cholesterol and phospholipid to effect permeabilization 
(Milhaud, 1992), the more concentrated TKCC-22 cell-line would be expected to 
require greater concentrations of filipin to induce the same level of 
permeabilization as TKCC-02. 
 
The results of filipin III staining optimisation indicate that cholesterol localisation 
differs between TKCC-22 and TKCC-02 (Figure 5.9). Though staining was carried 
out in the absence of additional cell markers, it appears that staining was localised 
to cell membranes in TKCC-22 at high concentrations of filipin III, with the 
boundaries of observable cell clusters visibly stained, along with what appears to 
well defined cell boundaries. However, in TKCC-02, staining appears centralised to 
perinuclear puncta, suggesting a localisation within the ER, where cholesterol 
biosynthesis is carried out, or within the Golgi network/transport vesicles. This 
suggests the upregulation of active flux of cholesterol in squamous PDCLs. 
 
5.4.3  Lipid rafts are enriched in select squamous PDCLs, while CAV1 
appears to colocalise with cholesterol 
 
It was decided to assess the impact, if any, of pitavastatin treatment on caveolae 
formation, while simultaneously investigating CAV1 localisation within PDCLs. 
Caveolae imaging was achieved via exposure to cholera toxin subunit B (CT-B), a 
protein that binds to gangliosides GM1 found in lipid rafts, including caveolae 
(Holmgren et al., 1975; Parton, 1994), conjugated to a fluorescent tag, allowing 
for the visualisation of lipid rafts as described in past publications (Calay et al., 
2010; Irwin et al., 2011). 
 
In the squamous PDCLs tested, CAV1 was found to form puncta in a very similar 
manner to cholesterol in TKCC-02, representative of the squamous subtype (Figure 
5.10). This suggests a colocalization of the two and is consistent with the finding 
that CAV1 cycles between the ER, the Golgi network and caveolae at the plasma 
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membrane, leading to the hypothesis that this flux of CAV1 facilitates cholesterol 
transport (Dupree et al., 1993; Conrad et al., 1995). In contrast, very little 
staining was evident in Mayo-5289, suggesting absence or low levels of CAV1 and 
lipid rafts. The observation that CAV1 and cholesterol likely colocalise to 
 
 
Figure 5.10| Lipid rafts and CAV1 are visible only in squamous cell-lines, while pitavastatin has 
a minor effect on lipid raft formation. Confocal images at 40X magnification showing imaging of 
CAV1 protein localisation (green), as well as lipid rafts stained with fluorescently tagged cholera 
toxin B (red) and nuclei stained with DAPI (blue). Images were acquired in TKCC-02 (left), TKCC-10 
(centre) and Mayo-5289 (right), with cells exposed to DMSO (top) or 1 µM pitavastatin (bottom) for 
72 hours. As can be seen, CAV1 and lipid rafts were most detectable within squamous PDCLs (blue), 
while the classical cell-line (brown), Mayo-5289, exhibited a lower intensity of staining with less 
discernible patterning, possibly reflecting noise rather than a true signal. This suggests a greater 
abundance of both CAV1 and lipid rafts in squamous PDCLs, with CAV1 accumulating in perinuclear 
puncta and lipid rafts detectable along cell membranes. Additionally, pitavastatin appears to have 
a minor impact on lipid raft formation, with a slight decrease in signal associated with treatment as 
compared to control, while no observable effect was seen on CAV1 localisation. 
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organelles associated with intracellular transport selectively in squamous PDCLs 
therefore supports the theory that interplay between the two molecules effects 
pitavastatin sensitivity. Though speculative, this may involve differential 
cholesterol efflux or sequestration, with the possibility that these phenomena 
influence HMGCR degradation via the negative feedback loop described in chapter 
5.3 . 
 
Secondarily, pitavastatin was found not to induce a major change in lipid raft 
formation or CAV1 localisation in either subtype, with patterns of staining 
remaining consistent between vehicle control (DMSO) and pitavastatin treatments 
(Figure 5.10). There did appear to be some slight decrease in signal of lipid raft 
staining along cell membranes upon pitavastatin treatment, however, it was not 
possible to quantify intensities. This suggests that pitavastatin has a minimal 
impact on lipid raft formation. In order to validate the subtype specificity of lipid 
rafts and CAV1 localisation, the analysis could be extended to additional PDCLs. 
 
 
5.5  Interrogating downstream arms of mevalonate pathway 
implicates GGPP and cholesterol in mediating sensitivity 
to statins 
 
5.5.1  Mevalonate pathway intermediates and cancer initiation and 
progression 
 
A number of metabolites downstream within the mevalonate pathway have been 
associated with cancer development and progression, with mevalonate itself 
facilitating growth within various cancer models (Larson and Yachnin, 1984; 
Duncan, El-Sohemy and Archer, 2004), implicating this pathway in oncogenesis. 
This project focused on the involvement of two specific metabolites within the 
mevalonate pathway: cholesterol and geranylgeranyl pyrophosphate (GGPP). These 
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were selected due to their well-documented involvement in processes associated 
with pancreatic cancer. 
 
Cholesterol’s involvement in cancer development may be in part attributed to its 
role as a facilitator of a number of signalling pathways dependent on receptors 
associated with lipid rafts (Mollinedo and Gajate, 2015). This includes the PI3K/Akt 
pathway, which is often found activated in pancreatic cancers (Bondar et al., 
2002). GGPP, along with farnesyl pyrophosphate (FPP), are necessary for protein 
prenylation. 
 
These targeted protein modifications have been demonstrated to be necessary for 
localisation of signalling proteins to cell membranes (Moores et al., 1991; Hart and 
Donoghue, 1997), including KRAS (Chandra et al., 2011), the mutated form of 
which is a common driver of pancreatic cancer. Due to the link between these 
metabolites and pancreatic cancer, as well as the widespread dietary availability 
of both (de Wolf et al., 2017), it was decided to assess the impact of exposure to 
these molecules on pitavastatin sensitivity. 
 
5.5.1  Dietary metabolites within mevalonate pathway induce 
pitavastatin resistance in squamous PDCLs 
 
In order to assess the impact that these metabolites may have on pitavastatin 
sensitivity, dose-response curves were carried out in the absence or presence of 
mevalonate, cholesterol, and GGPP. As all media used to culture PDCLs were 
supplemented with FBS, which is highly rich in lipids, generally containing ~750 µM 
cholesterol (Whitford and Manwaring, 2004), it was necessary to delipidate FBS to 
accurately quantify cholesterol’s influence on pitavastatin sensitivity. 
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Figure 5.11| Supplementing various metabolites in the mevalonate pathway rescues pitavastatin-induced apoptosis in vitro. Schematic outlining the 
key metabolites in the mevalonate pathway (grey ellipses), as well as the enzymes that mediate its progression (red). As can be seen, pitavastatin targets 
the HMGCR-induced conversion of HMCG-CoA to mevalonate in the initial step of the pathway. a Dose-response curve showing the impact of 500 µM 
mevalonate on pitavastatin sensitivity in TKCC-02 and TKCC-10, two squamous PDCLs previously demonstrated to be highly sensitive to statins, after 72 
hours treatment. As can be seen, mevalonate supplementation fully rescues the effect of pitavastatin in sensitive PDCLs. b Dose-response curve showing 
the effect of 20 µM cholesterol in delipidated medium on pitavastatin sensitivity in TKCC-10, relative to fully supplemented medium. As can be seen, cells 
are more sensitive to pitavastatin in delipidated medium relative to medium with full serum, an effect that is nearly fully mitigated on addition of 
cholesterol. c Bar-plots showing sensitivity of squamous PDCLs to three concentrations of pitavastatin, comparing with or without supplementation of 10 
µM GGPP. As can be seen, addition of GGPP abrogates sensitivity to pitavastatin.
a 
b 
c 
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Primary findings showed that exposure to 500 µM mevalonate entirely mitigated 
sensitivity to pitavastatin in sensitive, squamous PDCLs (Figure 5.11a), thus fully 
implicating the mevalonate pathway and downstream components in mediating 
sensitivity to pitavastatin within this subtype. Further results showed that, while 
cells cultured in delipidated FBS exhibited enhanced sensitivity, cholesterol 
treatment also induced some resistance to pitavastatin in squamous PDCLs (Figure 
5.11b). Exposure to GGPP in particular was seen to nullify the effects of 
pitavastatin on cell viability in those sensitive cell-lines (Figure 5.11c). These 
results are in accordance with previous findings that sensitivity to statin treatment 
can be abrogated with the addition of mevalonate and GGPP in in vitro models of 
various cancer types (Greenaway et al., 2016; Ishikawa et al., 2018; 
Sheikholeslami et al., 2019), while the discovery that cholesterol supplementation 
can confer resistance to statin treatment is corroborated by observations that 
cholesterol can rescue statin mediated defects in myotube formation in myoblasts 
(Wei et al., 2016). 
 
These findings collectively highlight the potential of commonly found and 
widespread metabolites on mitigating the effects of pitavastatin, suggesting that 
additional precautions may be necessary when considering the clinical application 
of statins in treating pancreatic cancer. Before this family of therapeutics can 
represent a viable option in a clinical setting, efficacy will likely need to be 
enhanced through either diet limitation or potential combinatorial approaches. 
 
5.6  Statin sensitivity is enhanced by concomitant EGFR 
inhibition 
 
As clinical trials assessing the efficacy of statins in treating pancreatic cancer have 
yielded mixed results, as discussed in chapter 5.2.3 , an observation possibly 
influenced by dietary intake, it was decided to interrogate downstream effectors 
of statin sensitivity in squamous PDCLs. This line of research was performed with 
the view of identifying therapeutics with potential to use in combination with 
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pitavastatin to enhance performance of the drug in both a preclinical and clinical 
setting. 
 
5.6.1  Pitavastatin inhibits Akt activation in squamous PDCLs 
 
Previous research efforts have demonstrated that statins inhibit AKT activity in a 
range of preclinical models of cancer via various potential mechanisms of action 
(Calay et al., 2010; Wang et al., 2016; Beckwitt, Shiraha and Wells, 2018). This 
observation is of importance due to the involvement of the PI3K/Akt pathway in 
pancreatic cancer oncogenesis (Bondar et al., 2002). In order to confirm AKT as a 
downstream indicator of pitavastatin sensitivity in pancreatic cancer subtypes, the 
effect of pitavastatin treatment on AKT phosphorylation was assessed within 
PDCLs, with further on-target validation performed via HMGCR knockdown in 
TKCC-02, a sensitive cell-line classed as squamous (Figure 5.12). This revealed that 
both pitavastatin treatment and HMGCR KD were sufficient to reduce activation of 
AKT in the squamous PDCL, TKCC-02, while a resistant, classical cell-line, TKCC-
22, exhibited a minimal decrease in levels of phospho-AKT upon pitavastatin 
treatment. These results therefore support previous work that has linked statin 
mediated HMGCR inhibition to disruption of AKT signalling, while demonstrating 
that this phenomenon is associated with sensitivity to statin treatment. 
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Figure 5.12| Inhibition or loss of HMGCR leads to inactivation of AKT in sensitive PDCLs. 
Western blot showing the decrease in AKT phosphorylation in response to both siRNA mediated 
knockdown of HMGCR (left) and inhibition of HMGCR via 1 µM pitavastatin treatment (right) in 
TKCC-02 (blue) and TKCC-22 (brown), representatives of the sensitive, squamous subtype and 
resistant, classical subtype respectively. Within TKCC-02, a slight decrease can be seen in total AKT 
levels after treatment with pitavastatin or HMGCR KD, while a more pronounced effect can be 
observed in levels of phospho-AKT after both treatments. In TKCC-22, there appears to be a slight 
decrease in phospho-AKT levels, though this effect is markedly less than that observed in TKCC-02. 
 
5.6.2  Combinatorial gefitinib treatment induces cell-death at low 
pitavastatin concentration in squamous PDCLs 
 
Multiple studies have linked statin-mediated inactivation of AKT to epidermal 
growth factor (EGFR) inhibition (Mantha et al., 2005; Dimitroulakos, Lorimer and 
Goss, 2006), with EGFR being a well-established upstream activator of the PI3K-Akt 
pathway (Soltoff et al., 1994; Mattoon et al., 2004). Possible explanations for such 
a phenomenon suggest a displacement of EGFR from lipid rafts via cholesterol 
depletion (Irwin et al., 2011) or a dissociation of upstream effectors, such as Rho-
GTPases, from the cell membrane as a result in decreased prenylation, disrupting 
actin cytoskeleton organisation (T. T. Zhao et al., 2010). Both mechanisms of 
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action would account for a loss of EGFR activity, with the involvement of EGFR in 
statin sensitivity reinforced by the finding that statin treatment improves survival 
in lung cancer patients receiving EGFR inhibitors (Hung et al., 2017). With these 
findings in mind, it was decided to assess the efficacy of a combination of 
pitavastatin with erlotinib, a widely used EGFR inhibitor that has been shown to 
enhance gemcitabine sensitivity in pancreatic cancer (Moore et al., 2007). The 
expectation is that this combinatorial approach, introducing an additional means 
of inhibiting EGFR, will enhance the on-target effect of statin treatment, further 
disrupting signalling pathways essential within squamous PDCLs. 
 
Synergy between the two therapeutics was quantified via the SynergyFinder web 
application (Ianevski et al., 2017), which allowed for the presentation of zero 
interaction potency (ZIP) scores (Yadav et al., 2015) across all concentrations 
tested in both drugs. Combination treatments demonstrated that squamous PDCLs 
displayed high ZIP scores at low doses of both therapeutics, while classical cell-
lines required treatment with highly concentrated doses before any synergy was 
observed (Figure 5.13). These results indicate a synergistic effect of the two 
therapeutics selectively in the squamous subtype, while highlighting the possibility 
that this combination may be effective in patients, with clinically viable doses 
likely to induce an effect. 
 
5.1  Potential in vivo testing of statin efficacy 
 
In order to assess the potential of testing a regimen of statin treatment in mouse 
models, as well as establish potential subgrouping, it was decided to test 
pitavastatin in a variety of cell-lines established from a genetically engineered 
mouse model (GEMM) induced by concurrent mutations of Kras and Trp53 
(Hingorani et al., 2005). This model allows for the recapitulation of aggressive 
PDAC in mice that progresses in a similar fashion to the disease in human patients, 
bearing the hallmark genomic instability associated with human PDAC. Dose-
response curves generated in three cell-lines derived from KPC tumours displayed 
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Figure 5.13| Pitavastatin and erlotinib synergise at low concentrations in squamous PDCLs. 
Heatmaps showing synergies between erlotinib and pitavastatin in two PDCLs representative of 
each classical (top) and squamous (bottom) subtypes. For each PDCL, a heatmap representing the 
dose-response curves for each therapeutic is shown (left), as well as an equivalent heatmap 
displaying ZIP scores (right), with shading indicating areas of greatest synergy. Data corresponding 
to erlotinib is shown along the x-axis and pitavastatin along the y-axis. As can be seen, synergy in 
classical PDCLs is only seen at prohibitively high concentrations of both drugs, while in squamous 
cell-lines, synergy is observed at much lower concentrations (<5 µM pitavastatin, <10 µM Erlotinib). 
 
differential sensitivities (Figure 5.14), with one cell-line in particular (Panc47) 
exhibiting a sensitivity approaching that observed in sensitive, squamous PDCLs 
(IC50 = 2.6 µM). This is suggestive of the existence of partial subtypes, a finding 
with particular relevance due to the clinical relevance of this in vivo model in in 
vivo research. In order to further validate this potential subgrouping, it was 
decided to assess the degradation status of HMGCR via western blot, as well as the  
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Figure 5.14| Cell-lines derived from mouse models of pancreatic cancer exhibit differential 
sensitivity to pitavastatin treatment. Dose-response curve showing sensitivity of three KPC derived 
cell-lines after 72 hours exposure to pitavastatin. As can be seen, all cell-lines displayed some 
degree of sensitivity to treatment, with Panc47 in particular exhibiting loss of viability. 
 
presence/absence of additional subtype-associated proteins; these were selected 
as putative markers of pitavastatin sensitivity. 
 
Western blotting revealed the presence of the same ~60 kDa HMGCR degradation 
band as detected in PDCLs, with a complete absence this marker in Panc47, the 
cell-line most sensitive to pitavastatin treatment. In addition to this, there was a 
marked absence of HNF4A and slight decrease in HNF1A abundance, two 
transcription factors closely associated with the classical subtype in PDCLs (Figure 
5.15). This finding, in contrast to what was seen in the more resistant mice cell-
lines, further aligned Panc47 with the squamous subtype as presented in PDCLs. 
This close alignment suggests that the same mechanism of pitavastatin escape 
found in classical PDCLs may persist in the KPC model of pancreatic cancer, 
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therefore highlighting the potential of this in vivo system in modelling the 
complexities of subtype-associated responses to statin treatment and validating 
observations within PDCLs with the scope of greater clinical relevance. 
 
  
 
Figure 5.15| Subtype-specific markers of pitavastatin sensitivity persist in mice models of 
pancreatic cancer. Western blot showing quantities of various protein products associated with 
pitavastatin resistance in PDCLs across three cell-lines derived from KPC mice, ordered according to 
increasing pitavastatin sensitivity. As previously seen in PDCLs, presence of HMGCR degradation 
corresponded to pitavastatin resistance, as did presence of protein markers indicative of the 
classical subtype. This mirrors what is found in human derived cell-lines, with cell-lines exhibiting a 
more squamous-like phenotype displaying greater sensitivities to pitavastatin. 
 
5.2  Discussion 
 
This chapter described the establishment of a collaborative high-throughput drug 
repurposing screen conducted in PDCLs in collaboration with the Beatson Screening 
Facility. This study identified a variety of compounds that elicit a subtype-
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selective response, with a number of therapeutics implicated in DNA damage 
effecting sensitivity in squamous PDCLs (Table 5.2), including: bleomycin, which 
inhibits DNA ligase (Ono et al., 1976), resulting in DNA breaks (Tounekti et al., 
2001); etoposide and irinotecan, which target topoisomerases 1 and 2 respectively 
(Pommier, 2013), enzymes that effect over- or underwinding of DNA via induction 
of strand breaks (Champoux, 2001); and fluorouracil, which induces DNA damage 
via dTTP depletion (Longley, Harkin and Johnston, 2003). These compounds are 
regularly used as part of clinical anti-cancer treatments, with proven efficacy 
against a range of cancer types (Einhorn and Williams, 1980; IMPACT, 1995; Hanna 
et al., 2006), while irinotecan forms part of the FOLFIRINOX regimen which is used 
as standard of care in the treatment of PDAC (Conroy et al., 2011). These results 
therefore suggest that the squamous subtype may be more sensitive to clinically 
relevant compounds that inhibit components of DDR, a finding that aligns with 
work that has demonstrated that enhanced replication stress is a signature of 
squamous PDCLs, conferring a dependency on DDR proteins (Dreyer et al., 2019) 
including ATM and ATR serine/threonine kinases (ATM and ATR), which activate 
upon DNA damage (Durocher and Jackson, 2001; Bakkenist and Kastan, 2003), 
coordinating the cellular DDR response (Matsuoka et al., 2007). As this work was 
the focus of a separate project within the group, it was decided to take 
alternative hits forward for follow-up analysis. 
 
Beyond agents associated with DNA damage, screening results, supported by 
follow-up validation, identified the potential of statins to selectively induce cell-
death in squamous cell-lines. This anti-cancer effect was most readily observed 
upon treatment with pitavastatin, a minimally metabolised statin (Kajinami, 
Takekoshi and Saito, 2003; Mukhtar, Reid and Reckless, 2005) whose efficacy as a 
therapeutic in an oncological context has been demonstrated in in vitro and in vivo 
models of a range of cancers (You et al., 2016; Abdullah, Abed and Richardson, 
2017), including PC (Villarino et al., 2017). 
 
Despite many preclinical efforts over the past decades, the mechanism by which 
statins effect their anti-cancer potential is still disputed (Sorrentino et al., 2014; 
Wei et al., 2016; Yu et al., 2018). This chapter has attempted to determine these 
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mechanisms within pancreatic cancer cell-lines, taking an approach centred in 
comparisons between sensitive and resistant subtypes in PDCLs. This revealed a 
dysregulation of cholesterol homeostasis across subtypes, mediated by the absence 
or presence of caveolins. Those differences in cholesterol trafficking had apparent 
links to the activation of a negative feedback loop within the cholesterol 
biosynthesis pathway, potentially facilitating resistance to statin treatment. 
However, due to time constraints, it was not possible to assess the impact of CAV1 
depletion on pitavastatin sensitivity, HMGCR degradation, cholesterol localisation, 
and lipid raft formation. This series of experiments would have been ideal to 
further investigate caveolin’s involvement in cholesterol homeostasis and validate 
the relationship between intracellular trafficking and statin resistance, thus 
confirming the proposed mechanism of statin resistance. Despite this, it was 
determined that statins disrupted AKT signalling within sensitive cell-lines, with 
erlotinib selected as a therapeutic to partner with pitavastatin in order to take 
advantage of this downstream effect. 
 
Although recent, prospective clinical trials involving statins have yielded mixed 
results, trial design choices that fail to fully take into account experimental data 
generated in preclinical research are likely to have negatively influenced results. 
One review argues that a range of crucial factors such as dietary intake of patients 
and dosing of therapeutics have not been optimised for the clinical success of 
statins in the context of oncology, while supporting the view that pitavastatin is 
the ideal choice of statin for cancer studies due to a favourable pharmacodynamic 
profile (Abdullah et al., 2018). This importance of statin choice is reflected in a 
study that highlighted differential efficacy of a range of statins in in vitro and in 
vivo models of pancreatic cancer (Gbelcová et al., 2008), although pitavastatin 
was not included in this set of experiments. Dietary factors, as explored in brief 
within this chapter, are also likely to confound sensitivity to pitavastatin in 
patients with PDAC. Recent research has supported this possibility, with 
indications that geranylgeraniol, a metabolite downstream of mevalonate and 
upstream of cholesterol in the mevalonate pathway, can interfere with anti-cancer 
properties of pitavastatin in vivo (de Wolf et al., 2017), while demonstrating that 
this metabolite is present in a variety of widely consumed foodstuffs. This 
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highlights the need of clinical trial design to pay consideration to these concerns 
and echoes the findings that both cholesterol and GGPP mitigate pitavastatin 
sensitivity in PDCLs, as well as in a number of in vitro models of various cancer 
types (Greenaway et al., 2016; Wei et al., 2016; Sheikholeslami et al., 2019). 
 
Finally, findings described in this chapter have also highlighted the possibility of 
designing an effective therapeutic strategy in GEMMs in advance of clinical 
consideration, allowing for the in vivo assessment of pitavastatin efficacy. This 
would involve pitavastatin treatment with concurrent dietary limitation, ensuring a 
minimal intake of cholesterol and GGPP, with the additional possibility of treating 
with a combination of erlotinib. These in vivo experiments would be ideal for 
establishing a clinically viable regimen of therapeutic administration and dietary 
limitation, with the added benefit of facilitating dosage optimisation and allowing 
the assessment of efficacy of pitavastatin treatment in combination with erlotinib. 
  
  
 
159 
 
 
 
 
 
 
Chapter 6 Concluding Remarks 
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Concluding Remarks 
 
6.1  Summary of project findings 
 
In order to address the lack of therapeutics effective in treating pancreatic 
cancer, this body of work has outlined a subtype-focused approach. By harnessing 
an in vitro model of PDAC subtypes that reflects clinical subgrouping (Bailey et al., 
2016) and providing extensive characterisation of pathways associated with 
pancreatic cancer, it was intended to identify novel, stratified vulnerabilities 
likely to be represented in subgroups within a clinical setting. Interrogation of 
transcriptomic and proteomic data, in tandem with experiments quantifying rates 
of metabolic processes linked to PC (Ying et al., 2012; Kamphorst et al., 2013; 
Daemen et al., 2015), led to the identification of highly divergent metabolic 
phenotypes which aligned closely to subtypes: 
 
• Squamous; highly glycolytic phenotype, exhibiting increased aerobic 
glycolysis and decreased OXPHOS. 
• Classical; highly oxidative with high levels of FAO, with an associated 
upregulation of lipid biosynthesis suggesting a balance between catabolism 
and anabolism. 
 
This allowed for the generation of strategies to exploit potential vulnerabilities 
associated with these distinct metabolic dependencies, with two separate 
approaches developed in order to maximise the possibility of discovering effective 
therapeutics. This involved: (1) performing literature searches to identify novel 
drug targets corresponding to subtype-associated metabolic pathways, while 
incorporating all PDCL data available for review, including RNA-seq, proteomics, 
siRNA screening, and metabolic assays; (2) performing high-throughput drug 
repurposing screening, with libraries containing a variety of general purpose, 
metabolism-targeting compounds. 
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The first approach identified ALDOA, a highly active isoform of aldolase (Chang et 
al., 2018), a glycolytic enzyme that catalyses early glycolysis, upregulated in the 
squamous subtype, as a potential target of squamous-associated glycolysis. Follow-
up experiments involving a therapeutic inhibitor of ALDOA, TDZD-8 (Grandjean, de 
Jong, B. P. James, et al., 2016), demonstrated its potential to successfully inhibit 
glycolysis selectively in PDCLs belonging to the squamous subtype. This effectively 
induced cell death in vitro, however, in vivo experiments would be required to 
validate its efficacy in treating pancreatic cancer. This strategy also allowed for 
the characterisation of metabolic flexibility within classical PDCLs, as inhibition of 
FA biosynthesis resulted in a compensatory activation of glycolysis within this 
subtype. This phenomenon bears clear clinical relevance due to its potential to 
facilitate emergence of resistance to metabolic inhibition (Boudreau et al., 2016; 
Biancur et al., 2017) and as a result of these observations, JQ1 was discovered to 
therapeutically mitigate this resistance mechanism. This inhibitor of epigenetic 
reader proteins was found to act to induce widespread changes at the 
transcriptomic level, effecting dysregulation of a range of metabolic genes, 
consistent with other research conducted within PC (Sakamaki et al., 2017; 
Sherman et al., 2017), allowing for the sensitisation of classical cell-lines to the 
targeting of lipid biosynthesis via FASN inhibitors. 
 
The second approach of drug repurposing screening identified statins as a possible 
therapeutic effective selectively in squamous PDAC. In order to enhance clinical 
potential by finding optimal treatment strategies, the mechanism by which statin 
sensitivity is induced selectively in squamous PDCLs was investigated. This line of 
research identified the potential of pairing with the EGFR inhibitor erlotinib in 
vitro, alongside the possibility that dietary limitation may be necessary to induce a 
full response to statins in a clinical setting. 
 
6.2  Conclusions and future work 
 
Pancreatic cancer is highly aggressive, with the poor prognosis associated with the 
disease reflective of its refractory nature. Poor outcomes are in part accounted for 
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by the failure of standard of care therapeutics in effectively managing 
metastasised PDAC, with overall survivals of less than a year typically observed in 
patients receiving chemotherapeutic treatments (Kamisawa et al., 2016). This 
shortcoming must be addressed and viable therapeutics found in order to improve 
PC prognoses, with one area of emerging interest of clinical potential being the 
targeting of cell metabolism in PDAC (Blum and Kloog, 2014; Cohen et al., 2015; 
Garrido-Laguna and Hidalgo, 2015). This interest is driven by the degree of 
metabolic dysregulation observed in pancreatic cancer, with reprogramming in 
glycolysis (Zhou et al., 2011; Ying et al., 2012; Guillaumond et al., 2013), 
glutamine metabolism (Son et al., 2013; Biancur et al., 2017), autophagy (Perera 
et al., 2015; Yang et al., 2018) and FAO (Khasawneh et al., 2009; Kamphorst et 
al., 2013) associated with cancer development, while preclinical efforts have 
demonstrated the efficacy of a range of therapeutics that target each of these 
pathways (Maftouh et al., 2014; Ventura et al., 2015; Brandi et al., 2017). 
 
Heterogeneity is a dominant feature of PC, which is defined by a high number of 
low prevalence mutations found in patient genomes (Biankin et al., 2012; Waddell, 
Pajic, A.-M. Patch, et al., 2015). This is most clearly apparent when considering 
the wide range of mutations that have been implicated in driving oncogenesis, 
with one study which harnessed a transposon-based insertional mutagenesis screen 
having identified >500 genes as candidate drivers, primarily acting as potential 
tumour suppressors whose loss promotes cancer progression in in vivo models 
(Mann et al., 2012). In order to address this complex mutational landscape, recent 
efforts have focussed on subtyping patients into workable groups (Collisson et al., 
2011, 2019; Bailey et al., 2016), allowing for the identification of shared 
vulnerabilities. These subtypes are of particular relevance to the field of clinical 
pancreatic cancer research as recent work has demonstrated the capacity to 
rapidly subtype PDAC patients upon diagnosis (Aguirre et al., 2018). The work 
detailed as part of this thesis has described the definition of subtypes in vitro, 
which faithfully recapitulate those identified in patients. Due to this overlap, 
these cell-lines represent an ideal model to guide translational research efforts; as 
pathways dysregulated in patients are also perturbed in cell-lines, therapeutics 
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identified that act to inhibit these processes and which elicit a subtype-selective 
response are likely to be of clinical relevance. 
 
This work has demonstrated the existence of distinct metabolic phenotypes, which 
are associated with PDAC subtypes and exhibit differential sensitivities to 
metabolic inhibition via therapeutics. This can be summarised as such: in vitro, 
the squamous subtype is defined by upregulated glycolysis, with an enhanced 
sensitivity to inhibition of glycolysis, while the classical subtype exhibits increased 
FA biosynthesis and metabolism. The discovery of these phenotypes and inherent 
vulnerabilities is supported by a similar project that identified two in vitro 
metabolic subtypes in pancreatic cancer, subsequently demonstrating that the 
upregulation of glycolysis and FA biosynthesis associated with these distinct groups 
predict sensitivity to targeting these processes (Daemen et al., 2015). Efforts 
described in this thesis serve to expand on this, having identified a potential 
transcriptionally coordinated origin of metabolic reprogramming corresponding to 
gene dysregulation associated with subtypes (Bailey et al., 2016). This is further 
evidenced by the finding that dysregulation of genes involved in glycolysis at the 
transcriptome level informs metabolic subtypes found in patient populations (Follia 
et al., 2019). Work within has additionally identified metabolic flexibility 
associated with the classical subtype, a phenomenon described previously in 
pancreatic cancer (Kimmelman, 2015; Boudreau et al., 2016; Biancur et al., 2017), 
while JQ1, a therapeutic with clinically viable analogues (Alqahtani et al., 2019), 
was found to abrogate this flexibility in vitro. 
 
Expanding on the clinical utility of these described metabolic perturbations, the 
glycolytic phenotype associated with the squamous subtype has the potential for 
clinical detection via the diagnostic tool, FDG-PET. This imaging technique, 
described in chapter 1.5.1 , allows for detection of transformed cells exhibiting 
the increased glucose uptake associated with the Warburg Effect (Adams et al., 
1998). Regarding the use of this tool in diagnosing PC, historic efforts have 
identified some factors that may confound efficacy of PDAC detection, including 
hyperglycaemia and diabetes status (Diederichs et al., 1998, 2000), while recent 
meta-analyses have demonstrated that FDG-PET has limited utility in diagnosing PC 
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relative to alternative diagnostic tools (Wang et al., 2013; Rijkers et al., 2014). 
Despite these findings, FDG-PET has been shown demonstrate prognostic value, 
with a correlation found between FDG uptake and poor survival outcomes in 
patients with PC (Ahn et al., 2014; Yamamoto et al., 2015; Chen et al., 2016). 
These observations are particularly striking given the poor prognosis associated 
with patients classified with squamous PDAC (Bailey et al., 2016), along with the 
finding that glycolytic activation, as a result of the emergence of gemcitabine 
resistance in PDAC cell-lines, leads to enhanced FDG-PET detection upon 
implantation in in vivo models (Shukla et al., 2017), and serve to collectively 
suggest that patients with squamous PDAC may be more readily detected via FDG-
PET.  
 
In addition to this, future work has been suggested within this thesis which would 
involve the probing of efficacy of statins in in vivo models of PDAC. Research was 
initially conducted in order to determine the mechanism of action by which statins 
exert their subtype-selective response, with squamous PDCLs exhibiting greater 
sensitivity than classical, as observed in drug repurposing screening and 
subsequently validated. This demonstrated the potential of commonly found 
foodstuffs to limit the anti-cancer efficacy of statin treatment in vitro, a finding 
in-line with other preclinical research efforts (Greenaway et al., 2016; Wei et al., 
2016; Sheikholeslami et al., 2019), suggesting that dietary limitation may be an 
effective strategy in a clinical setting (de Wolf et al., 2017; Abdullah et al., 2018). 
Additionally, combination therapies demonstrated the potential of pairing 
pitavastatin with erlotinib in squamous PDCLs, which supports previous 
observations that EGFR inhibition enhances statin’s ability to inhibit cancer 
progression both in vitro (Mantha et al., 2005; Dimitroulakos, Lorimer and Goss, 
2006) and in patients with lung cancer (Hung et al., 2017). As proof that these 
findings can be translated into clinically viable strategies, future work would be 
required to assess the efficacy of both treatment approaches in in vivo models of 
PDAC, which would ideally be conducted within mouse models of PDAC subtypes. 
Early subtyping efforts indicated that cell-lines derived from GEMMs of PDAC 
exhibited both classical and squamous subtypes (Collisson et al., 2011), a finding 
supported by recent work that identified subtypes within the KPC model of PDAC 
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(Candido et al., 2018). Research conducted as part of this thesis utilising cell-lines 
derived from KPC mice suggests that these cell-lines exhibit differential 
sensitivities to pitavastatin according to subtype, as determined by select 
biomarkers. Collectively, these findings therefore suggest the potential of 
assessing pitavastatin efficacy in KPC mouse models. 
 
Finally, this work also describes the establishment of a collaborative high-
throughput screening project with the Beatson Screening Facility. This project has 
the potential to be expanded on in future work, with morphological data resulting 
from the screen to be analysed in-house by the Screening Facility. Results obtained 
from these analyses may inform future projects, with the potential to identify 
novel therapeutics effective in treating PDAC subtypes in vitro necessitating 
follow-up studies including validation experiments and in vivo testing. 
 
The work described within this thesis has outlined attempts to identify therapeutic 
strategies to effectively target metabolic processes in PDAC subtypes in vitro. This 
has revealed the potential of inhibiting both glycolysis and the mevalonate 
pathway within squamous cell-lines. It has also served to characterise metabolic 
flexibility associated with the classical subtype, which necessitates combinatorial 
strategies, targeting both flexibility and FA biosynthesis, to elicit a response. This 
work has therefore served to characterise associations between metabolic 
pathways and PDAC subtypes, facilitating the identification of a number of 
therapeutic targets, with screening projects initiated as part of this project poised 
to identify further clinically exploitable vulnerabilities. 
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